:: CLDF ::

Home | Contact Us | Bookmark

NASH

HCC

PEDIATRIC LIVER DISEASE

Centers of Educational Expertise

Live Events Slide Library Webcasts Abstract Library Committee Members

Conference Highlights

NASH | Abstract Library

The summaries are free for public use. The Chronic Liver Disease Foundation will continue to add and archive summaries of articles deemed relevant to CLDF by the Board of Trustees and its Advisors.

Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetes

PLoS One. 2021 Jun 2;16(6):e0251449. doi: 10.1371/journal.pone.0251449. eCollection 2021.

Kristin Alexandra Dayton¹, Fernando Bril^2 3, Diana Barb², Jinping Lai⁴, Srilaxmi Kalavalapalli², Kenneth Cusi^2 3

Step by Step: Managing the Complications of Cirrhosis

Hepat Med. 2021 May 25;13:45-57.doi: 10.2147/HMER.S278032. eCollection 2021.

Irene Perez¹, Fabian J Bolte¹, William Bigelow¹, Zachary Dickson², Neeral L Shah²

Week 4 Liver Fat Reduction on MRI as an Early Predictor of Treatment Response in Participants with Nonalcoholic Steatohepatitis

Radiology. 2021 Jun 1;204325. doi: 10.1148/radiol.2021204325. Online ahead of print.

Hanyu Jiang¹, Hubert C Chen¹, Kyle J Lafata¹, Mustafa R Bashir¹

Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis

Cochrane Database Syst Rev. 2021 Jun 11;6:CD013156.doi: 10.1002/14651858.CD013156.pub2.

Elena Buzzetti¹, Audrey Linden², Lawrence Mj Best², Angela M Madden³, Danielle Roberts², Thomas J G Chase⁴, Suzanne C Freeman⁵, Nicola J Cooper⁵, Alex J Sutton⁵, Dominic Fritche⁶, Elisabeth Jane Milne⁷, Kathy Wright⁸, Chavdar S Pavlov⁹, Brian R Davidson², Emmanuel Tsochatzis¹, Kurinchi Selvan Gurusamy^2 9

Infections at the nexus of metabolic-associated fatty liver disease

Arch Toxicol. 2021 May 24;1-19. doi: 10.1007/s00204-021-03069-1.Online ahead of print.

Joost Boeckmans^1 2, Matthias Rombaut³, Thomas Demuyser^4 5, Baptist Declerck⁴, Denis Piérard⁴, Vera Rogiers³, Joery De Kock³, Luc Waumans⁶, Koen Magerman^6 7, Reinoud Cartuyvels⁶, Jean-Luc Rummens⁶, Robim M Rodrigues^# 8, Tamara Vanhaecke^# 3

Hepatocellular Carcinoma in Patients Without Cirrhosis: The Fibrosis Stage Distribution, Characteristics and Survival

Dig Dis Sci. 2021 May 23. doi: 10.1007/s10620-021-07048-5. Online ahead of print.

Kanokwan Pinyopornpanish^1 2, Wael Al-Yaman³, Srinivasan Dasarathy^3 4, Carlos Romero-Marrero³, Arthur McCullough^3 4

The Growing Burden of Disability Related to Chronic Liver Disease in the United States: Data From the Global Burden of Disease Study 2007-2017

Hepatol Commun. 2021 Jan 14;5(5):749-759. doi: 10.1002/hep4.1673. eCollection 2021 May.

James M Paik¹, Pegah Golabi¹, Youssef Younossi², Nazaneen Saleh¹, Annan Nhyira¹, Zobair M Younossi^1 3

Discovery of novel modulators for the PPARa (peroxisome proliferator activated receptor a): Potential therapies for nonalcoholic fatty liver disease

Bioorg Med Chem. 2021 May 1;41:116193. doi: 10.1016/j.bmc.2021.116193. Online ahead of print.

Donna D Yu¹, Gregg Van Citters², Hongzhi Li³, Brian M Stoltz⁴, Barry M Forman³

The Patient's Perspective in Cirrhosis: Unmet Supportive Care Needs Differ by Disease Severity, Etiology, and Age

Hepatol Commun. 2021 Feb 6;5(5):891-905. doi: 10.1002/hep4.1681. eCollection 2021 May.

Patricia C Valery¹, Christina M Bernardes¹, Benjamin Mckillen^2 3, Samath Amarasena⁴, Katherine A Stuart², Gunter Hartel¹, Paul J Clark^2 5, Richard Skoien⁴, Tony Rahman⁶, Leigh Horsfall^2 3, Kelly Hayward^2 3, Rohit Gupta⁶, Andrew Lee⁵, Leshni Pillay⁷, Elizabeth E Powell^2 3

10.

Modelling the cost effectiveness of non-alcoholic fatty liver disease risk stratification strategies in the community setting

PLoS One. 2021 May 21;16(5):e0251741. doi: 10.1371/journal.pone.0251741. eCollection 2021.

Stephen E Congly^1 2, Abdel Aziz Shaheen^1 3, Mark G Swain¹

11.

Relationship of ELF and PIIINP With Liver Histology and Response to Vitamin E or Pioglitazone in the PIVENS Trial

Hepatol Commun. 2021 Feb 5;5(5):786-797. doi: 10.1002/hep4.1680. eCollection 2021 May.

Samer Gawrieh¹, Laura A Wilson², Katherine P Yates², Oscar W Cummings³, Eduardo Vilar-Gomez¹, Veeral Ajmera⁴, Kris V Kowdley⁵, William M Rosenberg⁶, James Tonascia², Naga Chalasani¹

12.

Individualized treatment options for patients with non-cirrhotic and cirrhotic liver disease

World J Gastroenterol. 2021 May 21;27(19):2281-2298.doi: 10.3748/wjg.v27.i19.2281.

Lukas Hartl¹, Joshua Elias², Gerhard Prager³, Thomas Reiberger¹, Lukas W Unger⁴

13.

coreNASH: Multi-stakeholder Consensus on Core Outcomes for Decision Making About Nonalcoholic Steatohepatitis Treatment

Hepatol Commun. 2021 Feb 12;5(5):774-785. doi: 10.1002/hep4.1678. eCollection 2021 May.

Elizabeth Clearfield¹, Veronica Miller², Joseph Nadglowski³, Katherine Barradas², Jennifer Al Naber¹, Arun J Sanyal⁴, Brent A Neuschwander-Tetri⁵, Donna A Messner¹, coreNASH Panel

Collaborators,

Collaborators

coreNASH Panel:

William Baldyga, Maria-Magdalena Balp, Catherine Brun-Strang, Robyn Carson, Wayne Eskridge, Kurinchi Gurusamy, Lars Hansen, Morten Hansen, Katy Harrison, Andras Harsanyi, Anders Hvelplund, Zoltán Kaló, Marko Korenjak, E J Milne, Euan McLeod, Michelle Mocarski, Joachim Musaeus, Fady Ntanios, Mazen Noureddin, Daniel Ollendorf, Jan Oscarsson, Stephen Rossi, Vlad Ratziu, Yaron Rotman, Leonardo Ruiz-Casas, Lewis Sandy, Jörn M Schattenberg, Mohammad Shadab Siddiqui, Gregory Steinberg, Ethan Weiss, Keith White, José Willemse, Kathy Wright, Michael Zemel

14.

Non-alcoholic fatty liver diseases: current challenges and future directions

Ann Transl Med. 2021 Apr;9(8):726. doi: 10.21037/atm-20-3760.

Elke Roeb¹

15.

Metabolic dysfunction-associated fatty liver disease (MAFLD) - rather a bystander than a driver of mortality

J Clin Endocrinol Metab. 2021 May 13;dgab339. doi: 10.1210/clinem/dgab339.Online ahead of print.

Georg Semmler^1 2, Sarah Wernly¹, Sebastian Bachmayer¹, Isabella Leitner¹, Bernhard Wernly³, Matthias Egger¹, Lena Schwenoha¹, Leonora Datz¹, Lorenz Balcar^1 2, Marie Semmler¹, Felix Stickel⁴, David Niederseer⁵, Elmar Aigner⁶, Christian Datz¹

16.

Obesity Management of Liver Transplant Waitlist Candidates and Recipients

Clin Liver Dis. 2021 Feb;25(1):1-18. doi: 10.1016/j.cld.2020.08.001.Epub 2020 Oct 12.

Danielle Brandman¹

17.

Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)

Liver Int. 2021 May 12. doi: 10.1111/liv.14943. Online ahead of print.

Patrizia Burra¹, Debora Bizzaro¹, Anna Gonta¹, Sarah Shalaby¹, Martina Gambato¹, Maria Cristina Morelli², Silvia Trapani³, Annarosa Floreani^4 5, Fabio Marra⁶, Maurizia Rossana Brunetto⁷, Gloria Taliani⁸, Erica Villa⁹, Special Interest Group Gender in Hepatology of the Italian Association for the Study of the Liver (AISF)

18.

The GLP-1 Receptor Agonist Semaglutide for the Treatment of Nonalcoholic Steatohepatitis

Hepatology. 2021 May 6. doi: 10.1002/hep.31886. Online ahead of print.

Laura E Dichtel¹

19.

Quantifying the progression of non-alcoholic fatty liver disease in human biomimetic liver microphysiology systems with fluorescent protein biosensors

Exp Biol Med (Maywood). 2021 May 6;15353702211009228. doi: 10.1177/15353702211009228.Online ahead of print.

Manush Saydmohammed¹, Anupma Jha¹, Vineet Mahajan¹, Dillon Gavlock¹, Tong Ying Shun¹, Richard DeBiasio¹, Daniel Lefever¹, Xiang Li¹, Celeste Reese¹, Erin E Kershaw², Vijay Yechoor², Jaideep Behari^3 4, Alejandro Soto-Gutierrez^5 6, Larry Vernetti^1 7, Andrew Stern^1 7, Albert Gough^1 7, Mark T Miedel^1 7, D Lansing Taylor^1 6 7

20.

New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease

Semin Liver Dis. 2021 Jan;41(1):87-102. doi: 10.1055/s-0040-1719174. Epub 2021 Jan 14.

Phillipp Hartmann^1 2, Bernd Schnabl^2 3

21.

Efficacy of Weight Reduction on Pediatric Nonalcoholic Fatty Liver Disease: Opportunities to Improve Treatment Outcomes Through Pharmacotherapy

Front Endocrinol (Lausanne). 2021 Apr 13;12:663351. doi: 10.3389/fendo.2021.663351.eCollection 2021.

Chance S Friesen¹, Chelsea Hosey-Cojocari², Sherwin S Chan^2 3, Iván L Csanaky^2 3 4, Jonathan B Wagner^2 3, Brooke R Sweeney^2 3 5, Alec Friesen¹, Jason D Fraser^2 3, Valentina Shakhnovich^2 3 4 5

22.

The interplay of Western diet and binge drinking on the onset, progression, and outlook of liver disease

Nutr Rev. 2021 May 9;nuab031. doi: 10.1093/nutrit/nuab031. Online ahead of print.

R Chris Skinner¹, Joel A Hagaman¹

23.

The Emerging Role of B Cells in the Pathogenesis of NAFLD

Hepatology. 2021 May 7. doi: 10.1002/hep.31889. Online ahead of print.

Fanta Barrow¹, Saad Khan², Haiguang Wang¹, Xavier S Revelo^1 3

24.

Physical activity is associated with reduced risk of liver disease in the prospective UK Biobank cohort

JHEP Rep. 2021 Mar 2;3(3):100263. doi: 10.1016/j.jhepr.2021.100263. eCollection 2021 Jun.

Carolin V Schneider¹, Inuk Zandvakili², Christoph A Thaiss^3 4 5, Kai Markus Schneider^3 4 5

25.

The Role of Lipid Sensing Nuclear Receptors (PPARs and LXR) and Metabolic Lipases in Obesity, Diabetes and NAFLD

Genes (Basel). 2021 Apr 26;12(5):645. doi: 10.3390/genes12050645.

Emmanuel D Dixon¹, Alexander D Nardo¹, Thierry Claudel¹, Michael Trauner¹

26.

Application of Artificial Intelligence for Diagnosis and Risk Stratification in NAFLD and NASH- the State of the Art

Hepatology. 2021 Apr 30. doi: 10.1002/hep.31869. Online ahead of print.

Amreen M Dinani¹, Kris V Kowdley², Mazen Noureddin³

27.

Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment

Front Med (Lausanne). 2021 Apr 14;8:615978. doi: 10.3389/fmed.2021.615978.eCollection 2021.

Leen J M Heyens^1 2 3, Dana Busschots^1 2, Ger H Koek^2 4, Geert Robaeys^1 3 5, Sven Francque^6 7

28.

Mechanisms and disease consequences of nonalcoholic fatty liver disease

Cell. 2021 May 13;184(10):2537-2564. doi: 10.1016/j.cell.2021.04.015.

Rohit Loomba¹, Scott L Friedman², Gerald I Shulman³

29.

Functional characterization of organoids derived from irreversibly damaged NASH patient liver

Hepatology. 2021 Apr 26. doi: 10.1002/hep.31857. Online ahead of print.

Sarah McCarron¹, Brooke Bathon¹, Donna M Conlon¹, Deepti Abbey¹, Daniel J Rader¹, Katerina Gawronski², Christopher D Brown², Kim M Olthoff³, Abraham Shaked³, Tobias D Raabe¹

30.

Free Fatty Acid Receptors as Mediators and Therapeutic Targets in Liver Disease

Front Physiol. 2021 Apr 7;12:656441. doi: 10.3389/fphys.2021.656441.eCollection 2021.

Jordan D Secor¹, Scott C Fligor¹, Savas T Tsikis¹, Lumeng J Yu¹, Mark Puder¹

31.

Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases

JHEP Rep. 2021 Feb 19;3(3):100255. doi: 10.1016/j.jhepr.2021.100255. eCollection 2021 Jun.

Arun J Sanyal¹, Lei Ling², Ulrich Beuers³, Alex M DePaoli², Hsiao D Lieu², Stephen A Harrison^4 5, Gideon M Hirschfield⁶

32.

Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet - a randomised controlled trial

JHEP Rep. 2021 Feb 17;3(3):100256. doi: 10.1016/j.jhepr.2021.100256. eCollection 2021 Jun.

Magnus Holmer^1 2, Catarina Lindqvist^3 4, Sven Petersson^5 6, John Moshtaghi-Svensson⁷, Veronika Tillander⁸, Torkel B Brismar^6 9, Hannes Hagström^1 2 10, Per Stål^1 2

33.

Combined analysis of gut microbiota, diet and PNPLA3 polymorphism in biopsy-proven non-alcoholic fatty liver disease

Liver Int. 2021 Apr 25. doi: 10.1111/liv.14899. Online ahead of print.

Sonja Lang^1 2, Anna Martin¹, Xinlian Zhang³, Fedja Farowski^4 5 6, Hilmar Wisplinghoff^7 8 9, Maria J G T Vehreschild^4 5 6, Marcin Krawczyk^10 11, Angela Nowag^7 9, Anne Kretzschmar⁷, Claus Scholz⁷, Philipp Kasper¹, Christoph Roderburg¹², Raphael Mohr¹³, Frank Lammert^10 14, Frank Tacke¹³, Bernd Schnabl^2 15, Tobias Goeser¹, Hans-Michael Steffen¹, Münevver Demir¹³

34.

Allele Specific Variation at APOE Increases Non-alcoholic Fatty Liver Disease and Obesity but Decreases Risk of Alzheimer's Disease and Myocardial Infarction

Hum Mol Genet. 2021 Apr 15;ddab096. doi: 10.1093/hmg/ddab096. Online ahead of print.

Nicholette D Palmer¹, Bratati Kahali^2 3, Annapurna Kuppa³, Yanhua Chen³, Xiaomeng Du³, Mary F Feitosa⁴, Lawrence F Bielak⁵, Jeffrey R O'Connell⁶, Solomon K Musani⁷, Xiuqing Guo⁸, Albert V Smith⁹, Kathleen A Ryan⁶, Gudny Eirksdottir⁹, Matthew A Allison¹⁰, Donald W Bowden¹, Matthew J Budoff¹¹, J Jeffrey Carr¹², Yii-Der I Chen⁸, Kent D Taylor⁸, Adolfo Correa⁷, Breland F Crudup⁷, Brian Halligan³, Jian Yang¹³, Sharon L R Kardia⁵, Lenore J Launer¹⁴, Yi-Ping Fu^15 16, Thomas H Mosley⁷, Jill M Norris¹⁷, James G Terry¹², Christopher J O'Donnell¹, Jerome I Rotter⁸, Lynne E Wagenknecht¹⁸, Vilmundur Gudnason^9 19, Michael A Province⁴, Patricia A Peyser⁵, Elizabeth K Speliotes³

35.

Definite and indeterminate NASH share similar clinical features and prognosis: a longitudinal study of 1893 biopsy-proven NAFLD subjects

Liver Int. 2021 Apr 25. doi: 10.1111/liv.14898. Online ahead of print.

Javier Ampuero^1 2 3, Rocío Aller⁴, Rocío Gallego-Durán^2 3, Javier Crespo⁵, Javier Abad⁶, Águeda González-Rodríguez⁷, Judith Gómez-Camarero⁸, Joan Caballería^3 9, Oreste Lo Iacono¹⁰, Luis Ibañez^3 11, Javier García-Samaniego^3 12, Rosa Martín-Mateos^3 13, Rubén Francés^3 14, Conrado Fernández-Rodríguez¹⁵, Moisés Diago¹⁶, Germán Soriano^3 17, Raúl J Andrade^3 18, Raquel Latorre¹⁹, Francisco Jorquera^3 20, Rosa María Morillas^3 21, Desamparados Escudero²², Pamela Estévez²³, Manuel Hernández Guerra²⁴, Salvador Augustín²⁵, María Jesús Pareja-Megia²⁶, Jesús M Banales^3 27, Patricia Aspichueta²⁸, Salvador Benlloch^3 29, José Miguel Rosales³⁰, Javier Salmerón³¹, Juan Turnes³², Manuel Romero Gómez^1 2 3, HEPAmet Registry

36.

Non-alcoholic fatty liver disease

Lancet. 2021 Apr 21;S0140-6736(20)32511-3.doi: 10.1016/S0140-6736(20)32511-3. Online ahead of print.

Elizabeth E Powell¹, Vincent Wai-Sun Wong², Mary Rinella³

37.

Clinical Management of Nonalcoholic Steatohepatitis (NASH) With the Use of Thiazolidinediones and the Additive Effect of Thiazolidinediones and a GLP-1 Agonist: Case Series

Cureus. 2021 Mar 24;13(3):e14082. doi: 10.7759/cureus.14082.

Valentina Rojas Ortiz¹, Jonathan Nieves², Enrique C Fernandez³

38.

Remodeling of Mitochondrial Plasticity: The Key Switch from NAFLD/NASH to HCC

Int J Mol Sci. 2021 Apr 17;22(8):4173. doi: 10.3390/ijms22084173.

Miriam Longo^1 2, Erika Paolini^1 3, Marica Meroni¹, Paola Dongiovanni¹

39.

The importance of glycemic equipoise in NASH

Hepatology. 2021 Apr 26. doi: 10.1002/hep.31866. Online ahead of print.

Alina M Allen¹, Brent A Neuschwander-Tetri²

40.

Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis

J Hepatol. 2021 Apr 19;S0168-8278(21)00248-8. doi: 10.1016/j.jhep.2021.04.013.Online ahead of print.

Geraldine J Ooi¹, Peter J Meikle², Kevin Huynh², Arul Earnest³, Stuart K Roberts⁴, William Kemp⁴, Benjamin L Parker⁵, Wendy Brown¹, Paul Burton⁶, Matthew J Watt⁷

41.

Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH

Hepatol Commun. 2021 Jan 4;5(4):573-588. doi: 10.1002/hep4.1657. eCollection 2021 Apr.

Stephen A Harrison^1 2, Mustafa Bashir³, Sam E Moussa⁴, Kevin McCarty⁵, Juan Pablo Frias⁶, Rebecca Taub⁷, Naim Alkhouri⁸

Affiliations expand

42.

Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study

Hepatology. 2021 Apr 3. doi: 10.1002/hep.31845. Online ahead of print.

Tracey G Simon^1 2 3, Bjorn Roelstraete⁴, Rajani Sharma^5 6, Hamed Khalili^1 2 3, Hannes Hagström^7 8, Jonas F Ludvigsson^4 9 10 11

43.

Cholesterol Accumulation as a Driver of Hepatic Inflammation Under Translational Dietary Conditions Can Be Attenuated by a Multicomponent Medicine

Front Endocrinol (Lausanne). 2021 Mar 18;12:601160. doi: 10.3389/fendo.2021.601160.eCollection 2021.

Andrea M Mueller¹, Robert Kleemann^2 3, Eveline Gart^2 4, Wim van Duyvenvoorde², Lars Verschuren⁵, Martien Caspers⁵, Aswin Menke², Natascha Krömmelbein¹, Kanita Salic², Yvonne Burmeister¹, Bernd Seilheimer¹, Martine C Morrison^2 4

44.

The relationship between liver histology and thyroid function tests in patients with non-alcoholic fatty liver disease (NAFLD)

PLoS One. 2021 Apr 6;16(4):e0249614. doi: 10.1371/journal.pone.0249614. eCollection 2021.

Roberta D'Ambrosio¹, Irene Campi², Marco Maggioni³, Riccardo Perbellini¹, Enza Giammona⁴, Roberta Stucchi⁴, Marta Borghi¹, Elisabetta Degasperi¹, Annalisa De Silvestri⁵, Luca Persani^2 6, Laura Fugazzola^2 7, Pietro Lampertico^1 7

45.

Allele Specific Variation at APOE Increases Non-alcoholic Fatty Liver Disease and Obesity but Decreases Risk of Alzheimer's Disease and Myocardial Infarction

Hum Mol Genet. 2021 Apr 15;ddab096. doi: 10.1093/hmg/ddab096. Online ahead of print.

46.

Saroglitazar, a PPAR-a/? Agonist, for Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Double-Blind Phase 2 Trial

Hepatology. 2021 Apr 2. doi: 10.1002/hep.31843. Online ahead of print.

Samer Gawrieh¹, Mazen Noureddin², Nicole Loo³, Rizwana Mohseni⁴, Vivek Awasty⁵, Kenneth Cusi⁶, Kris V Kowdley⁷, Michelle Lai⁸, Eugene Schiff⁹, Deven Parmar¹⁰, Pankaj Patel¹¹, Naga Chalasani¹

47.

MAFLD in Obese Children: A Challenging Definition

Children (Basel). 2021 Mar 23;8(3):247. doi: 10.3390/children8030247.

Anna Di Sessa¹, Stefano Guarino¹, Giuseppina Rosaria Umano¹, Mattia Arenella¹, Salvatore Alfiero¹, Gaetano Quaranta¹, Emanuele Miraglia Del Giudice¹, Pierluigi Marzuillo¹

48.

Role of Angiogenesis in the Pathogenesis of NAFLD

J Clin Med. 2021 Mar 24;10(7):1338. doi: 10.3390/jcm10071338.

Lin Lei¹, Haquima Ei Mourabit¹, Chantal Housset^1 2, Axelle Cadoret¹, Sara Lemoinne^1 2

49.

PNPLA3 Single Nucleotide Polymorphism Prevalence and Association with Liver Disease in a Diverse Cohort of Persons Living with HIV

Biology (Basel). 2021 Mar 21;10(3):242. doi: 10.3390/biology10030242.

Kenneth E Sherman¹, Susan D Rouster¹, Heidi Meeds¹, Javier Tamargo², Jun Chen³, Richard Ehman³, Marianna Baum²

50.

Comparison of Ketogenic Diets with and without Ketone Salts versus a Low-Fat Diet: Liver Fat Responses in Overweight Adults

Nutrients. 2021 Mar 17;13(3):966. doi: 10.3390/nu13030966.

Christopher D Crabtree¹, Madison L Kackley¹, Alexandru Buga¹, Brandon Fell¹, Richard A LaFountain¹, Parker N Hyde¹, Teryn N Sapper¹, William J Kraemer¹, Debbie Scandling², Orlando P Simonetti^2 3, Jeff S Volek¹

51.

PNPLA3 and SERPINA1 Variants Are Associated with Severity of Fatty Liver Disease at First Referral to a Tertiary Center

J Pers Med. 2021 Mar 1;11(3):165. doi: 10.3390/jpm11030165.

Georg Semmler^1 2 3, Lorenz Balcar^1 2, Hannes Oberkofler⁴, Stephan Zandanell¹, Michael Strasser¹, David Niederseer⁵, Alexandra Feldman¹, Felix Stickel⁶, Pavel Strnad⁷, Christian Datz³, Bernhard Paulweber¹, Elmar Aigner¹

52.

Association of obstructive sleep apnea with non-alcoholic fatty liver disease in patients with obesity: an observational study

Eat Weight Disord. 2021 Apr 3;1-9. doi: 10.1007/s40519-021-01182-9. Online ahead of print.

Silvia Bettini¹, Roberto Serra², Roberto Fabris², Chiara Dal Prà², Francesca Favaretto^3 2, Francesca Dassie³, Claudio Duso³, Roberto Vettor^3 2, Luca Busetto^3 2

53.

Comparison between magnetic resonance and ultrasound-derived indicators of hepatic steatosis in a pooled NAFLD cohort

PLoS One. 2021 Apr 1;16(4):e0249491. doi: 10.1371/journal.pone.0249491. eCollection 2021.

Cayden Beyer¹, Chloe Hutton¹, Anneli Andersson¹, Kento Imajo², Atsushi Nakajima², Dustin Kiker³, Rajarshi Banerjee¹, Andrea Dennis¹

54.

The Diabetes Syndrome - A Collection of Conditions with Common, Interrelated Pathophysiologic Mechanisms

Int J Gen Med. 2021 Mar 18;14:923-936. doi: 10.2147/IJGM.S305156. eCollection 2021.

Amy W Rachfal¹, Struan F A Grant^2 3 4, Stanley S Schwartz^5 6

55.

Experimental and Investigational Targeted Therapies for the Management of Fibrosis in NASH: An Update

J Exp Pharmacol. 2021 Mar 18;13:329-338. doi: 10.2147/JEP.S265286.eCollection 2021.

Tsipora M Huisman¹, Douglas T Dieterich¹, Scott L Friedman¹

56.

Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes

Front Endocrinol (Lausanne). 2021 Mar 4;12:642432. doi: 10.3389/fendo.2021.642432.eCollection 2021.

Jacqueline Bayliss¹, Geraldine J Ooi², William De Nardo¹, Yazmin Johari Halim Shah², Magdalene K Montgomery¹, Catriona McLean³, William Kemp⁴, Stuart K Roberts⁴, Wendy A Brown², Paul R Burton², Matthew J Watt¹

57.

The prevalence of metabolic associated fatty liver detected by FibroScan® in women with gestational diabetes in a multiethnic population

Diabetes Res Clin Pract. 2021 Mar 17;174:108757. doi: 10.1016/j.diabres.2021.108757.Online ahead of print.

Difei Deng¹, Jacob George², Dharmintra Pasupathy³, N Wah Cheung⁴

58.

Endoplasmic Reticulum Stress and Autophagy in the Pathogenesis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Evidence and Perspectives

Curr Obes Rep. 2021 Mar 22. doi: 10.1007/s13679-021-00431-3.Online ahead of print.

Christina-Maria Flessa^1 2, Ioannis Kyrou^2 3 4, Narjes Nasiri-Ansari¹, Gregory Kaltsas⁵, Athanasios G Papavassiliou¹, Eva Kassi^6 7, Harpal S Randeva^8 9

59.

Alternative Etiologies of Liver Disease in Children With Suspected NAFLD

Pediatrics. 2021 Mar 30;147(4):e2020009829. doi: 10.1542/peds.2020-009829.Online ahead of print.

Toshifumi Yodoshi¹, Sarah Orkin¹, Ana Catalina Arce-Clachar^1 2, Kristin Bramlage¹, Stavra A Xanthakos^1 2, Pamela L Valentino³, Marialena Mouzaki^4 2

60.

LI-RADS v2018 major criteria: Do hepatocellular carcinomas in non-alcoholic steatohepatitis differ from those in virus-induced chronic liver disease on MRI?

Eur J Radiol. 2021 Mar 11;138:109651. doi: 10.1016/j.ejrad.2021.109651. Online ahead of print.

Maxime Barat¹, Thi Thuy Linh Nguyen², Clémence Hollande³, Jean-Baptiste Coty⁴, Christine Hoeffel⁵, Benoit Terris⁶, Anthony Dohan⁴, Vincent Mallet³, Stanislas Pol³, Philippe Soyer⁴

61.

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Nature. 2021 Mar 24. doi: 10.1038/s41586-021-03362-0. Online ahead of print.

Dominik Pfister^1 2, Nicolás Gonzalo Núñez³, Roser Pinyol⁴, Olivier Govaere⁵, Matthias Pinter^6 7, Marta Szydlowska¹, Revant Gupta^8 9, Mengjie Qiu¹⁰, Aleksandra Deczkowska¹¹, Assaf Weiner¹¹, Florian Müller¹, Ankit Sinha^12 13, Ekaterina Friebel³, Thomas Engleitner^14 15 16, Daniela Lenggenhager¹⁷, Anja Moncsek¹⁸, Danijela Heide¹, Kristin Stirm¹, Jan Kosla¹, Eleni Kotsiliti¹, Valentina Leone^1 19, Michael Dudek²⁰, Suhail Yousuf¹⁰, Donato Inverso^21 22, Indrabahadur Singh^1 23, Ana Teijeiro²⁴, Florian Castet⁴, Carla Montironi⁴, Philipp K Haber²⁵, Dina Tiniakos^5 26, Pierre Bedossa⁵, Simon Cockell²⁷, Ramy Younes^5 28, Michele Vacca²⁹, Fabio Marra³⁰, Jörn M Schattenberg³¹, Michael Allison³², Elisabetta Bugianesi²⁸, Vlad Ratziu³³, Tiziana Pressiani³⁴, Antonio D'Alessio³⁴, Nicola Personeni^34 35, Lorenza Rimassa^34 35, Ann K Daly⁵, Bernhard Scheiner^6 7, Katharina Pomej^6 7, Martha M Kirstein^36 37, Arndt Vogel³⁶, Markus Peck-Radosavljevic³⁸, Florian Hucke³⁸, Fabian Finkelmeier³⁹, Oliver Waidmann³⁹, Jörg Trojan³⁹, Kornelius Schulze⁴⁰, Henning Wege⁴⁰, Sandra Koch⁴¹, Arndt Weinmann⁴¹, Marco Bueter⁴², Fabian Rössler⁴², Alexander Siebenhüner⁴³, Sara De Dosso⁴⁴, Jan-Philipp Mallm⁴⁵, Viktor Umansky^46 47, Manfred Jugold⁴⁸, Tom Luedde⁴⁹, Andrea Schietinger^50 51, Peter Schirmacher⁵², Brinda Emu¹, Hellmut G Augustin^21 22, Adrian Billeter⁵³, Beat Müller-Stich⁵³, Hiroto Kikuchi⁵⁴, Dan G Duda⁵⁴, Fabian Kütting⁵⁵, Dirk-Thomas Waldschmidt⁵⁵, Matthias Philip Ebert⁵⁶, Nuh Rahbari⁵⁷, Henrik E Mei⁵⁸, Axel Ronald Schulz⁵⁸, Marc Ringelhan^59 60 61, Nisar Malek⁶², Stephan Spahn⁶², Michael Bitzer⁶², Marina Ruiz de Galarreta^25 63, Amaia Lujambio^25 63 64, Jean-Francois Dufour^65 66, Thomas U Marron^25 67, Ahmed Kaseb⁶⁸, Masatoshi Kudo⁶⁹, Yi-Hsiang Huang^70 71, Nabil Djouder²⁴, Katharina Wolter^72 73, Lars Zender^72 73 74, Parice N Marche^75 76, Thomas Decaens^75 76 77, David J Pinato^78 79, Roland Rad^14 15 16, Joachim C Mertens¹⁸, Achim Weber^17 80, Kristian Unger¹⁹, Felix Meissner¹², Susanne Roth¹⁰, Zuzana Macek Jilkova^75 76 78, Manfred Claassen^8 9, Quentin M Anstee^5 81, Ido Amit¹¹, Percy Knolle²⁰, Burkhard Becher³, Josep M Llovet^82 83 84, Mathias Heikenwalder⁸⁵

Affiliations collapse

62.

Bariatric Surgery Reduces Cancer Risk in Adults with Nonalcoholic Fatty Liver Disease and Severe Obesity

Gastroenterology. 2021 Mar 17;S0016-5085(21)00529-1. doi: 10.1053/j.gastro.2021.03.021.Online ahead of print.

Vinod K Rustgi¹, You Li², Kapil Gupta², Carlos D Minacapelli², Abhishek Bhurwal², Carolyn Catalano², Mohamed I Elsaid²

63.

The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk

Curr Diab Rep. 2021 Mar 19;21(5):15. doi: 10.1007/s11892-021-01383-7.

Cyrielle Caussy¹, Adrien Aubin², Rohit Loomba^3 4 5

64.

Sex differences in NAFLD: estrogen influence on the liver-adipose tissue crosstalk

Antioxid Redox Signal. 2021 Mar 19. doi: 10.1089/ars.2021.0044. Online ahead of print.

Andrea Morán-Costoya^1 2, Ana María Proenza^1 3 4, Magdalena Gianotti^5 3 6, Isabel Lladó^1 3 7, Adamo Valle^1 3 8

65.

Ten Thousand Points of Light - Heterogeneity Among the Stars of NASH Fibrosis

Hepatology. 2021 Mar 16.doi: 10.1002/hep.31807. Online ahead of print.

James Carter¹, Shuang Wang¹, Scott L Friedman¹

66.

The clinical impact of cirrhosis on the postoperative outcomes of patients undergoing bariatric surgery: propensity score-matched analysis of 2011-2017 US hospitals

Expert Rev Gastroenterol Hepatol. 2021 Mar 12. doi: 10.1080/17474124.2021.1902803.Online ahead of print.

David Uihwan Lee¹, Gregory Hongyuan Fan¹, David Jeffrey Hastie¹, Elyse Ann Addonizio¹, Vibhav Narayan Prakasam¹, Ryan Richard Ahern¹, Kristen Jin Seog¹, Raffi Karagozian¹

67.

Awareness of non-alcoholic steatohepatitis and treatment guidelines: What are physicians telling us?

World J Hepatol. 2021 Feb 27;13(2):233-241. doi: 10.4254/wjh.v13.i2.233.

David Hermanus Wessels¹, Zeil Rosenberg²

68.

Coronary artery disease and non-alcoholic fatty liver disease: Clinical correlation using computed tomography coronary calcium scans

JGH Open. 2021 Feb 19;5(3):390-395. doi: 10.1002/jgh3.12509. eCollection 2021 Mar.

Richard S Kirby¹, Dina Halegoua-DeMarzio²

69.

Increased adipose tissue fibrogenesis, not impaired expandability, is associated with nonalcoholic fatty liver disease

Hepatology. 2021 Mar 20. doi: 10.1002/hep.31822. Online ahead of print.

Joseph W Beals¹, Gordon I Smith¹, Mahalakshmi Shankaran², Anja Fuchs³, George G Schweitzer¹, Jun Yoshino¹, Tyler Field², Marcy Matthews², Edna Nyangau², Darya Morozov⁴, Bettina Mittendorfer¹, Marc K Hellerstein², Samuel Klein¹

70.

European 'NAFLD Preparedness Index' - Is Europe ready to meet the challenge of fatty liver disease?

JHEP Rep. 2021 Jan 21;3(2):100234. doi: 10.1016/j.jhepr.2021.100234. eCollection 2021 Apr.

Jeffrey V Lazarus¹, Adam Palayew², Patrizia Carrieri³, Mattias Ekstedt⁴, Giulio Marchesini⁵, Katja Novak⁶, Vlad Ratziu⁷, Manuel Romero-Gómez⁸, Frank Tacke⁹, Shira Zelber-Sagi¹⁰, Helena Cortez-Pinto¹¹, Quentin M Anstee^12 13

71.

Treatment candidacy for pharmacologic therapies for NASH

Clin Gastroenterol Hepatol. 2021 Mar 9;S1542-3565(21)00228-7.doi: 10.1016/j.cgh.2021.03.005. Online ahead of print.

Ian A Rowe¹, Vincent Wai-Sun Wong², Rohit Loomba³

72.

The Impact of Macronutrient Intake on Non-alcoholic Fatty Liver Disease (NAFLD): Too Much Fat, Too Much Carbohydrate, or Just Too Many Calories?

Front Nutr. 2021 Feb 16;8:640557. doi: 10.3389/fnut.2021.640557. eCollection 2021.

Theresa Hydes^1 2, Uazman Alam^1 2, Daniel J Cuthbertson^1 2

73.

Treatments for NAFLD: State of Art

Int J Mol Sci. 2021 Feb 26;22(5):2350. doi: 10.3390/ijms22052350.

Alessandro Mantovani¹, Andrea Dalbeni²

74.

The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis

Contemp Clin Trials. 2021 Feb 28;106335. doi: 10.1016/j.cct.2021.106335. Online ahead of print.

Manal F Abdelmalek¹, Edgar D Charles², Arun J Sanyal³, Stephen A Harrison⁴, Brent A Neuschwander-Tetri⁵, Zachary Goodman⁶, Richard A Ehman⁷, Morten Karsdal⁸, Atsushi Nakajima⁹, Shuyan Du¹⁰, Giridhar S Tirucherai¹⁰, George H Klinger¹⁰, Johanna Mora¹⁰, Masayuki Yamaguchi¹⁰, Diane E Shevell¹⁰, Rohit Loomba¹¹

75.

Artificial Intelligence in NASH Histology: Human Teaches a Machine for the Machine to help Humans

Hepatology. 2021 Feb 26. doi: 10.1002/hep.31777. Online ahead of print.

Mazen Noureddin^1 2 3 4

76.

Case-finding strategies in non-alcoholic fatty liver disease

JHEP Rep. 2020 Dec 5;3(2):100219. doi: 10.1016/j.jhepr.2020.100219.eCollection 2021 Apr.

Jerome Boursier^1 2, Emmanuel A Tsochatzis^3 4

77.

Evaluation of a primary to secondary care referral pathway and novel nurse-led one-stop clinic for patients with suspected non-alcoholic fatty liver disease

Frontline Gastroenterol. 2020 Apr 7;12(2):102-107. doi: 10.1136/flgastro-2019-101304.eCollection 2021.

Andrew J Fowell¹, Kirsty Fancey¹, Karen Gamble¹, Kelly Bicknell², Joanna K Dowman¹, Paul Howden³, Richard J Aspinall¹

78.

Non-alcoholic fatty liver disease and cognitive function in middle-aged adults: the CARDIA study

BMC Gastroenterol. 2021 Mar 2;21(1):96. doi: 10.1186/s12876-021-01681-0.

Yariv Gerber^1 2 3, Lisa B VanWagner⁴, Kristine Yaffe⁵, James G Terry⁶, Jamal S Rana^7 5, Jared P Reis⁸, Stephen Sidney⁷

79.

Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease

Obes Surg. 2021 Feb 22. doi: 10.1007/s11695-020-04996-1. Online ahead of print.

Saleh A Alqahtani^1 2 3, Pegah Golabi^4 5, James M Paik^4 5, Brian Lam⁴, Amir H Moazez⁵, Hazem A Elariny⁵, Zachary Goodman⁴, Zobair M Younossi^6 7

80.

TLR9 in MAFLD and NASH: At the Intersection of Inflammation and Metabolism

Front Endocrinol (Lausanne). 2021 Jan 29;11:613639.doi: 10.3389/fendo.2020.613639. eCollection 2020.

Christopher R Shepard¹

81.

Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis

Front Endocrinol (Lausanne). 2021 Jan 27;11:575843. doi: 10.3389/fendo.2020.575843.eCollection 2020.

Andrea Dennis¹, Matt D Kelly¹, Carolina Fernandes¹, Sofia Mouchti¹, Jonathan A Fallowfield², Gideon Hirschfield³, Michael Pavlides^4 5 6, Stephen Harrison^4 7, Manu V Chakravarthy⁸, Rajarshi Banerjee¹, Arun Sanyal⁹

82.

Therapy for Nonalcoholic Fatty Liver Disease: Current Options and Future Directions

Clin Ther. 2021 Feb 11;S0149-2918(21)00048-5. doi: 10.1016/j.clinthera.2021.01.021.Online ahead of print.

Patrick Campbell¹, Allison Symonds², A Sidney Barritt 4th³

83.

Association of liver fibrosis risk scores with clinical outcomes in patients with heart failure with preserved ejection fraction: findings from TOPCAT

ESC Heart Fail. 2021 Feb 14. doi: 10.1002/ehf2.13250. Online ahead of print.

Anthony E Peters¹, Ambarish Pandey², Colby Ayers², Kara Wegermann³, Robert W McGarrah¹, Justin L Grodin², Manal F Abdelmalek³, Tarek Bekfani⁴, Vanessa L Blumer¹, Anna Mae Diehl³, Cynthia A Moylan³, Marat Fudim¹

84.

Noninvasive Evaluation for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

Clin Ther. 2021 Feb 10;S0149-2918(21)00016-3. doi: 10.1016/j.clinthera.2021.01.012.Online ahead of print.

Shannon Kogachi¹, Mazen Noureddin²

85.

A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis

J Hepatol. 2021 Feb 10;S0168-8278(21)00099-4. doi: 10.1016/j.jhep.2021.01.047.Online ahead of print.

Stephen A Harrison¹, Mustafa R Bashir², Kyoung-Jin Lee³, Jennifer Shim-Lopez³, Jonathan Lee³, Brandee Wagner³, Nicholas D Smith³, Hubert C Chen⁴, Eric J Lawitz⁵

86.

Insulin resistance dysregulates CYP7B1 leading to oxysterol accumulation: a pathway for NAFL to NASH transition

J Lipid Res. 2020 Dec;61(12):1629-1644. doi: 10.1194/jlr.RA120000924. Epub 2021 Jan 12.

Genta Kakiyama¹, Dalila Marques², Rebecca Martin³, Hajime Takei⁴, Daniel Rodriguez-Agudo², Sandra A LaSalle⁵, Taishi Hashiguchi⁶, Xiaoying Liu⁷, Richard Green⁷, Sandra Erickson⁸, Gregorio Gil⁹, Michael Fuchs², Mitsuyoshi Suzuki¹⁰, Tsuyoshi Murai¹¹, Hiroshi Nittono⁴, Phillip B Hylemon¹², Huiping Zhou¹², William M Pandak¹³

87.

Editorial: Emerging metabolic and transcriptomic signature of PNPLA3 associated NASH

Hepatology. 2021 Feb 5. doi: 10.1002/hep.31735. Online ahead of print.

Debanjan Dhar¹, Rohit Loomba^1 2 3

88.

Renaming NAFLD to MAFLD: Could the LDE System Assist in This Transition?

J Clin Med. 2021 Jan 31;10(3):492. doi: 10.3390/jcm10030492.

Amedeo Lonardo¹

89.

Tumor Incidence in Patients with Non-Alcoholic Fatty Liver Disease

Dtsch Arztebl Int. 2020 Oct 23;117(43):719-724. doi: 10.3238/arztebl.2020.0719.

Yvonne Huber¹, Christian Labenz, Maurice Michel, Marcus-A Wörns, Peter R Galle, Karel Kostev, Jörn M Schattenberg

90.

Detecting non-alcoholic fatty liver disease and risk factors in health databases: accuracy and limitations of the ICD-10-AM

BMJ Open Gastroenterol. 2021 Feb;8(1):e000572. doi: 10.1136/bmjgast-2020-000572.

Kelly Lee Hayward^1 2, Amy L Johnson^1 2, Leigh U Horsfall^1 2, Chris Moser³, Patricia C Valery^# 1 4, Elizabeth E Powell^# 5 2

91.

NAFLD-related HCC

Adv Cancer Res. 2021;149:143-169. doi: 10.1016/bs.acr.2020.11.001. Epub 2021 Jan 21.

Bubu A Banini¹, Arun J Sanyal²

92.

A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH

Hepatology. 2021 Feb 11. doi: 10.1002/hep.31750. Online ahead of print.

Amaro Taylor-Weiner¹, Harsha Pokkalla¹, Ling Han², Catherine Jia², Ryan Huss², Chuhan Chung², Hunter Elliott¹, Benjamin Glass¹, Kishalve Pethia¹, Oscar Carrasco-Zevallos¹, Chinmay Shukla¹, Urmila Khettry³, Robert Najarian⁴, Ross Taliano⁵, G Mani Subramanian², Robert P Myers², Ilan Wapinski¹, Aditya Khosla¹, Murray Resnick^1 5, Michael C Montalto¹, Quentin M Anstee⁶, Vincent Wai-Sun Wong⁷, Michael Trauner⁸, Eric J Lawitz⁹, Stephen A Harrison¹⁰, Takeshi Okanoue¹¹, Manuel Romero-Gomez¹², Zachary Goodman^13 14, Rohit Loomba¹⁵, Andrew H Beck¹, Zobair M Younossi^13 14

93.

Human Nonalcoholic Steatohepatitis on a Chip

Hepatol Commun. 2020 Nov 29;5(2):217-233. doi: 10.1002/hep4.1647. eCollection 2021 Feb.

May S Freag^1 2, Bumseok Namgung^1 2, Maria E Reyna Fernandez^1 2, Ermanno Gherardi³, Shiladitya Sengupta^1 2 4, Hae Lin Jang¹

94.

Nonalcoholic Fatty Liver Disease Screening in Type 2 Diabetes Mellitus Patients in the Primary Care Setting

Hepatol Commun. 2020 Oct 31;5(2):158-167. doi: 10.1002/hep4.1618.eCollection 2021 Feb.

Joana Vieira Barbosa^1 2, Michelle Lai¹

95.

Genetic Contribution to Non-alcoholic Fatty Liver Disease and Prognostic Implications

Curr Diab Rep. 2021 Feb 5;21(3):8. doi: 10.1007/s11892-021-01377-5.

Katherine Martin^1 2 3, Anas Hatab^4 5, Varinder S Athwal^4 5 6, Elliot Jokl^4 5, Karen Piper Hanley^7 8

96.

Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?

Gut. 2021 Feb 4;gutjnl-2020-322564. doi: 10.1136/gutjnl-2020-322564. Online ahead of print.

Ramy Younes^1 2 3, Olivier Govaere¹, Salvatore Petta⁴, Luca Miele^5 6, Dina Tiniakos^1 7, Alastair Burt¹, Ezio David³, Fabio Maria Vecchio^5 8, Marco Maggioni⁹, Daniela Cabibi¹⁰, Duncan McLeod¹¹, Maria Jesus Pareja¹², Anna Ludovica Fracanzani¹³, Rocio Aller¹⁴, Chiara Rosso³, Javier Ampuero¹⁵, Rocío Gallego-Durán¹⁵, Angelo Armandi³, Gian Paolo Caviglia³, Marco Y W Zaki^1 16, Antonio Liguori⁵, Paolo Francione¹³, Grazia Pennisi⁴, Antonio Grieco^5 6, Giovanni Birolo³, Piero Fariselli³, Mohammed Eslam¹⁷, Luca Valenti¹⁸, Jacob George¹⁷, Manuel Romero-Gómez¹⁵, Quentin Mark Anstee^19 20, Elisabetta Bugianesi²¹

97.

Serum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non-alcoholic fatty liver disease

Sci Rep. 2021 Feb 3;11(1):2858. doi: 10.1038/s41598-021-82315-z.

Katharine M Irvine^# 1 2, Satomi Okano^# 3, Preya J Patel^4 5, Leigh U Horsfall^4 6, Suzanne Williams⁷, Anthony Russell^8 9, Elizabeth E Powell^10 11

98.

Administrative coding in electronic health care record-based research of NAFLD: an expert panel consensus statement

Hepatology. 2021 Jan 23. doi: 10.1002/hep.31726. Online ahead of print.

Hannes Hagström^1 2 3, Leon A Adams⁴, Alina M Allen⁵, Christopher D Byrne^6 7, Yoosoo Chang⁸, Henning Grønbaek⁹, Mona Ismail^10 11, Peter Jepsen⁹, Fasiha Kanwal¹², Jennifer Kramer¹², Jeffrey V Lazarus¹³, Michelle T Long¹⁴, Rohit Loomba¹⁵, Philip N Newsome^16 17, Ian A Rowe¹⁸, Seungho Ryu^8 19, Jörn M Schattenberg²⁰, Marina Serper²¹, Nick Sheron²², Tracey G Simon^23 24, Elliot B Tapper²⁵, Sarah Wild²⁶, Vincent Wai-Sun Wong²⁷, Yusuf Yilmaz^28 29, Shira Zelber-Sagi³⁰, Fredrik Åberg^31 32

99.

NAFLD as a metabolic disease in humans: A literature review

Diabetes Obes Metab. 2021 Jan 19. doi: 10.1111/dom.14322. Online ahead of print.

Bertrand Cariou¹, Christopher D Byrne², Rohit Loomba³, Arun J Sanyal⁴

100.

Pathophysiology of NASH in endocrine diseases

Endocr Connect. 2021 Jan 1;EC-20-0490.R1. doi: 10.1530/EC-20-0490.Online ahead of print.

Karim Gariani¹, François R Jornayvaz²

101.

Adherence to Ideal Cardiovascular Health Metrics Is Associated With Reduced Odds of Hepatic Steatosis

Hepatol Commun. 2020 Oct 10;5(1):74-82. doi: 10.1002/hep4.1614. eCollection 2021 Jan.

Leah R DeCoste¹, Na Wang², Joseph N Palmisano², Jean Mendez³, Udo Hoffmann⁴, Emelia J Benjamin^5 6 7, Michelle T Long³

102.

Association of liver enzymes with incident diabetes in US Hispanic/Latino adults

Diabet Med. 2021 Jan 12;e14522. doi: 10.1111/dme.14522. Online ahead of print.

Simin Hua¹, Qibin Qi¹, Jorge R Kizer², Jessica Williams-Nguyen³, Howard D Strickler¹, Bharat Thyagarajan⁴, Martha Daviglus⁵, Gregory A Talavera⁶, Neil Schneiderman⁷, Scott J Cotler⁸, Jianwen Cai⁹, Robert Kaplan^1 3, Carmen R Isasi¹

103.

Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease

Diagnostics (Basel). 2021 Jan 9;11(1):E98. doi: 10.3390/diagnostics11010098.

Stefano Ballestri¹, Alessandro Mantovani², Enrica Baldelli³, Simonetta Lugari⁴, Mauro Maurantonio⁴, Fabio Nascimbeni⁴, Alessandra Marrazzo¹, Dante Romagnoli⁵, Giovanni Targher², Amedeo Lonardo⁶

104.

Liver Fat Quantification by Ultrasound in Children: A Prospective Study

AJR Am J Roentgenol. 2021 Jan 13. doi: 10.2214/AJR.20.24874. Online ahead of print.

Aurélie D'Hondt¹, Erika Rubesova¹, Hua Xie², Vijay Shamdasani³, Richard A Barth¹

105.

Metabolic associated fatty liver disease: Addressing a new era in liver transplantation

World J Hepatol. 2020 Dec 27;12(12):1168-1181. doi: 10.4254/wjh.v12.i12.1168

Madeleine G Gill¹, Avik Majumdar¹

106.

Digital Intervention With Lifestyle Coach Support to Target Dietary and Physical Activity Behaviors of Adults With Nonalcoholic Fatty Liver Disease: Systematic Development Process of VITALISE Using Intervention Mapping

J Med Internet Res. 2021 Jan 15;23(1):e20491. doi: 10.2196/20491.

Kate Hallsworth^1 2 3, Stuart McPherson^1 2 3, Quentin M Anstee^1 2 3, Darren Flynn⁴, Laura Haigh^1 2 3, Leah Avery^3 4

107.

Ceramide Salvage, Gut Mucosal IgA Signaling, and Diet-Induced NASH

Hepatology. 2021 Jan 15. doi: 10.1002/hep.31707. Online ahead of print.

Scott A McHenry¹, Nicholas O Davidson¹

108.

Gut microbiome changes in Nonalcoholic fatty liver disease & alcoholic liver disease

Transl Gastroenterol Hepatol. 2021 Jan 5;6:3. doi: 10.21037/tgh.2020.02.18.eCollection 2021.

Eric K Kwong¹, Puneet Puri^2 3

109.

Basic science to clinical trials in non-alcoholic fatty liver disease and alcohol-related liver disease: collaboration with industry

Transl Gastroenterol Hepatol. 2021 Jan 5;6:5. doi: 10.21037/tgh.2020.01.04.eCollection 2021.

Amon Asgharpour¹, Amreen Dinani¹, Scott L Friedman¹

110.

Maternal Diet Alters Trained Immunity in the Pathogenesis of Pediatric NAFLD

J Cell Immunol. 2020;2(6):315-325. doi: 10.33696/immunology.2.061.

Karen R Jonscher^1 2, Jesse Abrams², Jacob E Friedman^2 3

111.

Non-alcoholic Fatty Liver and Liver Fibrosis Predictive Analytics: Risk Prediction and Machine Learning Techniques for Improved Preventive Medicine

J Med Syst. 2021 Jan 11;45(2):22. doi: 10.1007/s10916-020-01693-5.

Orit Goldman¹, Ofir Ben-Assuli², Ori Rogowski³, David Zeltser³, Itzhak Shapira³, Shlomo Berliner³, Shira Zelber-Sagi^4 5, Shani Shenhar-Tsarfaty³

112.

Efficacy and Safety of Intragastric Balloon (IGB) in Non-alcoholic Fatty Liver Disease (NAFLD): a Comprehensive Review and Meta-analysis

Obes Surg. 2021 Jan 6. doi: 10.1007/s11695-020-05084-0. Online ahead of print.

Saurabh Chandan¹, Babu P Mohan², Shahab R Khan³, Antonio Facciorusso⁴, Daryl Ramai⁵, Lena L Kassab⁶, Neil Bhogal⁷, Ravishankar Asokkumar⁸, Gortrand Lopez-Nava⁸, Stephanie McDonough², Douglas G Adler⁹

113.

Dietary approaches to managing nonalcoholic fatty liver disease

Nurse Pract. 2020 Dec 31;Publish Ahead of Print. doi: 10.1097/01.NPR.0000731560.23509.ff.Online ahead of print.

Dalia El Khoury¹, Rosemary J Pauley, Carol Lynn Berseth

114.

Lean NAFLD: an underrecognized and challenging disorder in medicine

Rev Endocr Metab Disord. 2021 Jan 3. doi: 10.1007/s11154-020-09621-1.Online ahead of print.

Sheila Maier¹, Amanda Wieland², Melanie Cree-Green³, Kristen Nadeau³, Shelby Sullivan⁴, Miguel A Lanaspa⁵, Richard J Johnson⁵, Thomas Jensen^6 7

115.

Cannabis use history is associated with increased prevalence of ascites among patients with nonalcoholic fatty liver disease: A nationwide analysis

World J Hepatol. 2020 Nov 27;12(11):993-1003. doi: 10.4254/wjh.v12.i11.993.

Catherine J Choi¹, Stanley H Weiss², Umair M Nasir¹, Nikolaos T Pyrsopoulos³

116.

Insulin Resistance is Mechanistically Linked to Hepatic Mitochondrial Remodeling in Nonalcoholic Fatty Liver Disease

Mol Metab. 2020 Dec 22;101154. doi: 10.1016/j.molmet.2020.101154. Online ahead of print.

Chris E Shannon¹, Mukundan Ragavan², Juan Pablo Palavicini³, Marcel Fourcaudot¹, Terry Bakewell¹, Ivan A Valdez¹, Iriscilla Ayala¹, Eunsook S Jin⁴, Muniswamy Madesh⁵, Xianlin Han⁶, Matthew E Merritt², Luke Norton⁷

117.

Glycogenosis is Common in Nonalcoholic Fatty Liver Disease and is Independently Associated with Ballooning, but Lower Steatosis and Lower Fibrosis

Liver Int. 2020 Dec 22. doi: 10.1111/liv.14773. Online ahead of print.

Daniela S Allende¹, Samer Gawrieh², Oscar W Cummings³, Patricia Belt⁴, Laura Wilson⁴, Mark Van Natta⁴, Cynthia A Behling⁵, Danielle Carpenter⁶, Ryan M Gill⁷, David E Kleiner⁸, Mathew M Yeh⁹, Naga Chalasani², Cynthia D Guy¹⁰, NASH Clinical Research Network

118.

Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steato-hepatitis: a hierarchical network meta-analysis

Diabetes Obes Metab. 2020 Dec 23. doi: 10.1111/dom.14304. Online ahead of print.

Simona Panunzi¹, Sabina Maltese², Ornella Verrastro^3 4, Luca Labbate², Andrea De Gaetano¹, Maurizio Pompili^3 4, Esmeralda Capristo^3 4, Stefan R Bornstein^5 6, Geltrude Mingrone^3 4 6

119.

FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases

Front Endocrinol (Lausanne). 2020 Dec 14;11:601290.doi: 10.3389/fendo.2020.601290. eCollection 2020.

Erik J Tillman¹, Tim Rolph¹

120.

Development of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative Study

Patient. 2020 Dec 18. doi: 10.1007/s40271-020-00485-w. Online ahead of print.

Lynda C Doward¹, Maria-Magdalena Balp², James Twiss³, Christina Slota⁴, Donna Cryer⁵, Clifford A Brass⁶, Quentin M Anstee^7 8, Arun J Sanyal⁹

121.

Metabolic drivers of non-alcoholic fatty liver disease

Mol Metab. 2020 Dec 17;101143. doi: 10.1016/j.molmet.2020.101143. Online ahead of print.

Kendra K Bence¹, Morris J Birnbaum²

122.

Incidence of Depression and Anxiety in a Cohort of Adolescents with Nonalcoholic Fatty Liver Disease

J Pediatr Gastroenterol Nutr. 2020 Dec 16;Publish Ahead of Print.doi: 10.1097/MPG.0000000000003024. Online ahead of print.

Sheila Noon¹, Danielle D'Annibale, Melanie Schwimmer, Jacqueline Shiels, Jennifer Arin, Janis Durelle, Kimberly Newton, Nidhi Goyal, Jeffrey Schwimmer

123.

Evaluation of Non-Alcoholic Fatty Liver Disease in Pediatric Patients with Inflammatory Bowel Disease

J Pediatr Gastroenterol Nutr. 2020 Dec 16;Publish Ahead of Print.doi: 10.1097/MPG.0000000000003023. Online ahead of print.

Mallory E Cohen¹, Parakkal Deepak, Geetika Khanna, Charles M Samson

124.

Prevalence and risk factors of nonalcoholic fatty liver disease in patients with inflammatory bowel diseases: A cross-sectional and longitudinal analysis

World J Gastroenterol. 2020 Dec 14;26(46):7367-7381. doi: 10.3748/wjg.v26.i46.7367.

Peter Hoffmann¹, Victoria Jung², Rouven Behnisch³, Annika Gauss²

125.

Non-alcoholic fatty liver disease - a special consideration in TIPS?

Liver Transpl. 2020 Dec 21. doi: 10.1002/lt.25976. Online ahead of print.

Sarah Wang¹, Juan G Abraldes¹

126.

A large-scale internal validation study of unsupervised virtual trichrome staining technologies on nonalcoholic steatohepatitis liver biopsies

Mod Pathol. 2020 Dec 9. doi: 10.1038/s41379-020-00718-1. Online ahead of print.

Joshua J Levy^1 2 3, Nasim Azizgolshani⁴, Michael J Andersen Jr⁵, Arief Suriawinata⁵, Xiaoying Liu⁵, Mikhail Lisovsky⁵, Bing Ren⁵, Carly A Bobak^6 7 8 9, Brock C Christensen^4 10 11, Louis J Vaickus⁵

127.

Current Concepts, Opportunities, and Challenges of Gut Microbiome-Based Personalized Medicine in Nonalcoholic Fatty Liver Disease

Cell Metab. 2020 Dec 3;S1550-4131(20)30605-7. doi: 10.1016/j.cmet.2020.11.010.Online ahead of print.

S R Sharpton¹, B Schnabl², R Knight³, R Loomba⁴

128.

NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment

Diabetes Metab. 2020 Dec 6;101215. doi: 10.1016/j.diabet.2020.101215.Online ahead of print.

Giovanni Targher¹, Kathleen E Corey², Christopher D Byrne^3a

129.

The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease

Clin Mol Hepatol. 2020 Dec 10. doi: 10.3350/cmh.2020.0129. Online ahead of print.

Erica Jennison¹, Christopher D Byrne^2 3

130.

Emerging Therapies for the Treatment of Non-Alcoholic Steatohepatitis: A Systematic Review

Pharmacotherapy. 2020 Dec 5. doi: 10.1002/phar.2489. Online ahead of print.

Erenie Guirguis¹, Yasmin Grace¹, Anthony Bolson¹, Matthew J DellaVecchia¹, Melissa Ruble²

131.

Fibrosis progression rate in a systematic review of placebo-treated nonalcoholic steatohepatitis

Liver Int. 2020 Dec 7. doi: 10.1111/liv.14749. Online ahead of print.

Anna Roskilly¹, Amy Hicks¹, Eleanor J Taylor¹, Rebecca Jones¹, Richard Parker¹, Ian A Rowe^1 2

132.

Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations

Am J Gastroenterol. 2020 Dec 7. doi: 10.14309/ajg.0000000000001054. Online ahead of print.

Zobair M Younossi¹, Mazen Noureddin², David Bernstein³, Paul Kwo⁴, Mark Russo⁵, Mitchell L Shiffman⁶, Ziad Younes⁷, Manal Abdelmalek⁸

133.

Regulation of gene transcription by thyroid hormone receptor ß agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH)

PLoS One. 2020 Dec 11;15(12):e0240338. doi: 10.1371/journal.pone.0240338. eCollection 2020.

Xuan G Luong¹, Sarah K Stevens¹, Andreas Jekle¹, Tse-I Lin², Kusum Gupta¹, Dinah Misner¹, Sushmita Chanda¹, Sucheta Mukherjee¹, Caroline Williams¹, Antitsa Stoycheva¹, Lawrence M Blatt¹, Leonid N Beigelman¹, Julian A Symons¹, Pierre Raboisson², David McGowan², Koen Vandyck², Jerome Deval¹

134.

The Association of Histologic and Non-invasive Tests with Adverse Clinical and Patient-Reported Outcomes in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH)

Gastroenterology. 2020 Dec 8;S0016-5085(20)35529-3. doi: 10.1053/j.gastro.2020.12.003.Online ahead of print.

Zobair M Younossi¹, Quentin M Anstee², Vincent Wai-Sun Wong³, Michael Trauner⁴, Eric J Lawitz⁵, Stephen A Harrison⁶, Marianne Camargo⁷, Kathryn Kersey⁷, G Mani Subramanian⁷, Robert P Myers⁷, Maria Stepanova⁸

135.

Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression

Metabolism. 2020 Dec 1;154457. doi: 10.1016/j.metabol.2020.154457. Online ahead of print.

Nisreen Nimer¹, Ibrahim Choucair², Zeneng Wang², Ina Nemet², Lin Li², Janet Gukasyan³, Taylor L Weeks², Naim Alkhouri⁴, Nizar Zein⁵, W H Wilson Tang⁶, Michael A Fischbach⁵, J Mark Brown², Hooman Allayee³, Srinivasan Dasarathy⁷, Valentin Gogonea⁸, Stanley L Hazen⁹

136.

Microbiome Biomarkers: One Step Closer in NAFLD-Cirrhosis

Hepatology. 2020 Nov 29. doi: 10.1002/hep.31660. Online ahead of print.

Tracey G Simon^1 2 3, Andrew T Chan^{1 2 3 4 5 6}, Curtis Huttenhower^5 6 7

137.

Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver

Curr Hypertens Rev. 2020 Dec 9. doi: 10.2174/1573402116999201209203534.Online ahead of print.

Eddison Godinez-Leiva¹, Fernando Bril²

138.

The Growing Burden of Disability Related to Nonalcoholic Fatty Liver Disease: Data From the Global Burden of Disease 2007-2017

Hepatol Commun. 2020 Sep 14;4(12):1769-1780. doi: 10.1002/hep4.1599. eCollection 2020 Dec.

James M Paik¹, Pegah Golabi¹, Youssef Younossi², Manirath Srishord¹, Alita Mishra³, Zobair M Younossi¹³

139.

AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease (NAFLD): Expert Review

Gastroenterology. 2020 Dec 8;S0016-5085(20)35538-4.doi: 10.1053/j.gastro.2020.11.051. Online ahead of print.

Zobair M Younossi¹, Kathleen E Corey², Joseph K Lim³

140.

Epidemiology and natural history of non-alcoholic fatty liver disease

Metabolism. 2016 Aug;65(8):1017-25. doi: 10.1016/j.metabol.2016.01.012.Epub 2016 Jan 29.

Yousef Fazel¹, Aaron B Koenig¹, Mehmet Sayiner¹, Zachary D Goodman², Zobair M Younossi³

141.

Liver Transplantation for NASH-Related Hepatocellular Carcinoma Versus Non-NASH Etiologies of Hepatocellular Carcinoma

Transplantation. 2018 Apr;102(4):640-647.doi: 10.1097/TP.0000000000002043.

Erin M Sadler^1 2, Neil Mehta³, Mamatha Bhat^1 4, Anand Ghanekar^1 2, Paul D Greig^1 2, David R Grant^1 2, Francis Yao³, Gonzalo Sapisochin^1 2

142.

A diabetologist

Liver Int. 2020 Feb;40 Suppl 1:82-88. doi: 10.1111/liv.14350.

Kenneth Cusi^1 2

143.

Non-alcoholic steatohepatitis (NASH): where are we now and where are we going?

Gut. 2002 May;50(5):585-8.doi: 10.1136/gut.50.5.585.

C P Day¹

144.

Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis: Data from the Scientific Registry of Transplant Recipients (SRTR): 1994 to 2016

Medicine (Baltimore). 2018 Aug;97(31):e11518.doi: 10.1097/MD.0000000000011518.

Pegah Golabi¹, Haley Bush¹, Maria Stepanova², Cameron T Locklear³, Ira M Jacobson⁴, Alita Mishra³, Gregory Trimble³, Madeline Erario³, Chapy Venkatesan³, Issah Younossi², Zachary Goodman^1 3, Zobair M Younossi^1 3

145.

Practice patterns in NAFLD and NASH: real life differs from published guidelines

Therap Adv Gastroenterol. 2016 Jan;9(1):4-12. doi: 10.1177/1756283X15611581.

Mary E Rinella¹, Zurabi Lominadze², Rohit Loomba³, Michael Charlton⁴, Brent A Neuschwander-Tetri⁵, Stephen H Caldwell⁶, Kris Kowdley⁷, Stephen A Harrison⁸

146.

Transient Versus 2-Dimensional Shear-Wave Elastography in a Multistep Strategy to Detect Advanced Fibrosis in NAFLD

Hepatology. 2020 Nov 24. doi: 10.1002/hep.31655. Online ahead of print.

Christophe Cassinotto^1 2, Jérome Boursier^3 4, Anita Paisant⁵, Boris Guiu¹, Marie Irles-Depe⁶, Clémence Canivet^3 4, Christophe Aube^4 5, Victor de Ledinghen⁶

147.

Can You Trust Your Gut? Implicating a Disrupted Intestinal Microbiome in the Progression of NAFLD/NASH

Front Endocrinol (Lausanne). 2020 Oct 21;11:592157.doi: 10.3389/fendo.2020.592157. eCollection 2020.

Kavita Jadhav¹, Taylor S Cohen¹

148.

Nonalcoholic Fatty Liver Disease: Common Questions and Answers on Diagnosis and Management

Am Fam Physician. 2020 Nov 15;102(10):603-612.

Erin Westfall¹, Robert Jeske¹, Andrew R Bader²

149.

GPCRs get Fatty: The Role of G Protein-Coupled Receptor Signaling in the Development and Progression of Nonalcoholic Fatty Liver Disease

Am J Physiol Gastrointest Liver Physiol. 2020 Nov 18. doi: 10.1152/ajpgi.00275.2020.Online ahead of print.

Ryan Kurtz¹, Meghan F Anderman¹, Blythe D Shepard¹

150.

NAFLD and COVID-19: a Pooled Analysis

SN Compr Clin Med. 2020 Nov 6;1-4. doi: 10.1007/s42399-020-00631-3. Online ahead of print.

Sonali Sachdeva¹, Harshwardhan Khandait², Jonathan Kopel³, Mark M Aloysius⁴, Rupak Desai⁵, Hemant Goyal⁴

151.

Genetic and epigenetic factors determining NAFLD risk

Mol Metab. 2020 Nov 4;101111. doi: 10.1016/j.molmet.2020.101111. Online ahead of print.

Wenke Jonas¹, Annette Schürmann²

152.

Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient-Reported Outcomes

Hepatol Commun. 2020 Aug 28;4(11):1637-1650. doi: 10.1002/hep4.1581. eCollection 2020 Nov.

Zobair M Younossi^1 2, Vincent Wai-Sun Wong³, Quentin M Anstee^4 5, Manuel Romero-Gomez⁶, Michael H Trauner⁷, Stephen A Harrison⁸, Eric J Lawitz⁹, Takeshi Okanoue¹⁰, Marianne Camargo¹¹, Kathryn Kersey¹¹, Robert P Myers¹¹, Zachary Goodman^1 2, Maria Stepanova¹²

153.

Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis due to NASH

Hepatology. 2020 Nov 10. doi: 10.1002/hep.31622. Online ahead of print.

Rohit Loomba¹, Mazen Noureddin², Kris V Kowdley³, Anita Kohli⁴, Aasim Sheikh⁵, Guy Neff⁶, Bal Raj Bhandari⁷, Nadege Gunn⁸, Stephen H Caldwell⁹, Zachary Goodman¹⁰, Ilan Wapinski¹¹, Murray Resnick¹¹, Andrew H Beck¹¹, Dora Ding¹², Catherine Jia¹², Jen-Chieh Chuang¹², Ryan S Huss¹², Chuhan Chung¹², G Mani Subramanian¹², Robert P Myers¹², Keyur Patel¹³, Brian B Borg¹⁴, Reem Ghalib¹⁵, Heidi Kabler¹⁶, John Poulos¹⁷, Ziad Younes¹⁸, Magdy Elkhashab¹⁹, Tarek Hassanein²⁰, Rajalakshmi Iyer²¹, Peter Ruane²², Mitchell L Shiffman²³, Simone Strasser²⁴, Vincent Wai-Sun Wong²⁵, Naim Alkhouri²⁶, ATLAS Investigators

154.

MRI-PDFF treatment response criteria in nonalcoholic steatohepatitis

Hepatology. 2020 Nov 11. doi: 10.1002/hep.31624. Online ahead of print.

Rohit Loomba^1 2

155.

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

N Engl J Med. 2020 Nov 13. doi: 10.1056/NEJMoa2028395. Online ahead of print.

Philip N Newsome¹, Kristine Buchholtz¹, Kenneth Cusi¹, Martin Linder¹, Takeshi Okanoue¹, Vlad Ratziu¹, Arun J Sanyal¹, Anne-Sophie Sejling¹, Stephen A Harrison¹, NN9931-4296 Investigators

156.

Retrospective analysis of a dedicated care pathway for nonalcoholic fatty liver disease in an integrated US healthcare system demonstrates support of weight management and improved ALT

BMC Gastroenterol. 2020 Oct 31;20(1):362. doi: 10.1186/s12876-020-01492-9.

Heather Patton^1 2, Raoul Burchette³, Stephanie Tovar³, Jose Pio³, Jiaxiao Shi³, Lisa M Nyberg^4 3

157.

Relationship of IGF-1 and IGF Binding Proteins to Disease Severity and Glycemia in Non-Alcoholic Fatty Liver Disease

J Clin Endocrinol Metab. 2020 Oct 30;dgaa792. doi: 10.1210/clinem/dgaa792.Online ahead of print.

Takara L Stanley¹, Lindsay T Fourman¹, Isabel Zheng¹, Colin M McClure¹, Meghan N Feldpausch¹, Martin Torriani², Kathleen E Corey³, Raymond T Chung³, Hang Lee⁴, David E Kleiner⁵, Colleen M Hadigan⁶, Steven K Grinspoon¹

158.

NASH: Connecting the dots with patients in mind

Endocrinol Diabetes Metab. 2020 Oct 21;3(4):e00109. doi: 10.1002/edm2.109.eCollection 2020 Oct.

Donna R Cryer¹

159.

Drug discovery and treatment paradigms in nonalcoholic steatohepatitis

Endocrinol Diabetes Metab. 2019 Dec 10;3(4):e00105. doi: 10.1002/edm2.105.eCollection 2020 Oct.

Mazen Noureddin¹, Mark D Muthiah^2 3, Arun J Sanyal⁴

160.

Determinants of Physical Activity Engagement in Patients With Nonalcoholic Fatty Liver Disease: The Need for an Individualized Approach to Lifestyle Interventions

Phys Ther. 2020 Oct 26;pzaa195. doi: 10.1093/ptj/pzaa195. Online ahead of print.

Philip O'Gorman¹, Ann Monaghan¹, Marie McGrath², Sara Naimimohasses^2 3, John Gormley¹, Suzanne Norris^2 3

161.

Hospital admission with non-alcoholic fatty liver disease is associated with increased all-cause mortality independent of cardiovascular risk factors

PLoS One. 2020 Oct 27;15(10):e0241357. doi: 10.1371/journal.pone.0241357. eCollection 2020.

Jake P Mann^1 2 3, Paul Carter^3 4, Matthew J Armstrong⁵, Hesham K Abdelaziz^6 7, Hardeep Uppal³, Billal Patel⁶, Suresh Chandran⁸, Ranjit More⁶, Philip N Newsome^9 10, Rahul Potluri³

162.

Current NAFLD guidelines for risk stratification in diabetic patients have poor diagnostic discrimination

Sci Rep. 2020 Oct 27;10(1):18345. doi: 10.1038/s41598-020-75227-x.

Valentin Blank^1 2, David Petroff^2 3, Sebastian Beer¹, Albrecht Böhlig⁴, Maria Heni¹, Thomas Berg⁴, Yvonne Bausback⁵, Arne Dietrich^2 6, Anke Tönjes⁷, Marcus Hollenbach¹, Matthias Blüher^2 7, Volker Keim¹, Johannes Wiegand⁴, Thomas Karlas⁸

163.

Nonalcoholic fatty liver disease: Reporting histologic findings in clinical practice

Hepatology. 2020 Oct 27. doi: 10.1002/hep.31599. Online ahead of print.

Elizabeth M Brunt¹, David E Kleiner², Danielle H Carpenter³, Mary Rinella⁴, Stephen A Harrison⁵, Rohit Loomba⁶, Zobair Younossi⁷, Brent A Neuschwander-Tetri⁸, Arun J Sanyal⁹, American Association for the Study of Liver Diseases NASH Task Force

164.

Non-alcoholic fatty liver disease (NAFLD) in non-obese individuals

Frontline Gastroenterol. 2019 Dec 13;11(6):478-483.doi: 10.1136/flgastro-2018-101119. eCollection 2020 Oct.

Meaghan Phipps¹, Julia Wattacheril²

165.

Performance of morphologic criteria for the diagnosis of cirrhosis in patients with non-alcoholic steatohepatitis compared to other etiologies of chronic liver disease: effect of level of training and experience

Abdom Radiol (NY). 2020 Sep 9. doi: 10.1007/s00261-020-02719-9. Online ahead of print.

Roberto Cannella^1 2, Navya Dasyam³, Su-Hun Seo⁴, Alessandro Furlan³, Amir A Borhani^3 5

166.

Lipoprotein and Metabolic Profiles Indicate Similar Cardiovascular Risk of Liver Steatosis and NASH

Digestion. 2020 Oct 20;1-11. doi: 10.1159/000510600. Online ahead of print.

Aline Gottlieb^1 2, Anna-Sophia Leven³, Jan-Peter Sowa^2 4, Katrin Borucki⁵, Alexander Link², Elvan Yilmaz⁶, Sitke Aygen⁶, Ali Canbay⁷, Mustafa Porsch-Özcürümez⁴

167.

Pathogenesis and pathways: nonalcoholic fatty liver disease & alcoholic liver disease

Transl Gastroenterol Hepatol. 2020 Oct 5;5:49. doi: 10.21037/tgh.2019.12.05.eCollection 2020.

Kyle E Robinson¹, Vijay H Shah¹

168.

Non-alcoholic Fatty Liver Disease as a Canonical Example of Metabolic Inflammatory-Based Liver Disease Showing a Sex-Specific Prevalence: Relevance of Estrogen Signaling

Front Endocrinol (Lausanne). 2020 Sep 18;11:572490.doi: 10.3389/fendo.2020.572490. eCollection 2020.

Sara Della Torre¹

169.

What's Past Is Prologue: History of Nonalcoholic Fatty Liver Disease

Metabolites. 2020 Oct 8;10(10):E397. doi: 10.3390/metabo10100397.

Giovanni Targher¹

170.

Pediatric Non-Alcoholic Fatty Liver Disease: Nutritional Origins and Potential Molecular Mechanisms

Nutrients. 2020 Oct 16;12(10):E3166. doi: 10.3390/nu12103166.

Ashok Mandala¹, Rachel C Janssen¹, Sirish Palle², Kevin R Short^1 3 4, Jacob E Friedman^1 3 4

171.

Expert Panel Review on Non-Alcoholic Fatty Liver Disease in Persons with HIV

Clin Gastroenterol Hepatol. 2020 Oct 15;S1542-3565(20)31431-2.doi: 10.1016/j.cgh.2020.10.018. Online ahead of print.

Jordan E Lake¹, Turner Overton², Susanna Naggie³, Mark Sulkowski⁴, Rohit Loomba⁵, David E Kleiner⁶, Jennifer C Price⁷, Kara W Chew⁸, Raymond T Chung⁹, Kathleen E Corey¹⁰

172.

Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers

Contemp Clin Trials. 2020 Oct 8;106174. doi: 10.1016/j.cct.2020.106174. Online ahead of print.

Stephen A Harrison¹, Salvatore Calanna², Kenneth Cusi³, Martin Linder⁴, Takeshi Okanoue⁵, Vlad Ratziu⁶, Arun Sanyal⁷, Anne-Sophie Sejling⁸, Philip N Newsome⁹

173.

Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis

J Hepatol. 2020 Oct 7;S0168-8278(20)33673-4. doi: 10.1016/j.jhep.2020.09.029.Online ahead of print.

Catherine Frenette¹, Zeid Kayali², Edward Mena³, Parvez S Mantry⁴, Kathryn J Lucas⁵, Guy Neff⁶, Miguel Rodriguez⁷, Paul J Thuluvath⁸, Ethan Weinberg⁹, Bal R Bhandari¹⁰, James Robinson¹¹, Nicole Wedick¹², Jean L Chan¹¹, David T Hagerty¹¹, Kris V Kowdley¹³, IDN-6556-17 Study Investigators

174.

One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial

J Clin Med. 2020 Oct 6;9(10):E3213. doi: 10.3390/jcm9103213.

Louise Vedtofte^1 2, Emilie Bahne^1 2, Signe Foghsgaard^1 2 3, Jonatan I Bagger^1 2, Camilla Andreasen^1 2, Charlotte Strandberg⁴, Peter M Gørtz⁵, Jens J Holst^6 7, Henning Grønbæk⁸, Jens A Svare⁹, Tine D Clausen¹⁰, Elisabeth R Mathiesen^11 12, Peter Damm^12 13, Lise L Gluud^12 14, Filip K Knop^1 2 7 12, Tina Vilsbøll^1 2 12

175.

The European NAFLD registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease

Contemp Clin Trials. 2020 Oct 9;106175. doi: 10.1016/j.cct.2020.106175. Online ahead of print.

Timothy Hardy¹, Kristy Wonders², Ramy Younes³, Guruprasad P Aithal⁴, Rocio Aller⁵, Michael Allison⁶, Pierre Bedossa², Fay Betsou⁷, Jerome Boursier⁸, M Julia Brosnan⁹, Alastair Burt¹, Jeremy Cobbold¹⁰, Helena Cortez-Pinto¹¹, Chris P Day¹, Jean-Francois Dufour¹², Mattias Ekstedt¹³, Sven Francque¹⁴, Stephen Harrison¹⁵, Luca Miele¹⁶, Patrik Nasr¹³, George Papatheodoridis¹⁷, Salvatore Petta¹⁸, Dina Tiniakos¹⁹, Richard Torstenson²⁰, Luca Valenti²¹, Adriaan G Holleboom²², Hannele Yki-Jarvinen²³, Andreas Geier²⁴, Manuel Romero-Gomez²⁵, Vlad Ratziu²⁶, Elisabetta Bugianesi²⁷, Jörn M Schattenberg²⁸, Quentin M Anstee²⁹, LITMUS Consortium

176.

Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort

Gut. 2020 Oct 9;gutjnl-2020-322786. doi: 10.1136/gutjnl-2020-322786. Online ahead of print.

Tracey G Simon^1 2 3, Bjorn Roelstraete⁴, Hamed Khalili^1 2 3, Hannes Hagström⁵, Jonas F Ludvigsson^{6 7 8 9 10}

177.

Testosterone is Associated With Nonalcoholic Steatohepatitis (NASH) and Fibrosis in Pre-Menopausal Women With NAFLD

Clin Gastroenterol Hepatol. 2020 Sep 30;S1542-3565(20)31375-6.doi: 10.1016/j.cgh.2020.09.045. Online ahead of print.

Monika Sarkar¹, Ayako Suzuki², Manal Abdelmalek², Katherine Yates³, Laura Wilson³, Nathan M Bass⁴, Ryan Gill², Marcelle Cedars⁵, Norah Terrault⁶, NASH Clinical Research Network (NASH CRN)

178.

Non-Alcoholic Fatty Liver Disease in a sample of individuals with Bipolar Disorders: Results From the FACE-BD Cohort

Acta Psychiatr Scand. 2020 Oct 4. doi: 10.1111/acps.13239. Online ahead of print.

Ophelia Godin^1 2, Marion Leboyer^1 2, Raoul Belzeaux^1 3, Frank Bellivier^1 4, Joséphine Loftus^1 5, Philippe Courtet^1 6, Caroline Dubertret^1 7, Sebastien Gard^1 8, Chantal Henry⁹, Pierre-Michel Llorca^1 10, Raymund Schwan^1 11, Christine Passerieux^1 12, Mircea Polosan^1 13, Ludovic Samalin^1 10, Emilie Olié^1 6, Bruno Etain^1 4, FondaMental Advanced Centers of Expertise in Bipolar Disorders (FACE-BD) Collaborators

Collaborators

FondaMental Advanced Centers of Expertise in Bipolar Disorders (FACE-BD) Collaborators:

B Etain, C Henry, E Olié, M Leboyer, E Haffen, P M Llorca, V Barteau, S Bensalem, O Godin, H Laouamri, K Souryis, H Mondor, S Hotier, A Pelletier, N Drancourt, J P Sanchez, E Saliou, C Hebbache, J Petrucci, L Willaume, E Bourdin, F Bellivier, M Carminati, B Etain, J Maruani, E Marlinge, M Meyrel, B Antoniol, A Desage, S Gard, A Jutant, K Mbailara, I Minois, L Zanouy, L Bardin, A Cazals, P Courtet, B Deffinis, D Ducasse, M Gachet, A Henrion, F Molière, B Noisette, E Olié, G Tarquini, R Belzeaux, N Correard, F Groppi, A Lefrere, L Lescalier, E Moreau, J Pastol, M Rebattu, B Roux, N Viglianese, R Cohen, Raymund Schwan, J P Kahn, M Milazzo, O Wajsbrot-Elgrabli, T Bougerol, B Fredembach, A Suisse, B Halili, A Pouchon, M Polosan, A M Galliot, I Grévin, A S Cannavo, N Kayser, C Passerieux, P Roux, V Aubin, I Cussac, M A Dupont, J Loftus, I Medecin, C Dubertret, N Mazer, C Portalier, C Scognamiglio, A Bing

179.

Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease

Curr Diab Rep. 2020 Oct 5;20(11):59. doi: 10.1007/s11892-020-01349-1.

Jeffrey Budd¹, Kenneth Cusi^2 3

180.

Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease

Aliment Pharmacol Ther. 2020 Oct;52(7):1185-1194. doi: 10.1111/apt.16016. Epub 2020 Aug 17.

Ali Canbay¹, Nandita Kachru², Jennifer Scarlet Haas³, Jan-Peter Sowa¹, Dominic Meise³, Ahmet Burak Ozbay²

181.

Identifying High-Risk NASH Patients: What We Know so Far

Hepat Med. 2020 Aug 21;12:125-138. doi: 10.2147/HMER.S265473.eCollection 2020.

Marten Schulz¹, Frank Tacke¹

182.

Systematic review of the impact of non-alcoholic fatty liver disease on mortality and adverse clinical outcomes for individuals with chronic kidney disease

BMJ Open. 2020 Sep 28;10(9):e040970. doi: 10.1136/bmjopen-2020-040970.

Theresa Hydes¹, Ryan Buchanan², Oliver J Kennedy², Simon Fraser², Julie Parkes², Paul Roderick²

183.

Late diagnosis of chronic liver disease in a community cohort (UK biobank): determinants and impact on subsequent survival

Public Health. 2020 Sep 26;187:165-171. doi: 10.1016/j.puhe.2020.07.017. Online ahead of print.

H Innes¹, J R Morling², E A Aspinall³, D J Goldberg³, S J Hutchinson³, I N Guha⁴

184.

Clinical Characteristics of a Non-Alcoholic Fatty Liver Disease Population Across the Fibrosis Spectrum Measured by Magnetic Resonance Elastography: Analysis of Screening Data

Adv Ther. 2020 Oct 1.doi: 10.1007/s12325-020-01503-x. Online ahead of print.

Grit Andersen¹, Leona Plum-Mörschel², Paul D Hockings^3 4, Anni Morsing⁵, Mads S Palle⁶, Olivia Svolgaard⁵, Anne Flint⁷

185.

The pharmacological treatment of non-alcoholic fatty liver disease in children

Expert Rev Clin Pharmacol. 2020 Sep 26. doi: 10.1080/17512433.2020.1829468.Online ahead of print.

Annalisa Crudele¹, Nadia Panera¹, Maria Rita Braghini¹, Clara Balsano², Anna Alisi¹

186.

Liver Stiffness by Magnetic Resonance Elastography Predicts Future Cirrhosis, Decompensation and Death in NAFLD

Clin Gastroenterol Hepatol. 2020 Sep 30;S1542-3565(20)31374-4.doi:10.1016/j.cgh.2020.09.044. Online ahead of print.

Tolga Gidener¹, Omar T Ahmed¹, Joseph J Larson², Kristin C Mara², Terry M Therneau², Sudhakar K Venkatesh³, Richard L Ehman³, Meng Yin³, Alina M Allen⁴

187.

The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care

JHEP Rep. 2020 Aug 4;2(6):100168. doi: 10.1016/j.jhepr.2020.100168. eCollection 2020 Dec.

Wolf Peter Hofmann^1 2, Peter Buggisch^2 3, Lisa Schubert^1 4, Nektarios Dikopoulos⁵, Jeannette Schwenzer⁶, Marion Muche⁴, Gisela Felten⁷, Renate Heyne⁸, Patrick Ingiliz⁹, Anna Schmidt¹⁰, Kerstin Stein¹¹, Heiner Wedemeyer¹², Thomas Berg¹³, Johannes Wiegand¹³, Frank Lammert¹⁴, Stefan Zeuzem¹⁵, Jörn M Schattenberg^16 17

188.

A composite biomarker using multiparametric magnetic resonance imaging and blood analytes accurately identifies patients with non-alcoholic steatohepatitis and significant fibrosis

Sci Rep. 2020 Sep 17;10(1):15308. doi: 10.1038/s41598-020-71995-8.

Andrea Dennis¹, Sofia Mouchti², Matt Kelly², Jonathan A Fallowfield³, Gideon Hirschfield⁴, Michael Pavlides⁵, Rajarshi Banerjee²

189.

Abnormal cardiac and metabolic measures correlate significantly with lower performance and activity in overweight chronic liver disease

J Clin Hypertens (Greenwich). 2020 Sep 17. doi: 10.1111/jch.13938. Online ahead of print.

Jillian Price¹, Carey Escheik^1 2, Ali Weinstein³, Patrice Winter^1 2, Lynn Gerber¹, Zobair Younossi^1 2

190.

A look to the future in non-alcoholic fatty liver disease: Are GLP-1 analogues or SGLT-2 inhibitors the answer?

Diabetes Obes Metab. 2020 Sep 18. doi: 10.1111/dom.14196. Online ahead of print.

Rebecca K Vincent^# 1, David M Williams^# 2, Marc Evans²

191.

Histological Endpoints for Nonalcoholic Steatohepatitis Trials: Lights and Shadows

Semin Liver Dis. 2020 Sep 9. doi: 10.1055/s-0040-1709491. Online ahead of print.

Ian A Rowe^1 2 3

192.

Nonalcoholic Fatty Liver Disease Is Common in IBD Patients However Progression to Hepatic Fibrosis by Noninvasive Markers Is Rare

Dig Dis Sci. 2020 Sep 7. doi: 10.1007/s10620-020-06588-6. Online ahead of print.

Gabrielle Ritaccio¹, Gianna Stoleru¹, Ameer Abutaleb², Raymond K Cross², Kirti Shetty², Sasan Sakiani², Uni Wong³

193.

A Fad too Far? Dietary Strategies for the Prevention and Treatment of NAFLD

Obesity (Silver Spring). 2020 Sep 6. doi: 10.1002/oby.22964. Online ahead of print.

Mary P Moore^# 1 2, Rory P Cunningham^# 1 2, Ryan J Dashek^1 3, Justine M Mucinski², R Scott Rector^1 2 4

194.

Change in MRI-PDFF and Histologic Response in Patients with Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis

Clin Gastroenterol Hepatol. 2020 Aug 31;S1542-3565(20)31220-9.doi: 10.1016/j.cgh.2020.08.061. Online ahead of print.

Jonathan G Stine, Nagambika Munaganuru, Abbey Barnard, Jennifer L Wang, Kellee Kaulback, Curtis K Argo, Siddarth Singh, Kathryn J Fowler, Claude B Sirlin, Rohit Loomba

195.

Non-Alcoholic Fatty Liver Disease Modifies Serum Gamma-Glutamyl Transferase in Cigarette Smokers

J Clin Med Res. 2020 Aug;12(8):472-482. doi: 10.14740/jocmr3932. Epub 2020 Jul 22.

Ebenezer T Oni¹, Vincent Figueredo², Ehimen Aneni³, Emir Veladar⁴, John W McEvoy⁵, Michael J Blaha^5 6, Roger S Blumenthal⁵, Raquel D Conceicao⁷, Jose A M Carvalho⁷, Raul D Santos^7 8, Khurram Nasir⁹

196.

Improvement in Insulin Resistance and Estimated Hepatic Steatosis and Fibrosis after Endoscopic Sleeve Gastroplasty

Gastrointest Endosc. 2020 Aug 27;S0016-5107(20)34733-7. doi:10.1016/j.gie.2020.08.023.Online ahead of print.

Kaveh Hajifathalian¹, Amit Mehta¹, Bryan Ang², Daniel Skaf², Shawn Shah¹, Monica Saumoy³, Qais Dawod¹, Enad Dawod², Alpana Shukla⁴, Louis Aronne⁴, Robert Brown¹, David Cohen¹, Andrew J Dannenberg⁵, Brett Fortune¹, Sonal Kumar¹, Reem Z Sharaiha⁶

197.

Liver fibrosis score, physical frailty, and the risk of dementia in older adults: The Italian Longitudinal Study on Aging

Alzheimers Dement (N Y). 2020 Aug 24;6(1):e12065.doi: 10.1002/trc2.12065. eCollection 2020.

Vincenzo Solfrizzi¹, Emanuele Scafato^2 3, Carlo Custodero¹, Francesca Loparco¹, Alessandro Ciavarella¹, Francesco Panza^4 5, Davide Seripa^4 6, Bruno Pietro Imbimbo⁷, Madia Lozupone⁸, Nicola Napoli¹, Giuseppina Piazzolla¹, Lucia Galluzzo³, Claudia Gandin², Marzia Baldereschi⁹, Antonio Di Carlo⁹, Domenico Inzitari^9 10, Alberto Pilotto^1 11, Carlo Sabbà¹, Italian Longitudinal Study on Aging Working Group

198.

Tackling NAFLD: Three Targeted Populations

Hepatology. 2020 Aug 31. doi: 10.1002/hep.31533. Online ahead of print.

Kara Wegermann¹, Ayako Suzuki^1 2, Alisha M Mavis³, Manal F Abdelmalek¹, Anna Mae Diehl¹, Cynthia A Moylan^1 2

199.

Too Much of a Good Thing? An Evolutionary Theory to Explain the Role of Ceramides in NAFLD

Front Endocrinol (Lausanne). 2020 Jul 31;11:505. doi: 10.3389/fendo.2020.00505.eCollection 2020.

Annelise M Poss¹, Scott A Summers¹

200.

NAFLD fibrosis score (NFS) can be used in outpatient services to identify chronic vascular complications besides advanced liver fibrosis in type 2 diabetes

J Diabetes Complications. 2020 Jul 17;107684. doi: 10.1016/j.jdiacomp.2020.107684.Online ahead of print.

Rosa Lombardi¹, Lorena Airaghi², Giovanni Targher³, Gaetano Serviddio⁴, Gabriele Maffi², Alessandro Mantovani³, Claudio Maffeis⁵, Antonio Colecchia⁶, Rosanna Villani⁴, Luca Rinaldi⁷, Emanuela Orsi⁸, Giuseppina Pisano², Luigi Elio Adinolfi⁷, Silvia Fargion², Anna Ludovica Fracanzani²

201.

Mechanisms of nonalcoholic fatty liver disease and implications for surgery

Langenbecks Arch Surg. 2020 Aug 24. doi: 10.1007/s00423-020-01965-1.Online ahead of print.

Benedikt Kaufmann^1 2, Agustina Reca¹, Baocai Wang², Helmut Friess², Ariel E Feldstein¹, Daniel Hartmann³

202.

Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic

JHEP Rep. 2020 Oct;2(5):100169. doi: 10.1016/j.jhepr.2020.100169.Epub 2020 Aug 4.

Tobias Boettler¹, Thomas Marjot², Philip N Newsome^3 4, Mario U Mondelli⁵, Mojca Maticic^6 7, Elisa Cordero⁸, Rajiv Jalan⁹, Richard Moreau^10 11, Markus Cornberg^12 13, Thomas Berg¹⁴

203.

Validating a non-invasive, ALT-based non-alcoholic fatty liver phenotype in the million veteran program

PLoS One. 2020 Aug 25;15(8):e0237430.doi: 10.1371/journal.pone.0237430. eCollection 2020.

Marina Serper^1 2 3, Marijana Vujkovic¹, David E Kaplan^1 2, Rotonya M Carr^1 2, Kyung Min Lee^4 5 6, Qing Shao⁴, Donald R Miller⁴, Peter D Reaven⁷, Lawrence S Phillips^8 9, Christopher J O'Donnell^10 11, James B Meigs¹², Peter W F Wilson^8 9, Rachel Vickers-Smith¹³, Henry R Kranzler^13 14, Amy C Justice^15 16 17, John M Gaziano^10 18, Sumitra Muralidhar¹⁹, Saiju Pyarajan^10 11, Scott L DuVall^6 20, Themistocles L Assimes^21 22, Jennifer S Lee^21 22, Philip S Tsao^21 22, Daniel J Rader^{2 23 24 25}, Scott M Damrauer^1 26, Julie A Lynch^6 27, Danish Saleheen^1 28, Benjamin F Voight^1 23 29, Kyong-Mi Chang^1 2, VA Million Veteran Program

204.

History of Nonalcoholic Fatty Liver Disease

Int J Mol Sci. 2020 Aug 16;21(16):E5888. doi: 10.3390/ijms21165888.

Amedeo Lonardo¹, Simona Leoni², Khalid A Alswat³, Yasser Fouad⁴

205.

Maintaining Patient Safety and Data Integrity of NASH Clinical Trials During the SARS-CoV-2 Pandemic

Hepatology. 2020 Aug 14;10.1002/hep.31522. doi: 10.1002/hep.31522. Online ahead of print.

Naim Alkhouri¹, Anita Kohli¹, Rohit Loomba², Stephen A Harrison³

206.

The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in Nonalcoholic Steatohepatitis

Hepatology. 2020 Aug 13. doi: 10.1002/hep.31523. Online ahead of print.

Rohit Loomba¹, Lei Ling², Duy M Dinh³, Alex M DePaoli², Hsiao D Lieu², Stephen A Harrison^4 5, Arun J Sanyal⁶

207.

Anti-inflammatory Activities of Green Tea Catechins along the Gut-liver Axis in Nonalcoholic Fatty Liver Disease: Lessons Learned from Preclinical and Human Studies

J Nutr Biochem. 2020 Aug 12;108478. doi: 10.1016/j.jnutbio.2020.108478.Online ahead of print.

Joanna K Hodges¹, Geoffrey Y Sasaki¹, Richard S Bruno²

208.

Resection of NAFLD-Associated HCC: Patient Selection and Reported Outcomes

J Hepatocell Carcinoma. 2020 Jul 30;7:107-116. doi: 10.2147/JHC.S252506.eCollection 2020.

Claudia Campani^# 1, Carolina Bensi^# 1, Stefano Milani¹, Andrea Galli¹, Mirko Tarocchi¹

209.

Racial and Socioeconomic Disparities in Hospitalization of Pediatrics with Liver Disease from 2005 to 2015

Dig Dis Sci. 2020 Aug 14. doi: 10.1007/s10620-020-06530-w. Online ahead of print.

Melissa Martin¹, Biyao Zou², Joseph Hoang², Donghak Jeong², Rachel Bensen¹, Mindie H Nguyen³

210.

Trimethylamine N-Oxide levels are associated with NASH in obese subjects with type 2 diabetes

Diabetes Metab. 2020 Aug 10;S1262-3636(20)30102-6. doi: 10.1016/j.diabet.2020.07.010.Online ahead of print.

Paola León-Mimila¹, Hugo Villamil-Ramírez², Xinmin S Li³, Diana M Shih¹, Simon T Hui¹, Elvira Ocampo-Medina², Blanca López-Contreras², Sofía Morán-Ramos⁴, Marisol Olivares-Arevalo², Paula Grandini-Rosales², Luis Macías-Kauffer², Israel González-González⁵, Rogelio Hernández-Pando⁶, Francisco Gómez-Pérez⁷, Francisco Campos-Pérez⁵, Carlos Aguilar-Salinas⁸, Elena Larrieta-Carrasco⁹, Teresa Villarreal-Molina¹⁰, Zeneng Wang³, Aldons J Lusis¹, Stanley L Hazen¹¹, Adriana Huertas-Vazquez¹², Samuel Canizales-Quinteros¹³

211.

Prevalence of NASH/NAFLD in people with obesity who are currently classified as metabolically healthy

Surg Obes Relat Dis. 2020 Jul 14;S1550-7289(20)30411-1. doi: 10.1016/j.soard.2020.07.009.Online ahead of print.

Sébastien Frey¹, Stéphanie Patouraux², Tarek Debs³, Jean Gugenheim⁴, Rodolphe Anty⁵, Antonio Iannelli⁶

212.

Vitamin E as an Adjuvant Treatment for Non-alcoholic Fatty Liver Disease in Adults: A Systematic Review of Randomized Controlled Trials

Cureus. 2020 Jul 6;12(7):e9018. doi: 10.7759/cureus.9018.

Muhammad Usman^1 2, Nabiyah Bakhtawar³

213.

NAFLD and NASH in postmenopausal women: implications for diagnosis and treatment

Endocrinology. 2020 Aug 10;bqaa134.doi: 10.1210/endocr/bqaa134. Online ahead of print.

Johanna K DiStefano¹

214.

Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis

Gastroenterology. 2020 Aug 8;S0016-5085(20)35018-6. doi: 10.1053/j.gastro.2020.08.004.Online ahead of print.

Stephen A Harrison¹, Guy Neff², Cynthia D Guy³, Mustafa R Bashir⁴, Angelo H Paredes⁵, Juan P Frias⁶, Ziad Younes⁷, James F Trotter⁸, Nadege T Gunn⁹, Sam E Moussa¹⁰, Anita Kohli¹¹, Kristin Nelson¹², Mildred Gottwald¹², William C G Chang¹², Andrew Z Yan¹², Alex M DePaoli¹², Lei Ling¹³, Hsiao D Lieu¹²

215.

Microbiota and Fatty Liver Disease-the Known, the Unknown, and the Future

Cell Host Microbe. 2020 Aug 12;28(2):233-244. doi: 10.1016/j.chom.2020.07.007.

Sonja Lang¹, Bernd Schnabl²

216.

A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study

Lancet Gastroenterol Hepatol. 2020 Aug 4;S2468-1253(20)30252-1.doi: 10.1016/S2468-1253(20)30252-1. Online ahead of print.

Stephen A Harrison¹, Vlad Ratziu², Jérôme Boursier³, Sven Francque⁴, Pierre Bedossa⁵, Zouher Majd⁶, Geneviève Cordonnier⁶, Fouad Ben Sudrik⁶, Raphael Darteil⁷, Roman Liebe⁸, Jérémy Magnanensi⁶, Yacine Hajji⁶, John Brozek⁶, Alice Roudot⁶, Bart Staels⁹, Dean W Hum⁶, Sophie Jeannin Megnien¹⁰, Suneil Hosmane⁶, Noémie Dam⁶, Pierre Chaumat⁶, Rémy Hanf¹¹, Quentin M Anstee¹², Arun J Sanyal¹³

217.

Mortality of NAFLD According to the Body Composition and Presence of Metabolic Abnormalities

Hepatol Commun. 2020 May 19;4(8):1136-1148. doi: 10.1002/hep4.1534. eCollection 2020 Aug.

Pegah Golabi¹, James M Paik¹, Tamoore Arshad², Youssef Younossi³, Alita Mishra², Zobair M Younossi^1 2

218.

The Emerging Role of Hepatocellular eNOS in Non-alcoholic Fatty Liver Disease Development

Physiol. 2020 Jul 3;11:767. doi: 10.3389/fphys.2020.00767. eCollection 2020.

Rory P Cunningham^1 2, Ryan D Sheldon³, R Scott Rector^1 2 4

219.

Non-invasive diagnostic tools for pediatric NAFLD: where are we now?

Expert Rev Gastroenterol Hepatol. 2020 Jul 25.doi: 10.1080/17474124.2020.1801413.Online ahead of print.

Antonella Mosca¹, Nadia Panera², Annalisa Crudele², Anna Alisi²

220.

Protocol for a phase IV, open-label feasibility study investigating non-invasive markers of hepatic fibrosis in people living with HIV-1 and non-alcoholic fatty liver disease randomised to receiving optimised background therapy (OBT) plus maraviroc or OBT alone

BMJ Open. 2020 Jul 6;10(7):e035596. doi: 10.1136/bmjopen-2019-035596.

Daniel Bradshaw¹, Yvonne Gilleece², Sumita Verma³, Iga Abramowicz³, Stephen Bremner³, Nicky Perry³

221.

A Description of Risk Factors for Non-alcoholic Fatty Liver Disease in the Southern Community Cohort Study: A Nested Case-Control Study

Front Nutr. 2020 May 21;7:71. doi: 10.3389/fnut.2020.00071. eCollection 2020.

Sudipa Sarkar¹, Loren Lipworth^2 3, Edmond K Kabagambe^2 3, Aihua Bian^3 4, Thomas G Stewart⁴, William J Blot^2 5, T Alp Ikizler^3 6, Adriana M Hung^3 6

222.

Baseline HOMA IR and Circulating FGF21 Levels Predict NAFLD Improvement in Patients Undergoing a Low Carbohydrate Dietary Intervention for Weight Loss: A Prospective Observational Pilot Study

Nutrients. 2020 Jul 18;12(7):E2141. doi: 10.3390/nu12072141.

Mikiko Watanabe¹, Renata Risi¹, Elisabetta Camajani¹, Savina Contini¹, Agnese Persichetti¹, Dario Tuccinardi², Ilaria Ernesti³, Stefania Mariani¹, Carla Lubrano¹, Alfredo Genco³, Giovanni Spera¹, Lucio Gnessi¹, Sabrina Basciani¹

223.

Brain MR Spectroscopy Markers of Encephalopathy Due to Nonalcoholic Steatohepatitis

J Neuroimaging. 2020 Jul 23. doi: 10.1111/jon.12728. Online ahead of print.

Thao T Tran¹, Ke Wei¹, Soren Cole¹, Edward Mena², Marie Csete¹, Kevin S King¹

224.

Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials

J Hepatol. 2020 Jun 28;S0168-8278(20)30399-8. doi: 10.1016/j.jhep.2020.06.025.Online ahead of print.

Beth A Davison¹, Stephen A Harrison², Gad Cotter³, Naim Alkhouri⁴, Arun Sanyal⁵, Christopher Edwards³, Jerry R Colca⁶, Julie Iwashita⁶, Gary G Koch⁷, Howard C Dittrich⁶

225.

Review article: The impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis

Aliment Pharmacol Ther. 2020 Jul 8. doi: 10.1111/apt.15935. Online ahead of print.

Margery A Connelly¹, Jonathan Velez Rivera², John R Guyton², Mohammad Shadab Siddiqui³, Arun J Sanyal³

226.

Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH

Clin Mol Hepatol. 2020 Jul 17. doi: 10.3350/cmh.2020.0067. Online ahead of print.

Theresa J Hydes¹, Sujan Ravi¹, Rohit Loomba², Meagan E Gray¹

227.

Lean Americans With Nonalcoholic Fatty Liver Disease Have Lower Rates of Cirrhosis and Co-morbid Diseases

Ethan M Weinberg¹, Huy N Trinh², Roberto J Firpi³, Kalyan Ram Bhamidimarri⁴, Samuel Klein⁵, Jonathan Durlam⁶, Stephanie Watkins⁶, K Rajender Reddy¹, Michael Weiss⁷, Richard C Zink⁶, Anna S Lok⁸

Clin Gastroenterol Hepatol. 2020 Jul 3;S1542-3565(20)30930-7. doi:10.1016/j.cgh.2020.06.066.Online ahead of print.

228.

Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices

Aliment Pharmacol Ther. 2020 Aug;52(3):513-526. doi: 10.1111/apt.15830. Epub 2020 Jun 29.

Zobair M Younossi¹, Kathleen E Corey², Naim Alkhouri³, Mazen Noureddin⁴, Ira Jacobson⁵, Brian Lam¹, Stephen Clement¹, Rita Basu⁶, Stuart Gordon⁷, Natarajan Ravendhra⁸, Puneet Puri⁹, Mary Rinella¹⁰, Peter Scudera¹, Ashwani K Singal¹¹, Linda Henry¹², US Members of the Global Nash Council

229.

Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial

Am J Gastroenterol. 2020 Jul;115(7):1055-1065. doi: 10.14309/ajg.0000000000000661.

Laura Craven¹, Adam Rahman^2 3, Seema Nair Parvathy⁴, Melanie Beaton^2 3, Justin Silverman⁵, Karim Qumosani^2 3, Irene Hramiak^2 6, Rob Hegele^2 6 7, Tisha Joy^2 6, Jon Meddings⁸, Brad Urquhart², Ruth Harvie⁹, Charles McKenzie^2 7, Kelly Summers^1 2, Gregor Reid^1 2 9, Jeremy P Burton^1 2 9, Michael Silverman^1 2 4

230.

Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes

Diabet Med. 2020 Jul 3. doi: 10.1111/dme.14356. Online ahead of print.

T J Hydes¹, N Summers², E Brown^3 4, U Alam^3 4 5, H Thomaides-Brears⁶, J P H Wilding^3 4, D J Cuthbertson^3 4

231.

Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)

Hepatol Int. 2020 Jul 4;1-11.doi: 10.1007/s12072-020-10072-8. Online ahead of print.

Shiv Kumar Sarin¹, Ashok Choudhury², George K Lau³, Ming-Hua Zheng^3 4, Dong Ji^3 5, Sherief Abd-Elsalam⁶, Jaeseok Hwang⁷, Xiaolong Qi⁸, Ian Homer Cua⁹, Jeong Ill Suh¹⁰, Jun Gi Park¹⁰, Opass Putcharoen¹¹, Apichat Kaewdech¹², Teerha Piratvisuth¹², Sombat Treeprasertsuk¹¹, Sooyoung Park¹³, Salisa Wejnaruemarn¹¹, Diana A Payawal¹⁴, Oidov Baatarkhuu¹⁵, Sang Hoon Ahn¹⁶, Chang Dong Yeo¹⁶, Uzziel Romar Alonzo¹⁴, Tserendorj Chinbayar¹⁷, Imelda M Loho¹⁸, Osamu Yokosuka¹⁹, Wasim Jafri²⁰, Soeksiam Tan²¹, Lau Ing Soo²¹, Tawesak Tanwandee²², Rino Gani²³, Lovkesh Anand²⁴, Eslam Saber Esmail⁶, Mai Khalaf⁶, Shahinul Alam²⁵, Chun-Yu Lin²⁶, Wan-Long Chuang²⁶, A S Soin²⁷, Hitendra K Garg²⁸, Kemal Kalista²⁹, Badamnachin Batsukh¹⁵, Hery Djagat Purnomo³⁰, Vijay Pal Dara³¹, Pravin Rathi³², Mamun Al Mahtab²⁵, Akash Shukla³³, Manoj K Sharma², Masao Omata^34 35, APASL COVID Task Force, APASL COVID Liver Injury Spectrum Study (APCOLIS Study-NCT 04345640)

232.

Role of Extracellular Vesicles in the Pathophysiology, Diagnosis and Tracking of Non-Alcoholic Fatty Liver Disease

J Clin Med. 2020 Jun 29;9(7):E2032. doi: 10.3390/jcm9072032.

Lauren A Newman¹, Michael J Sorich¹, Andrew Rowland¹

233.

Health Care Use and Costs Among Patients With Nonalcoholic Steatohepatitis With Advanced Fibrosis Using the Fibrosis-4 Score

Hepatol Commun.. 2020 May 26;4(7):998-1011. doi: 10.1002/hep4.1524. eCollection 2020 Jul.

Stuart C Gordon¹, Nandita Kachru², Emily Parker³, Stephanie Korrer³, A Burak Ozbay², Robert J Wong⁴

234.

Evolving Role for Pharmacotherapy in NAFLD/NASH

Clin Transl Sci. 2020 Jun 25. doi: 10.1111/cts.12839. Online ahead of print.

Suzanna L Attia¹, Samir Softic^1 2 3, Marialena Mouzaki⁴

235.

Nonalcoholic Fatty Liver Disease (NAFLD) Is an Independent Risk Factor for Nephrolithiasis in Women: Findings From NHANES III

J Endourol. 2020 Jun 22.doi: 10.1089/end.2020.0486. Online ahead of print.

Rourke Douglas Decker¹, Eric M Ghiraldi², Alexandra H Weiss³, John P Gaughan⁴, Justin I Friedlander^5 6

236.

Dysregulated Neurovascular Control Underlies Declining Microvascular Functionality in People With Non-alcoholic Fatty Liver Disease (NAFLD) at Risk of Liver Fibrosis

Front Physiol. 2020 Jun 3;11:551. doi: 10.3389/fphys.2020.00551. eCollection 2020.

Geraldine F Clough¹, Andrew J Chipperfield², Marjola Thanaj², Eleonora Scorletti^1 3 4, Philip C Calder^1 3, Christopher D Byrne^1 3

237.

Cirrhosis in a Young Child Due to Fatty Liver; Importance of Early Screening: A Case Report and Review of the Literature

Am J Case Rep. 2020 Jun 25;21:e923250. doi: 10.12659/AJCR.923250.

Hamza Hassan Khan¹, Christine E Klingert^1 2, Sanjay Kumar^2 3, Hernando Lyons^2 3

238.

COVID-19 and Nonalcoholic Fatty Liver Disease: Two Intersecting Pandemics

Eur J Clin Invest. 2020 Jun 26;e13338. doi: 10.1111/eci.13338. Online ahead of print.

Piero Portincasa¹, Marcin Krawczyk^2 3, Wiktor Smyk⁴, Frank Lammert², Agostino Di Ciaula¹

239.

A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease

Ann Pharmacother. 2020 Jun 22;1060028020935105. doi: 10.1177/1060028020935105.Online ahead of print.

John A Dougherty¹, Erenie Guirguis¹, Krisy-Ann Thornby¹

240.

Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States

Gastroenterol Hepatol. 2020 Jun 9;S1542-3565(20)30775-8.doi: 10.1016/j.cgh.2020.05.064. Online ahead of print.

Zobair M Younossi¹, Maria Stepanova², Janus Ong³, Greg Trimble⁴, Saleh AlQahtani⁵, Issah Younossi², Aijaz Ahmed⁶, Andrei Racila⁷, Linda Henry²

241.

Selonsertib for Patients With Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results From Randomized Phase III STELLAR Trials

Hepatol. 2020 Jul;73(1):26-39. doi: 10.1016/j.jhep.2020.02.027. Epub 2020 Mar 6.

Stephen A Harrison¹, Vincent Wai-Sun Wong², Takeshi Okanoue³, Natalie Bzowej⁴, Raj Vuppalanchi⁵, Ziad Younes⁶, Anita Kohli⁷, Shiv Sarin⁸, Stephen H Caldwell⁹, Naim Alkhouri¹⁰, Mitchell L Shiffman¹¹, Marianne Camargo¹², Georgia Li¹², Kathryn Kersey¹², Catherine Jia¹², Yanni Zhu¹², C Stephen Djedjos¹², G Mani Subramanian¹², Robert P Myers¹², Nadege Gunn¹³, Aasim Sheikh¹⁴, Quentin M Anstee¹⁵, Manuel Romero-Gomez¹⁶, Michael Trauner¹⁷, Zachary Goodman¹⁸, Eric J Lawitz¹⁰, Zobair Younossi¹⁸, STELLAR-3 and STELLAR-4 Investigators

242.

Development of an Algorithm to Identify Cases of Nonalcoholic Steatohepatitis Cirrhosis in the Electronic Health Record

Dig Dis Sci. 2020 Jun 13. doi: 10.1007/s10620-020-06388-y. Online ahead of print.

Christopher J Danford¹, Jennifer Y Lee², Ian A Strohbehn³, Kathleen E Corey³, Michelle Lai⁴

243.

From NAFLD to MAFLD: Implications of a Premature Change in Terminology

Hepatology. 2020 Jun 16. doi: 10.1002/hep.31420. Online ahead of print.

Zobair M Younossi^1 2, Mary E Rinella³, Arun Sanyal⁴, Stephen A Harrison⁵, Elizabeth Brunt⁶, Zachary Goodman^1 2, David E Cohen⁷, Rohit Loomba⁸

244.

Novel Antisense Inhibition of Diacylglycerol O-acyltransferase 2 for Treatment of Non-Alcoholic Fatty Liver Disease: A Multicentre, Double-Blind, Randomised, Placebo-Controlled Phase 2 Trial

Lancet Gastroenterol Hepatol. 2020 Jun 15;S2468-1253(20)30186-2.doi: 10.1016/S2468-1253(20)30186-2. Online ahead of print.

Rohit Loomba¹, Erin Morgan², Lynnetta Watts², Shuting Xia², Lisa A Hannan², Richard S Geary², Brenda F Baker², Sanjay Bhanot²

245.

Effect of Gut Microbiota and PNPLA3 rs738409 Variant on Non-Alcoholic Fatty Liver Disease (NAFLD) in Obese Youth

J Clin Endocrinol Metab. 2020 Jun 19;dgaa382. doi: 10.1210/clinem/dgaa382.Online ahead of print.

Ayesha Monga Kravetz^1 2, Todd Testerman³, Brittany Galuppo², Joerg Graf³, Bridget Pierpont², Stephan Siebel², Richard Feinn¹, Nicola Santoro^2 4

246.

Effect of TSH on Non-Alcoholic Fatty Liver Disease (NAFLD) Independent of Obesity in Children of Predominantly Hispanic/Latino Ancestry by Causal Mediation Analysis

PLoS One. 2020 Jun 22;15(6):e0234985. doi: 10.1371/journal.pone.0234985. eCollection 2020.

Presley H Nichols¹, Yue Pan², Benjamin May³, Martina Pavlicova², John C Rausch^1 4, Ali A Mencin⁴, Vidhu V Thaker⁴

247.

Non-alcoholic Fatty Liver Disease in Pregnancy Is Associated With Adverse Maternal and Perinatal Outcomes

J Hepatol. 2020 Apr 15;S0168-8278(20)30215-4. doi: 10.1016/j.jhep.2020.03.049.Online ahead of print.

Monika Sarkar¹, Joshua Grab², Jennifer L Dodge³, Erica P Gunderson⁴, Jessica Rubin⁵, Roxanna A Irani⁶, Marcelle Cedars⁷, Norah Terrault⁸

248.

Use of Metabolic Syndrome Severity to Assess Treatment With Vitamin-E and Pioglitazone for Non-alcoholic Steatohepatitis

Gastroenterol Hepatol. 2020 Jun 7. doi: 10.1111/jgh.15131. Online ahead of print.

Matthew J Gurka¹, Jasmine A Mack¹, Xiaofei Chi¹, Mark D DeBoer²

249.

Biopsy Rate and Nonalcoholic Steatohepatitis (NASH) in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)

Scand J Gastroenterol. 2020 Jun 1;1-6. doi: 10.1080/00365521.2020.1766554.Online ahead of print.

Florian Gerhardt¹, David Petroff², Valentin Blank^1 3, Albrecht Böhlig¹, Florian van Bömmel¹, Christian Wittekind⁴, Thomas Berg¹, Thomas Karlas¹, Johannes Wiegand¹

250.

Nonalcoholic Fatty Liver Disease and Type 2 Diabetes: Where Do Diabetologists Stand?

Clin Diabetes Endocrinol. 2020 Jun 5;6:9. doi: 10.1186/s40842-020-00097-1.eCollection 2020.

Shaheen Tomah^1 2, Naim Alkhouri³, Osama Hamdy^1 2

251.

Prediction of Advanced Fibrosis in Non-Alcoholic Fatty Liver Disease Using Gut Microbiota-Based Approaches Compared With Simple Non-Invasive Tools

Sci Rep. 2020 Jun 10;10(1):9385. doi: 10.1038/s41598-020-66241-0.

Sonja Lang^1 2, Fedja Farowski^3 4 5, Anna Martin¹, Hilmar Wisplinghoff^6 7 8, Maria J G T Vehreschild^3 4 5, Marcin Krawczyk^9 10, Angela Nowag^6 8, Anne Kretzschmar⁶, Claus Scholz⁶, Philipp Kasper¹, Christoph Roderburg¹¹, Frank Lammert⁹, Tobias Goeser¹, Hans-Michael Steffen¹, Münevver Demir^12 13

252.

Nonalcoholic Fatty Liver Disease: An Important Consideration for Primary Care Providers in Hawai

Hawaii J Health Soc Welf. 2020 Jun 1;79(6):180-186.

Robert J Pattison¹, James Phillip Esteban², Tomoki Sempokuya³, Jakrin Kewcharoen¹, Sumodh Kalathil⁴, Scott K Kuwada⁵

253.

Noninvasive Tests in the Assessment of NASH and NAFLD Fibrosis: Now and Into the Future

Semin Liver Dis. 2020 Jun 11. doi: 10.1055/s-0040-1713006. Online ahead of print.

Leon A Adams^1 2, Wah-Kheong Chan³

254.

Burden of Nonalcoholic Fatty Liver Disease in Canada, 2019-2030: A Modelling Study

CMAJ Open. 2020 Jun 9;8(2):E429-E436. doi: 10.9778/cmajo.20190212. Print Apr-Jun 2020.

Mark G Swain¹, Alnoor Ramji¹, Keyur Patel¹, Giada Sebastiani¹, Abdel Aziz Shaheen¹, Edward Tam¹, Paul Marotta¹, Magdy Elkhashab¹, Harpreet S Bajaj¹, Chris Estes², Homie Razavi¹

255.

Utilization of Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis: A Systematic Review and Meta-Analysis

Hepatology. 2020 May 8.doi: 10.1002/hep.31309. Online ahead of print.

Erin Wolf¹, Nicole E Rich¹, Jorge A Marrero¹, Neehar Parikh², Amit G Singal¹

256.

Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies

Clin Exp Hepatol. May-Jun 2020;10(3):245-254. doi: 10.1016/j.jceh.2019.07.002.Epub 2019 Jul 15.

Yala K Reddy¹, Hemnishil K Marella¹, Yu Jiang², Surosree Ganguli³, Peter Snell¹, Pradeep S B Podila⁴, Benedict Maliakkal¹, Sanjaya K Satapathy⁵

257.

Advances in Non-Invasive Biomarkers for the Diagnosis and Monitoring of Non-Alcoholic Fatty Liver Disease

Metabolism. 2020 May 5;154259. doi: 10.1016/j.metabol.2020.154259.Online ahead of print.

Michelle T Long¹, Sanil Gandhi², Rohit Loomba³

258.

Genetic Determinants of Cirrhosis and Hepatocellular Carcinoma Due to Fatty Liver Disease: What's the Score?

Hepatology. 2020 Jun 7. doi: 10.1002/hep.31413. Online ahead of print.

Ruth M Pfeiffer¹, Yaron Rotman², Thomas R O'Brien¹

259.

Comparison of MAFLD and NAFLD Diagnostic Criteria in Real World

Liver Int .2020 Jun 1. doi: 10.1111/liv.14548. Online ahead of print.

Su Lin¹, Jiaofeng Huang¹, Mingfang Wang¹, Rahul Kumar², Yuxiu Liu¹, Shiying Liu¹, Yinlian Wu¹, Xiaozhong Wang³, Yueyong Zhu¹

260.

Combination Therapy for Non-Alcoholic Steatohepatitis: Rationale, Opportunities and Challenges

Gut. 2020 May 7;gutjnl-2019-319104. doi: 10.1136/gutjnl-2019-319104.Online ahead of print.

Jean-François Dufour^1 2, Cyrielle Caussy^3 4, Rohit Loomba⁵

261.

Review Article: The Emerging Role of Genetics in Precision Medicine for Patients With Non-Alcoholic Steatohepatitis

Aliment Pharmacol Ther. 2020 Jun;51(12):1305-1320. doi: 10.1111/apt.15738.Epub 2020 May 7.

Björn Carlsson¹, Daniel Lindén^1 2, Gabriella Brolén³, Mathias Liljeblad¹, Mikael Bjursell¹, Stefano Romeo^4 5 6, Rohit Loomba⁷

262.

Increased Atherogenic Lipoprotein Profile in Children With Non-Alcoholic Steatohepatitis

Pediatr Obes. 2020 May 4;e12648 doi: 10.1111/ijpo.12648. Online ahead of print.

Eduardo Castillo-Leon¹, Margery A Connelly², Juna V Konomi¹, Shelley Caltharp^3 4, Rebecca Cleeton¹, Miriam B Vos^1 4 5

263.

Nonalcoholic Fatty Liver Disease and Alcoholic Liver Disease Are Major Drivers of Liver Mortality in the United States

Hepatol Commun. 2020 Apr 4;4(6):890-903. doi: 10.1002/hep4.1510. eCollection 2020 Jun.

James M Paik¹, Pegah Golabi¹, Rakesh Biswas¹, Saleh Alqahtani², Chapy Venkatesan¹, Zobair M Younossi^1 3

264.

Low Thyroid Function in Nonalcoholic Fatty Liver Disease Is an Independent Predictor of All-Cause and Cardiovascular Mortality

Am J Gastroenterol. 2020 Jun 3. doi: 10.14309/ajg.0000000000000654. Online ahead of print.

Donghee Kim¹, Luis Miguel Vazquez-Montesino², Jessica A Escober¹, Christopher T Fernandes¹, George Cholankeril¹, Rohit Loomba^3 4, Stephen A Harrison^5 6, Zobair M Younossi⁷, Aijaz Ahmed¹

265.

Biopsy Rate and Nonalcoholic Steatohepatitis (NASH) in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)

Scand J Gastroenterol. 2020 Jun 1;1-6. doi: 10.1080/00365521.2020.1766554.Online ahead of print.

Florian Gerhardt¹, David Petroff², Valentin Blank^1 3, Albrecht Böhlig¹, Florian van Bömmel¹, Christian Wittekind⁴, Thomas Berg¹, Thomas Karlas¹, Johannes Wiegand¹

266.

Standardization of Diet and Exercise in Clinical Trials of NAFLD-NASH: Recommendations From the Liver Forum

J Hepatol. 2020 Apr 27;S0168-8278(20)30274-9.doi: 10.1016/j.jhep.2020.04.030.Online ahead of print.

Oliver Glass¹, Claudia Filozof², Mazen Noureddin³, Mark Berner-Hansen⁴, Elmer Schabel⁵, Stephanie O Omokaro⁶, Jörn M Schattenberg⁷, Katherine Barradas⁸, Veronica Miller⁸, Sven Francque⁹, Manal F Abdelmalek¹⁰, Liver Forum Standard of Care Working Group

267.

Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial

Gastroenterol. 2020 May 15. doi: 10.14309/ajg.0000000000000661. Online ahead of print.

268.

Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease

Gastroenterol. 2020 May 25. doi: 10.14309/ajg.0000000000000676. Online ahead of print.

Ramy Younes^1 2, Olivier Govaere², Salvatore Petta³, Luca Miele^4 5, Dina Tiniakos², Alastair Burt², Ezio David⁶, Fabio M Vecchio^4 7, Marco Maggioni⁸, Daniela Cabibi⁹, Anna L Fracanzani¹⁰, Chiara Rosso¹, Maria J Garcia Blanco¹¹, Angelo Armandi¹, Gian Paolo Caviglia¹, Marco Y W Zaki^2 12, Antonio Liguori⁴, Paolo Francione¹⁰, Grazia Pennisi³, Antonio Grieco^4 5, Luca Valenti¹³, Quentin M Anstee^2 14, Elisabetta Bugianesi¹

269.

Nonalcoholic Fatty Liver Disease Progression Rates to Cirrhosis and Progression of Cirrhosis to Decompensation and Mortality: A Real World Analysis of Medicare Data

Aliment Pharmacol Ther. 2020 Jun;51(11):1149-1159. doi: 10.1111/apt.15679. Epub 2020 May 5.

Rohit Loomba^1 2, Robert Wong³, Jeremy Fraysse⁴, Sanatan Shreay⁴, Suying Li⁵, Stephen Harrison⁶, Stuart C Gordon⁷

270.

Alanine Aminotransferase and Gamma Glutamyl Transpeptidase Predict Histologic Improvement in Pediatric Nonalcoholic Steatohepatitis

Hepatology. 2020 May 16.doi: 10.1002/hep.31317. Online ahead of print.

Kimberly P Newton^1 2, Joel E Lavine³, Laura Wilson^4 5, Cynthia Behling^6 7, Miriam B Vos⁸, Jean P Molleston⁹, Philip Rosenthal¹⁰, Tamir Miloh¹¹, Mark H Fishbein¹², Ajay K Jain¹³, Karen F Murray¹⁴, Jeffrey B Schwimmer^1 2, Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)

Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN):

Donna Garner, Paula Hertel, Ryan Himes, Alicia Lawson, Tamir Miloh, Nicole Triggs, Kristin Bramlage, April Carr, Kim Cecil, Meghan McNeill, Marialena Mouzaki, Andrew Trout, Stavra Xanthakos, Kimberlee Bernstein, Stephanie DeVore, Rohit Kohli, Kathleen Lake, Daniel Podberesky, Alex Towbin, Joel E Lavine, Ali Mencin, Elena Reynoso, Adina Alazraki, Rebecca Cleeton, Maria Cordero, Albert Hernandez, Saul Karpen, Jessica Cruz Munos, Nicholas Raviele, Miriam Vos, Molly Bozic, Laura Carr, Oscar W Cummings, Kathryn Harlow, Ann Klipsch, Jean P Molleston, Emily Ragozzino, Girish Rao, Kimberly Kafka, Ann Scheimann, Mark H Fishbein, Saeed Mohammad, Peter F Whitington, Sarah Barlow, Elizabeth M Brunt, Danielle Carpenter, Theresa Cattoor, Jose Derdoy, Janet Freebersyser, Ajay Jain Debra King, Jinping Lai, Joan Siegner, Susan Stewart, Susan Torretta, Kristina Wriston, Jennifer Arin, Cynthia Behling, Craig Bross, Carissa Carrier, Diana De La Pena, Janis Durelle, Mary Catherine Huckaby, Michael S Middleton, Kimberly Newton, Jeffrey B Schwimmer, Claude Sirlin, Patricia Ugalde-Nicalo, Jesse Courtier, Ryan Gill, Camille Langlois, Emily Rothbaum Perito, Philip Rosenthal, Patrika Tsai, Niviann Blondet, Kara Cooper, Karen Murray, Randolph Otto, Matthew Yeh, Melissa Young, Elizabeth M Brunt, Kathryn Fowler, David E Kleiner, Edward C Doo, Sherry Hall, Jay H Hoofnagle, Patricia R Robuck, Averell H Sherker, Rebecca Torrance, Patricia Belt, Jeanne M Clark, John Dodge, Michele Donithan, Milana Isaacson, Mariana Lazo, Jill Meinert, Laura Miriel, Emily P Sharkey, Jacqueline Smith, Michael Smith, Alice Sternberg, James Tonascia, Mark L Van Natta, Annette Wagoner, Laura A Wilson, Goro Yamada, Katherine P Yates

271.

Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research

Clin Med. 2020 Apr 28;9(5):E1278. doi: 10.3390/jcm9051278.

Amedeo Lonardo¹, Ayako Suzuki²

272.

Evolving Aspects of Liver Transplantation for Nonalcoholic Steatohepatitis

Curr Opin Organ Transplant. 2013 Jun;18(3):251-8.doi: 10.1097/MOT.0b013e3283615d30.

Michael Charlton¹

273.

Non-alcoholic Liver Disease and Childhood Obesity

Arch Dis Child. 2020 May 14;archdischild-2019-318063.doi: 10.1136/archdischild-2019-318063. Online ahead of print.

Meera Shaunak¹, Christopher D Byrne^2 3, Nikki Davis^1 2, Paul Afolabi^2 3, Saul N Faust^2 3 4, Justin Huw Davies^5 2

274.

Decompensated Cirrhosis Is the Commonest Presentation for NAFLD Patients Undergoing Liver Transplant Assessment

Clin Med (Lond). 2020 May;20(3):313-318. doi: 10.7861/clinmed.2019-0250.

Ahmed Hussain¹, Preya J Patel¹, Freya Rhodes¹, Ankur Srivastava¹, David Patch¹, William Rosenberg²

275.

Risk Stratification of Patients With Nonalcoholic Fatty Liver Disease Using a Case Identification Pathway in Primary Care: A Cross-Sectional Study

MAJ Open. 2020 May 15;8(2):E370-E376.doi: 10.9778/cmajo.20200009. Print Apr-Jun 2020.

Abdel Aziz Shaheen¹, Kiarash Riazi², Alexandra Medellin², Deepak Bhayana², Gilaad G Kaplan², Jason Jiang², Roy Park², Wendy Schaufert², Kelly W Burak², Monica Sargious², Mark G Swain²

276.

The Effect of Sleep on Gastrointestinal Functioning in Common Digestive Diseases

Lancet Gastroenterol Hepatol. 2020 Jun;5(6):616-624.doi: 10.1016/S2468-1253(19)30412-1.

William C Orr¹, Ronnie Fass², Shikha S Sundaram³, Ann O Scheimann⁴

277.

Intragastric Balloon Placement Induces Significant Metabolic and Histologic Improvement in Patients With Nonalcoholic Steatohepatitis

Clin Gastroenterol Hepatol. 2020 Apr 30;S1542-3565(20)30613-3.doi: 10.1016/j.cgh.2020.04.068. Online ahead of print.

Fateh Bazerbachi¹, Eric J Vargas², Monika Rizk², Daniel B Maselli², Taofic Mounajjed³, Sudhakar K Venkatesh⁴, Kymberly D Watt², John D Port⁴, Rita Basu⁵, Andres Acosta², Ibrahim Hanouneh², Naveen Gara⁶, Meera Shah⁷, Manpreet Mundi⁷, Matthew Clark⁷, Karen Grothe⁷, Andrew C Storm², Michael J Levy², Barham K Abu Dayyeh⁸

278.

Niche-Specific Reprogramming of Epigenetic Landscapes Drives Myeloid Cell Diversity in Nonalcoholic Steatohepatitis

Immunity. 2020 May 1;S1074-7613(20)30159-X. doi: 10.1016/j.immuni.2020.04.001.Online ahead of print.

Jason S Seidman¹, Ty D Troutman², Mashito Sakai¹, Anita Gola³, Nathanael J Spann¹, Hunter Bennett¹, Cassi M Bruni¹, Zhengyu Ouyang¹, Rick Z Li¹, Xiaoli Sun⁴, BaoChau T Vu¹, Martina P Pasillas¹, Kaori M Ego¹, David Gosselin⁵, Verena M Link⁶, Ling-Wa Chong⁷, Ronald M Evans⁸, Bonne M Thompson⁹, Jeffrey G McDonald⁹, Mojgan Hosseini¹⁰, Joseph L Witztum⁴, Ronald N Germain³, Christopher K Glass¹¹

279.

Combination Therapy for Non-Alcoholic Steatohepatitis: Rationale, Opportunities and Challenges

Gut. 2020 May 7;gutjnl-2019-319104. doi: 10.1136/gutjnl-2019-319104.Online ahead of print.

Jean-François Dufour^1 2, Cyrielle Caussy^3 4, Rohit Loomba⁵

280.

Standardization of Diet and Exercise in Clinical Trials of NAFLD-NASH: Recommendations From the Liver Forum

J Hepatol. 2020 Apr 27;S0168-8278(20)30274-9 doi: 10.1016/j.jhep.2020.04.030.Online ahead of print.

281.

Antitumour Necrosis Factor-a Agents and Development of New-Onset Cirrhosis or Non-Alcoholic Fatty Liver Disease: A Retrospective Cohort

BMJ Open Gastroenterol. 2020 Apr 15;7(1):e000349.doi: 10.1136/bmjgast-2019-000349.eCollection 2020.

Kuo-Tung Tang^1 2 3, Jean-François Dufour^4 5, Po-Hung Chen⁶, Ruben Hernaez^7 8, Susan Hutfless⁶

282.

Biomarkers of NAFLD and NASH

Metabolism. 2020 May 5;154259. doi: 10.1016/j.metabol.2020.154259.Online ahead of print.

Michelle T Long¹, Sanil Gandhi², Rohit Loomba³

283.

Macrophages in Metabolic Associated Fatty Liver Disease

World J Gastroenterol. 2020 Apr 28;26(16):1861-1878.doi: 10.3748/wjg.v26.i16.1861.

Jawaher Alharthi¹, Olivier Latchoumanin¹, Jacob George¹, Mohammed Eslam²

284.

Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies

J Clin Exp Hepatol. May-Jun 2020;10(3):245-254.doi: 10.1016/j.jceh.2019.07.002.Epub 2019 Jul 15.

Yala K Reddy¹, Hemnishil K Marella¹, Yu Jiang², Surosree Ganguli³, Peter Snell¹, Pradeep S B Podila⁴, Benedict Maliakkal¹, Sanjaya K Satapathy⁵

285.

Blood Lead Level Is Associated With Advanced Liver Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease: A Nationwide Survey (NHANES 2011-2016)

Ann Hepatol. 2020 Apr 4;S1665-2681(20)30028-4. doi: 10.1016/j.aohep.2020.03.006.Online ahead of print.

Debashis Reja¹, Aayush Visaria², Briette Karanfilian³, Vinod Rustgi⁴

286.

Review Article: The Emerging Role of Genetics in Precision Medicine for Patients With Non-Alcoholic Steatohepatitis

Aliment Pharmacol Ther. 2020 May 7. doi: 10.1111/apt.15738. Online ahead of print.

Björn Carlsson¹, Daniel Lindén^1 2, Gabriella Brolén³, Mathias Liljeblad¹, Mikael Bjursell¹, Stefano Romeo^4 5 6, Rohit Loomba⁷

287.

Epidemiology and Pathophysiology of the Association Between NAFLD and Metabolically Healthy or Metabolically Unhealthy Obesity

Ann Hepatol. 2020 Mar 21;S1665-2681(20)30023-5.doi: 10.1016/j.aohep.2020.03.001. Online ahead of print.

Amedeo Lonardo¹, Alessandro Mantovani², Simonetta Lugari³, Giovanni Targher²

288.

The Association Between Cholecystectomy, Metabolic Syndrome, and Nonalcoholic Fatty Liver Disease: A Population-Based Study

Clin Transl Gastroenterol. 2020 Apr;11(4):e00170. doi: 10.14309/ctg.0000000000000170.

Carmen S S Latenstein¹, Louise J M Alferink², Sarwa Darwish Murad², Joost P H Drenth³, Cornelis J H M van Laarhoven¹, Philip R de Reuver¹

289.

Nonalcoholic Fatty Liver Disease Progression Rates to Cirrhosis and Progression of Cirrhosis to Decompensation and Mortality: A Real World Analysis of Medicare Data

Aliment Pharmacol Ther. 2020 May 5. doi: 10.1111/apt.15679. Online ahead of print.

Rohit Loomba^1 2, Robert Wong³, Jeremy Fraysse⁴, Sanatan Shreay⁴, Suying Li⁵, Stephen Harrison⁶, Stuart C Gordon⁷

290.

Nutrition and Genetics in NAFLD: The Perfect Binomium

Int J Mol Sci. 2020 Apr 23;21(8):E2986. doi: 10.3390/ijms21082986.

Marica Meroni^1 2, Miriam Longo^1 3, Alice Rustichelli¹, Paola Dongiovanni¹

291.

Hepatocellular Carcinoma in Non Alcoholic Fatty Liver Disease

Curr Pharm Des. 2020 Apr 28.doi: 10.2174/1381612826666200429093648.Online ahead of print.

Francesco Tovoli¹, Silvia Ferri², Fabio Piscaglia¹

292.

Thyroid Hormone Signaling and the Liver

Hepatology. 2020 Apr 28.doi: 10.1002/hep.31296. Online ahead of print.

Megan J Ritter¹, Izuki Amano^1 2, Anthony N Hollenberg¹

293.

Extrahepatic Manifestations and Healthcare Expenditures of Non-Alcoholic Fatty Liver Disease in the Medicare Population

Hepatol Int. 2020 Apr 16. doi: 10.1007/s12072-020-10038-w. Online ahead of print.

Mehmet Sayiner^1 2, Tamoore Arshad¹, Pegah Golabi², James Paik², Freba Farhat¹, Zobair M Younossi^3 4

294.

How Good Are Controlled Attenuation Parameter Scores From Fibroscan to Assess Steatosis, NASH, and Fibrosis?

Dig Dis Sci. 2020 Apr 27.doi: 10.1007/s10620-020-06269-4. Online ahead of print.

Joshua Trowell¹, Joseph Alukal¹, Talan Zhang¹, Li Liu², Anurag Maheshwari^1 3, Hwan Y Yoo¹, Paul J Thuluvath^4 5

295.

Distinguishing NASH Histological Severity Using a Multiplatform Metabolomics Approach

Metabolites. 2020 Apr 24;10(4):E168. doi: 10.3390/metabo10040168.

George N Ioannou^1 2 3, G A Nagana Gowda⁴, Danijel Djukovic⁴, Daniel Raftery^4 5 6

296.

Extrahepatic Manifestations and Healthcare Expenditures of Non-Alcoholic Fatty Liver Disease in the Medicare Population

Hepatol Int. 2020 Apr 16. doi: 10.1007/s12072-020-10038-w. Online ahead of print.

Mehmet Sayiner^1 2, Tamoore Arshad¹, Pegah Golabi², James Paik², Freba Farhat¹, Zobair M Younossi^3 4

297.

Is Bariatric Surgery Resolving NAFLD via Microbiota-Mediated Bile Acid Ratio Reversal? A Comprehensive Review

Surg Obes Relat Dis. 2020 Mar 20;S1550-7289(20)30131-3. doi: 10.1016/j.soard.2020.03.013.Online ahead of print.

Eider Talavera-Urquijo¹, Marc Beisani², José M Balibrea³, John C Alverdy⁴

298.

Standardization of Diet and Exercise in Clinical Trials of NAFLD-NASH: Recommendations From the Liver Forum

J Hepatol. 2020 Apr 27;S0168-8278(20)30274-9. doi: 10.1016/j.jhep.2020.04.030.Online ahead of print.

299.

Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research

J Clin Med. 2020 Apr 28;9(5):E1278. doi: 10.3390/jcm9051278.

Amedeo Lonardo¹, Ayako Suzuki²

300.

Metabolic Risk Factors and Incident Advanced Liver Disease in Non-Alcoholic Fatty Liver Disease (NAFLD): A Systematic Review and Meta-Analysis of Population-Based Observational Studies

Med. 2020 Apr 30;17(4):e1003100. doi: 10.1371/journal.pmed.1003100.eCollection 2020 Apr.

Helen Jarvis¹, Dawn Craig¹, Robert Barker¹, Gemma Spiers¹, Daniel Stow¹, Quentin M Anstee^2 3, Barbara Hanratty¹

301.

African Americans Have a Distinct Clinical and Histologic Profile With Lower Prevalence of NASH and Advanced Fibrosis Relative to Caucasians

Eur J Gastroenterol Hepatol. 2020 Apr 20. doi: 10.1097/MEG.0000000000001735.Online ahead of print.

Sanjaya K Satapathy^1 2, Hemnishil K Marella³, Rajiv P Heda³, Surosree Ganguli⁴, Yala Kirthi Reddy⁵, Pradeep S B Podila¹, Ian Clark⁶, Benedict Maliakkal¹

302.

Potential Implications of COVID-19 in Non-Alcoholic Fatty Liver Disease

Liver Int. 2020 Apr 19. doi: 10.1111/liv.14484. Online ahead of print.

Grietje H Prins¹, Peter Olinga¹

303.

Obesity as a Risk Factor for Greater Severity of COVID-19 in Patients With Metabolic Associated Fatty Liver Disease

Metabolism. 2020 Apr 19;154244. doi: 10.1016/j.metabol.2020.154244. Online ahead of print.

Kenneth I Zheng¹, Feng Gao², Xiao-Bo Wang³, Qing-Feng Sun⁴, Ke-Hua Pan⁵, Ting-Yao Wang⁶, Hong-Lei Ma¹, Wen-Yue Liu⁷, Jacob George⁸, Ming-Hua Zheng⁹

304.	FXR Agonists as Therapy for Liver Disease
	Hoofnagle JH¹. Hepatology. 2020 Apr 10. doi: 10.1002/hep.31265. [Epub ahead of print]

305.	Obeticholic acid for the treatment of nonalcoholic steatohepatitis
	Shah RA¹, Kowdley KV¹. Expert Rev Gastroenterol Hepatol. 2020 Apr 3. doi: 10.1080/17474124.2020.1748498. [Epub ahead of print]

306.	Bile acids associate with specific gut microbiota, low level alcohol consumption and liver fibrosis in patients with non-alcoholic fatty liver disease
	Adams LA^1,2, Wang Z^1,2, Liddle C³, Melton PE^4,5, Ariff A⁴, Chandraratna H⁶, Tan J⁷, Ching H¹, Coulter S³, de Boer B⁸, Christophersen CT^9,10, O'Sullivan TA⁹, Morrison M¹¹, Jeffrey GP^1,2. Liver Int. 2020 Apr 3. doi: 10.1111/liv.14453. [Epub ahead of print]

307.	Dietary Factors in Relation to Liver Fat Content: A Cross-sectional Study
	Watzinger C¹, Nonnenmacher T², Grafetstätter M¹, Sowah SA^1,3, Ulrich CM⁴, Kauczor HU², Kaaks R¹, Schübel R^1,2, Nattenmüller J², Kühn T¹. Nutrients. 2020 Mar 20;12(3). pii: E825. doi: 10.3390/nu12030825.

308.	Relationship between Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease in Persons with HIV
	Kaplan A^1,2, Simon TG², Henson JB², Wang T², Zheng H³, Osganian SA², Rosenblatt R¹, Lake J⁴, Corey KE². J Acquir Immune Defic Syndr. 2020 Mar 31. doi: 10.1097/QAI.0000000000002359. [Epub ahead of print]

309.	Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study
	Newsome PN¹, Palmer M², Freilich B³, Sheikh MY⁴, Sheikh A⁵, Sarles H⁶, Herring R⁷, Mantry P⁸, Kayali Z⁹, Hassanein T¹⁰, Lee HM², Aithal GP¹¹; Volixibat in Adults study group. J Hepatol. 2020 Mar 28. pii: S0168-8278(20)30186-0. doi: 10.1016/j.jhep.2020.03.024. [Epub ahead of print]

310.	Familial non-alcoholic steatohepatitis leading to hepatocellular carcinoma
	Neuman MG Prof¹, Cohen LB Dr², Malnick S Dr³. Chem Biol Interact. 2020 Mar 23;323:109054. doi: 10.1016/j.cbi.2020.109054. [Epub ahead of print]

311.	Management of nonalcoholic fatty liver disease and the role of bariatric surgery: a brief review for surgeons
	Jorge JM¹, Golas A¹, Patel N¹, Gonzalvo JP¹, Murr MM². Surg Obes Relat Dis. 2020 Feb 5. pii: S1550-7289(20)30049-6. doi: 10.1016/j.soard.2020.01.028. [Epub ahead of print]

312.	Influence of adiposity, insulin resistance and intrahepatic triglyceride content on insulin kinetics
	Smith GI¹, Polidori DC², Yoshino M¹, Kearney ML¹, Patterson BW¹, Mittendorfer B¹, Klein S¹. J Clin Invest. 2020 Mar 19. pii: 136756. doi: 10.1172/JCI136756. [Epub ahead of print]

313.	Nonalcoholic Fatty Liver Disease in Children: Unique Considerations and Challenges
	Goldner D¹, Lavine JE². Gastroenterology. 2020 Mar 20. pii: S0016-5085(20)30168-2. doi: 10.1053/j.gastro.2020.01.048. [Epub ahead of print]

314.	Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It
	Traish AM¹. World J Mens Health. 2020 Mar 20. doi: 10.5534/wjmh.200012. [Epub ahead of print]

315.	Assessing physician preferences on future therapeutic options and diagnostic practices in non-alcoholic steatohepatitis
	Cook N¹, Geier A², Schmid A³, Hirschfield G⁴, Kautz A⁵, Schattenberg JM⁶, Balp MM¹. JHEP Rep. 2020 Feb 1;2(2):100081. doi: 10.1016/j.jhepr.2020.100081. eCollection 2020 Apr.

316.	Nonalcoholic Steatohepatitis: A Review
	Sheka AC¹, Adeyi O², Thompson J³, Hameed B⁴, Crawford PA⁵, Ikramuddin S¹. JAMA. 2020 Mar 24;323(12):1175-1183. doi: 10.1001/jama.2020.2298.

317.	Sarcopenia is a new risk factor of non-alcoholic fatty liver disease in patients with inflammatory bowel disease
	Kang MK, Kim KO, Kim MC, Park JG, Jang BI. Dig Dis. 2020 Mar 5. doi: 10.1159/000506938. [Epub ahead of print]

318.	Nonalcoholic Fatty Liver Disease and Sarcopenia Are Independently Associated With Cardiovascular Risk
	Han E¹, Lee YH^2,3, Kim YD⁴, Kim BK^2,5,6, Park JY^2,5,6, Kim DY^2,5,6, Ahn SH^2,5,6, Lee BW^2,3, Kang ES^2,3, Cha BS^2,3, Han KH^2,5,6, Nam HS⁴, Heo JH⁴, Kim SU^2,5,6. Am J Gastroenterol. 2020 Mar 3. doi: 10.14309/ajg.0000000000000572. [Epub ahead of print]

319.	Managing NAFLD in Type 2 Diabetes: The Effect of Lifestyle Interventions, a Narrative Review
	Parry SA¹, Hodson L^2,3. Adv Ther. 2020 Mar 7. doi: 10.1007/s12325-020-01281-6. [Epub ahead of print]

320.	Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review
	Pan CS¹, Stanley TL^1,2. Front Endocrinol (Lausanne). 2020 Feb 21;11:70. doi: 10.3389/fendo.2020.00070. eCollection 2020.

321.	Predictive Factors and Time to Development of Hepatic Decompensation in Patients with Non-alcoholic Fatty Liver Disease
	Ahmed HS^1,2, Pedersen N³, Jayanna MB^3,4, Ten Eyck P⁵, Sanchez A³, Murali AR^3,6. J Gen Intern Med. 2020 Mar 10. doi: 10.1007/s11606-020-05725-1. [Epub ahead of print]

322.

Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials

Harrison SA¹, Wai-Sun Wong V², Okanoue T³, Bzowej N⁴, Vuppalanchi R⁵, Younes Z⁶, Kohli A⁷, Sarin S⁸, Caldwell SH⁹, Alkhouri N¹⁰, Shiffman ML¹¹, Camargo M¹², Li G¹², Kersey K¹², Jia C¹², Zhu Y¹², Djedjos CS¹², Subramanian GM¹², Myers RP¹², Gunn N¹³, Sheikh A¹⁴, Anstee QM¹⁵, Romero-Gomez M¹⁶, Trauner M¹⁷, Goodman Z¹⁸, Lawitz EJ¹⁰, Younossi Z¹⁸; STELLAR-3 and STELLAR-4 Investigators. J Hepatol. 2020 Mar 5. pii: S0168-8278(20)30126-4. doi: 10.1016/j.jhep.2020.02.027. [Epub ahead of print]

323.

Cilofexor, a Nonsteroidal FXR Agonist, in Non-Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial

Patel K¹, Harrison SA², Elkashab M³, Trotter JF⁴, Herring R⁵, Rojter S⁶, Kayali Z⁷, Wong VW⁸, Greenbloom S⁹, Jayakumar S¹⁰, Shiffman ML¹¹, Freilich B¹², Lawitz EJ, Gane E^13,14, Harting E¹⁵, Xu J¹⁵, Billin AN¹⁵, Chung C¹⁵, Djedjos CS¹⁵, Subramanian GM¹⁵, Myers RP¹⁵, Middleton MS¹⁰, Rinella M¹⁶, Noureddin M¹⁷. Hepatology. 2020 Mar 1. doi: 10.1002/hep.31205. [Epub ahead of print]

324.	Thyroid hormones and thyromimetics: A new approach to NASH?
	Sinha RA¹, Bruinstroop E², Singh BK³, Yen PM³. Hepatology. 2020 Feb 27. doi: 10.1002/hep.31204. [Epub ahead of print]

325.	Epidemiology of Non-alcoholic Fatty Liver Disease in North America
	Arshad T¹, Golabi P², Henry L³, Younossi ZM¹. Curr Pharm Des. 2020 Mar 2. doi: 10.2174/1381612826666200303114934. [Epub ahead of print]

326.	Sarcopenia in nonalcoholic fatty liver disease: new challenges for clinical practice
	El Sherif O¹, Dhaliwal A^1,2, Newsome PN^1,2,3, Armstrong MJ^1,2,3. Expert Rev Gastroenterol Hepatol. 2020 Feb 23:1-9. doi: 10.1080/17474124.2020.1731303. [Epub ahead of print]

327.	Advances in non-invasive assessment of hepatic fibrosis
	Loomba R¹, Adams LA². Gut. 2020 Feb 17. pii: gutjnl-2018-317593. doi: 10.1136/gutjnl-2018-317593. [Epub ahead of print]

328.	A Microbial Signature Identifies Advanced Fibrosis in Patients with Chronic LiverDisease Mainly Due to NAFLD
	Dong TS¹, Katzka W^1,2, Lagishetty V^1,2, Luu K^1,2, Hauer M^1,2, Pisegna J³, Jacobs JP^4,5,6. Sci Rep. 2020 Feb 17;10(1):2771. doi: 10.1038/s41598-020-59535-w.

329.	Longitudinal Association of Non-Alcoholic Fatty Liver Disease With Changes in Myocardial Structure and Function: The CARDIA Study
	VanWagner LB^1,2, Wilcox JE^2,3, Ning H², Lewis CE⁴, Carr JJ⁵, Rinella ME¹, Shah SJ³, Lima JAC⁶, Lloyd-Jones DM^2,3. J Am Heart Assoc. 2020 Feb 18;9(4):e014279. doi: 10.1161/JAHA.119.014279. Epub 2020 Feb 6.

330.	Adipose tissue-liver cross talk in the control of whole-body metabolism: implications in non-alcoholic fatty liver disease
	Azzu V¹, Vacca M², Virtue S², Allison M³, Vidal-Puig A⁴. Gastroenterology. 2020 Feb 12. pii: S0016-5085(20)30224-9. doi: 10.1053/j.gastro.2019.12.054.

331.	Circadian Rhythms in the Pathogenesis and Treatment of Fatty Liver Disease
	Saran AR¹, Dave S¹, Zarrinpar A². Gastroenterology. 2020 Feb 12. pii: S0016-5085(20)30221-3. doi: 10.1053/j.gastro.2020.01.050.

332.

A diabetologist's perspective of non-alcoholic steatohepatitis (NASH): Knowledge gaps and future directions

Cusi K^1,2. Liver Int. 2020 Feb;40 Suppl 1:82-88. doi: 10.1111/liv.14350.

333.	New drugs for non-alcoholic steatohepatitis
	Cardoso AC^1,2, de Figueiredo-Mendes C³, A Villela-Nogueira C^1,2, Sanyal AJ⁴. Liver Int. 2020 Feb;40 Suppl 1:96-101. doi: 10.1111/liv.14354.

334.	New drugs for non-alcoholic steatohepatitis and HIV infection: great expectations with a great absent?
	Guaraldi G¹, Maurice JB², Marzolini C³, Monteith K⁴, Milic J¹, Tsochatzis E⁵, Bhagani S⁶, Morse CG⁷, Price JC⁸, Ingiliz P^9,10, Lemoine M¹¹, Sebastiani G¹²; SHIVER Network. Hepatology. 2020 Feb 13. doi: 10.1002/hep.31177. [Epub ahead of print]

335.	The association of nonalcoholic steatohepatitis and hepatocellular carcinoma
	Asfari MM^1,2, Talal Sarmini M², Alomari M², Lopez R³, Dasarathy S^4,5,6, McCullough AJ^4,5,6. Eur J Gastroenterol Hepatol. 2020 Feb 18. doi: 10.1097/MEG.0000000000001681. [Epub ahead of print]

336.	MAFLD: A consensus-driven proposed nomenclature for metabolic associated fattyliver disease
	Eslam M¹, Sanyal AJ², George J³; an international consensus panel. Gastroenterology. 2020 Feb 7. pii: S0016-5085(20)30171-2. doi: 10.1053/j.gastro.2019.11.312. [Epub ahead of print]

337.	Nonalcoholic fatty liver disease burden: Australia, 2019-2030
	Adams LA¹, Roberts SK², Strasser SI³, Mahady SE^4,5, Powell E⁶, Estes C⁷, Razavi H⁷, George J⁸. J Gastroenterol Hepatol. 2020 Feb 11. doi: 10.1111/jgh.15009. [Epub ahead of print]

338.	NAFLD as a driver of chronic kidney disease
	Byrne CD¹, Targher G². J Hepatol. 2020 Feb 11. pii: S0168-8278(20)30030-1. doi: 10.1016/j.jhep.2020.01.013. [Epub ahead of print]

339.	NAFLD 2020: The State of the Disease
	Cotter TG¹, Rinella M². Gastroenterology. 2020 Feb 12. pii: S0016-5085(20)30223-7. doi: 10.1053/j.gastro.2020.01.052. [Epub ahead of print]

340.	Therapeutic landscape for NAFLD in 2020
	Neuschwander-Tetri BA¹. Gastroenterology. 2020 Feb 12. pii: S0016-5085(20)30222-5. doi: 10.1053/j.gastro.2020.01.051. [Epub ahead of print]

341.	Natural history of NASH and HCC
	Negro F¹. Liver Int. 2020 Feb;40 Suppl 1:72-76. doi: 10.1111/liv.14362.

342.	Mechanisms of Fibrosis Development in NASH
	Schwabe RF¹, Tabas I², Pajvani UB³. Gastroenterology. 2020 Feb 7. pii: S0016-5085(20)30169-4. doi: 10.1053/j.gastro.2019.11.311. [Epub ahead of print]

343.	Implications of Nonalcoholic Steatohepatitis as the Cause of End-Stage Liver Disease Before and After Liver Transplant
	Chandrakumaran A¹, Siddiqui MS². Gastroenterol Clin North Am. 2020 Mar;49(1):165-178. doi: 10.1016/j.gtc.2019.09.005.

344.	Burden of Disease due to Nonalcoholic Fatty Liver Disease
	Muthiah MD¹, Sanyal AJ². Gastroenterol Clin North Am. 2020 Mar;49(1):1-23. doi: 10.1016/j.gtc.2019.09.007.

345.	Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease
	Wattacheril J¹. Gastroenterol Clin North Am. 2020 Mar;49(1):141-149. doi: 10.1016/j.gtc.2019.10.002. Epub 2019 Dec 24.

346.	Exercise Training Rapidly Increases Hepatic Insulin Extraction in NAFLD
	Hari A¹, Fealy CE², Axelrod CL³, Haus JM⁴, Flask CA¹, McCullough AJ⁵, Kirwan JP^1,3. Med Sci Sports Exerc. 2020 Feb 5. doi: 10.1249/MSS.0000000000002273. [Epub ahead of print]

347.	Genetic Risk Factors and Disease Modifiers of Nonalcoholic Steatohepatitis
	Kozlitina J¹. Gastroenterol Clin North Am. 2020 Mar;49(1):25-44. doi: 10.1016/j.gtc.2019.09.001

348.	Is NAFLD Not a Risk Factor for Cardiovascular Disease: Not Yet Time for a Change of Heart
	Henson JB¹, Roden M^2,3,4, Targher G⁵, Corey KE⁶. Hepatology. 2020 Feb 3. doi: 10.1002/hep.31156. [Epub ahead of print]

349.	Non-Alcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know?
	Budd J¹, Cusi K². Am J Med. 2020 Feb 1. pii: S0002-9343(20)30100-5. doi: 10.1016/j.amjmed.2020.01.007. [Epub ahead of print]

350.	Extra-Hepatic Manifestations of Nonalcoholic Fatty Liver Disease: A Review
	Tariq R¹, Axley P², Singal AK³. J Clin Exp Hepatol. 2020 Jan-Feb;10(1):81-87. doi: 10.1016/j.jceh.2019.07.008. Epub 2019 Jul 25.

351.

Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis

Taylor RS¹, Taylor RJ², Bayliss S³, Hagstrom H⁴, Nasr P⁵, Schattenberg JM⁶, Ishigami M⁷, Toyoda H⁸, Wai-Sun Wong V⁹, Peleg N¹⁰, Shlomai A¹¹, Sebastiani G¹², Seko Y¹³, Bhala N¹⁴, Younossi ZM¹⁵, Anstee QM¹⁶, McPherson S¹⁷, Newsome PN¹⁸; Collaborators. Gastroenterology. 2020 Feb 3. pii: S0016-5085(20)30137-2. doi: 10.1053/j.gastro.2020.01.043. [Epub ahead of print]

352.	Herbal drug discovery for the treatment of nonalcoholic fatty liver disease
	Yan T¹, Yan N², Wang P^1,3, Xia Y^1,4, Hao H², Wang G², Gonzalez FJ¹. Acta Pharm Sin B. 2020 Jan;10(1):3-18. doi: 10.1016/j.apsb.2019.11.017. Epub 2019 Dec 10.

353.	How to Identify the Patient with Nonalcoholic Steatohepatitis Who Will Progress to Cirrhosis
	Henry ZH¹, Argo CK². Gastroenterol Clin North Am. 2020 Mar;49(1):45-62. doi: 10.1016/j.gtc.2019.09.002. Epub 2019 Dec 24.

354.	Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study
	Ratziu V¹, Sanyal A², Harrison SA³, Wong VW⁴, Francque S⁵, Goodman Z⁶, Aithal GP⁷, Kowdley KV⁸, Seyedkazemi S⁹, Fischer L⁹, Loomba R^10,11, Abdelmalek MF¹², Tacke F^13,14. Hepatology. 2020 Jan 13. doi: 10.1002/hep.31108. [Epub ahead of print]

355.	Multicenter validation of association between decline in MRI-PDFF and histologic response in nonalcoholic steatohepatitis
	Loomba R¹, Neuschwander-Tetri BA², Sanyal A³, Chalasani N⁴, Diehl AM⁵, Terrault N⁶, Kowdley K⁷, Dasarathy S⁸, Kleiner D⁹, Behling C¹, Lavine J¹⁰, Van Natta M¹¹, Middleton M¹, Tonascia J¹¹, Sirlin C¹; NASH Clinical Research Network. Hepatology. 2020 Jan 21. doi: 10.1002/hep.31121. [Epub ahead of print]

356.	Nonalcoholic Steatohepatitis Becomes the Leading Indication for Liver Transplant Registrants Among US Adults Born Between 1945 and 1965
	Shirazi F¹, Wang J¹, Wong RJ². J Clin Exp Hepatol. 2020 Jan-Feb;10(1):30-36. doi: 10.1016/j.jceh.2019.06.007. Epub 2019 Jul 10.

357.	Multiparametric Magnetic Resonance Elastography Improves the Detection of NASHRegression Following Bariatric Surgery
	Allen AM¹, Shah VH¹, Therneau TM², Venkatesh SK³, Mounajjed T⁴, Larson JJ², Mara KC², Kellogg TA⁵, Kendrick ML⁵, McKenzie TJ⁵, Greiner SM¹, Li J³, Glaser KJ³, Wells ML³, Gunneson TJ⁶, Ehman RL³, Yin M³. Hepatol Commun. 2019 Nov 5;4(2):185-192. doi: 10.1002/hep4.1446. eCollection 2020 Feb.

358.

FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study

Newsome PN¹, Sasso M², Deeks JJ³, Paredes A⁴, Boursier J⁵, Chan WK⁶, Yilmaz Y⁷, Czernichow S⁸, Zheng MH⁹, Wong VW¹⁰, Allison M¹¹, Tsochatzis E¹², Anstee QM¹³, Sheridan DA¹⁴, Eddowes PJ¹⁵, Guha IN¹⁵, Cobbold JF¹⁶, Paradis V¹⁷, Bedossa P¹⁸, Miette V², Fournier-Poizat C¹⁹, Sandrin L², Harrison SA²⁰. Lancet Gastroenterol Hepatol. 2020 Feb 3. pii: S2468-1253(19)30383-8. doi: 10.1016/S2468-1253(19)30383-8. [Epub ahead of print]

359.	Pharmacologic Treatment Strategies for Nonalcoholic Steatohepatitis
	Esteban JPG¹, Asgharpour A². Gastroenterol Clin North Am. 2020 Mar;49(1):105-121. doi: 10.1016/j.gtc.2019.10.003.

360.	Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C
	Tanwar S¹, Rhodes F¹, Srivastava A¹, Trembling PM¹, Rosenberg WM¹. World J Gastroenterol. 2020 Jan 14;26(2):109-133. doi: 10.3748/wjg.v26.i2.109.

361.	Proportion of NAFLD patients with normal ALT value in overall NAFLD patients: a systematic review and meta-analysis
	Ma X¹, Liu S^2,3, Zhang J¹, Dong M¹, Wang Y¹, Wang M¹, Xin Y^4,5. BMC Gastroenterol. 2020 Jan 14;20(1):10. doi: 10.1186/s12876-020-1165-z.

362.	Fibroblast growth factor (FGF)-21 based therapies: A magic bullet for nonalcoholic fatty liver disease (NAFLD)?
	Ritchie M¹, Hanouneh IA^1,2, Noureddin M³, Rolph T⁴, Alkhouri N⁵. Expert Opin Investig Drugs. 2020 Feb;29(2):197-204. doi: 10.1080/13543784.2020.1718104. Epub 2020 Jan 22.

363.

Synbiotic Alters Fecal Microbiomes, but not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Non-alcoholic Fatty Liver Disease

Scorletti E¹, Afolabi PR², Miles EA³, Smith DE², Almehmadi A³, Alshathry A³, Childs CE³, Del Fabbro S³, Beavis J³, Moyses HE⁴, Clough GF³, Sethi JK⁵, Patel J⁶, Wright M⁶, Breen DJ⁷, Peebles C⁷, Darekar A⁸, Aspinall R⁹, Fowell AJ⁹, Dowman JK⁹, Nobili V¹⁰, Targher G¹¹, Delzenne NM¹², Bindels LB¹², Calder PC¹³, Byrne CD². Gastroenterology. 2020 Jan 24. pii: S0016-5085(20)30124-4. doi: 10.1053/j.gastro.2020.01.031. [Epub ahead of print]

364.	Work up of fatty liver by primary care physicians, review
	Rikhi R¹, Singh T², Modaresi Esfeh J². Ann Med Surg (Lond). 2020 Jan 11;50:41-48. doi: 10.1016/j.amsu.2020.01.001. eCollection 2020 Feb.

365.	NASH (nonalcoholic steatohepatitis), diabetes, and macrovascular disease: multiple chronic conditions and a potential treatment at the metabolic root
	Colca J^1,2. Expert Opin Investig Drugs. 2020 Jan 23:1-6. doi: 10.1080/13543784.2020.1715940. [Epub ahead of print]

366.	Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date
	Albhaisi S¹, Sanyal AJ². Pharmaceut Med. 2019 Dec;33(6):451-463. doi: 10.1007/s40290-019-00305-z.

367.	Macrophage Function in the Pathogenesis of Non-alcoholic Fatty Liver Disease: The Mac Attack
	Oates JR^1,2,3, McKell MC^1,3,4, Moreno-Fernandez ME^1,2, Damen MSMA^1,2, Deepe GS Jr⁵, Qualls JE^1,3,4, Divanovic S^1,2,3,6. Front Immunol. 2019 Dec 12;10:2893. doi: 10.3389/fimmu.2019.02893. eCollection 2019.

368.	Presumed Nonalcoholic Fatty Liver Disease Among Medicare Beneficiaries With HIV, 2006-2016
	Paik JM¹, Henry L², Golabi P¹, Alqahtani SA³, Trimble G⁴, Younossi ZM^1,4. Open Forum Infect Dis. 2020 Jan 7;7(1):ofz509. doi: 10.1093/ofid/ofz509. eCollection 2020 Jan.

369.	Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials
	Mantovani A¹, Byrne CD², Scorletti E³, Mantzoros CS⁴, Targher G⁵. Diabetes Metab. 2020 Jan 7. pii: S1262-3636(20)30002-1. doi: 10.1016/j.diabet.2019.12.007. [Epub ahead of print]

370.	The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease
	Romero FA, Jones C, Xu Y, Fenaux M, Halcomb RL. J Med Chem. 2020 Jan 13. doi: 10.1021/acs.jmedchem.9b01701. [Epub ahead of print]

371.	A Model to Identify Heavy Drinkers at High Risk for Liver Disease Progression
	Delacôte C¹, Bauvin P¹, Louvet A², Dautrecque F³, Ntandja Wandji LC³, Lassailly G², Voican C⁴, Perlemuter G⁴, Naveau S⁴, Mathurin P², Deuffic-Burban S⁵. Clin Gastroenterol Hepatol. 2020 Jan 10. pii: S1542-3565(20)30039-2. doi: 10.1016/j.cgh.2019.12.041. [Epub ahead of print]

372.	Small but mighty: Platelets in NASH and other chronic liver diseases
	Hilscher MB¹, Shah VH¹. Hepatology. 2020 Jan 5. doi: 10.1002/hep.31101. [Epub ahead of print]

373.	Continued muscle loss increases mortality in cirrhosis- impact of etiology of liver disease
	Welch N^1,2, Dasarathy J³, Runkana A⁴, Penumatsa R², Bellar A², Reen J², Rotroff D⁵, McCullough AJ¹, Dasarathy S^1,2. Liver Int. 2019 Dec 31. doi: 10.1111/liv.14358. [Epub ahead of print]

374.	Childhood and Adolescent Nonalcoholic Fatty Liver Disease: Is It Different from Adults?
	Fitzpatrick E¹, Dhawan A¹. J Clin Exp Hepatol. 2019 Nov-Dec;9(6):716-722. doi: 10.1016/j.jceh.2019.05.005. Epub 2019 May 31.

375.	Carotenoids and fatty liver disease: Current knowledge and research gaps
	Clugston RD¹. Biochim Biophys Acta Mol Cell Biol Lipids. 2020 Jan 2:158597. doi: 10.1016/j.bbalip.2019.158597. [Epub ahead of print]

376.	Increased Glutaminolysis Marks Active Scarring in Nonalcoholic Steatohepatitis Progression
	Du K¹, Chitneni SK², Suzuki A¹, Wang Y¹, Henao R³, Hyun J¹, Premont RT¹, Naggie S⁴, Moylan CA¹, Bashir MR⁵, Abdelmalek MF¹, Diehl AM⁶. Cell Mol Gastroenterol Hepatol. 2019 Dec 24. pii: S2352-345X(19)30182-1. doi: 10.1016/j.jcmgh.2019.12.006. [Epub ahead of print]

377.

A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis

Harrison SA¹, Goodman Z², Jabbar A³, Vemulapalli R⁴, Younes ZH⁵, Freilich B⁶, Sheikh MY⁷, Schattenberg JM⁸, Kayali Z⁹, Zivony A¹⁰, Sheikh A¹¹, Garcia-Samaniego J¹², Satapathy SK¹³, Therapondos G¹⁴, Mena E¹⁵, Schuppan D¹⁶, Robinson J¹⁷, Chan JL¹⁷, Hagerty DT¹⁸, Sanyal AJ¹⁹. J Hepatol. 2019 Dec 27. pii: S0168-8278(19)30758-5. doi: 10.1016/j.jhep.2019.11.024. [Epub ahead of print]

378.	A Pilot Genome-Wide Analysis Study Identifies Loci Associated With Response to Obeticholic Acid in Patients With NASH
	Gawrieh S¹, Guo X², Tan J², Lauzon M², Taylor KD², Loomba R³, Cummings OW⁴, Pillai S⁵, Bhatnagar P⁵, Kowdley KV⁶, Yates K⁷, Wilson LA⁷, Chen YI², Rotter JI², Chalasani N¹; NASH Clinical Research Network. Hepatol Commun. 2019 Nov 3;3(12):1571-1584. doi: 10.1002/hep4.1439. eCollection 2019 Dec.

379.	Evaluation of Dietary Approaches for the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review
	Saeed N¹, Nadeau B¹, Shannon C², Tincopa M¹. Nutrients. 2019 Dec 16;11(12). pii: E3064. doi: 10.3390/nu11123064.

380.	Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study
	Baratta F¹, Pastori D², Angelico F³, Balla A⁴, Paganini AM⁴, Cocomello N¹, Ferro D¹, Violi F⁵, Sanyal AJ⁶, Del Ben M¹. Clin Gastroenterol Hepatol. 2019 Dec 27. pii: S1542-3565(19)31506-X. doi: 10.1016/j.cgh.2019.12.026. [Epub ahead of print]

381.	When the Liver Gets Stiff, the Tough Get Moving
	Nguyen TH¹, Wardell R¹, Chitturi S¹, Teoh N¹, Farrell G^1,2. J Gastroenterol Hepatol. 2019 Dec 22. doi: 10.1111/jgh.14963. [Epub ahead of print]

382.	Nonalcoholic Fatty Liver Disease: An Emerging Driver of Hypertension
	Zhao YC^1,2, Zhao GJ^1,2, Chen Z^1,2, She ZG^1,2,3,4, Cai J^1,5,2, Li H^1,2,3. Hypertension. 2020 Feb;75(2):275-284. doi: 10.1161/HYPERTENSIONAHA.119.13419. Epub 2019 Dec 23.

383.	Derivation and Internal Validation of a Clinical Prediction Tool to Predict Nonalcoholic FattyLiver Disease in Patients With Crohn
	McHenry S¹, Tirath A², Tsai R³, Sharma Y⁴, Flores AG¹, Davidson NO¹, Fowler KJ^3,5, Ciorba MA^1,4, Deepak P^1,6. Inflamm Bowel Dis. 2020 Jan 7. pii: izz324. doi: 10.1093/ibd/izz324. [Epub ahead of print]

384.	Noninvasive assessment of hepatic steatosis and fibrosis in patients with severe obesity
	Coccia F¹, Testa M¹, Guarisco G¹, Bonci E², Di Cristofano C³, Silecchia G⁴, Leonetti F⁵, Gastaldelli A⁶, Capoccia D¹. Endocrine. 2019 Dec 19. doi: 10.1007/s12020-019-02155-w. [Epub ahead of print]

385.

Randomized Placebo-Controlled Trial of Emricasan in Non-alcoholic Steatohepatitis (NASH) Cirrhosis with Severe Portal Hypertension

Garcia-Tsao G¹, Bosch J², Kayali Z³, Harrison SA⁴, Abdelmalek MF⁵, Lawitz E⁶, Satapathy SK⁷, Ghabril M⁸, Shiffman ML⁹, Younes ZH¹⁰, Thuluvath PJ¹¹, Berzigotti A¹², Albillos A¹³, Robinson JM¹⁴, Hagerty DT¹⁴, Chan JL¹⁴, Sanyal AJ¹⁵; IDN-6556-14 Investigators. J Hepatol. 2019 Dec 20. pii: S0168-8278(19)30724-X. doi: 10.1016/j.jhep.2019.12.010. [Epub ahead of print]

386.	Moderate Alcohol Intake in Non-Alcoholic Fatty Liver Disease: To Drink or Not to Drink?
	Petroni ML¹, Brodosi L¹, Marchignoli F¹, Musio A¹, Marchesini G¹. Nutrients. 2019 Dec 13;11(12). pii: E3048. doi: 10.3390/nu11123048.

387.	Effects of alternate-day fasting on body weight and dyslipidaemia in patients with non-alcoholic fatty liver disease: a randomised controlled trial
	Cai H¹, Qin YL¹, Shi ZY¹, Chen JH¹, Zeng MJ¹, Zhou W¹, Chen RQ¹, Chen ZY². BMC Gastroenterol. 2019 Dec 18;19(1):219. doi: 10.1186/s12876-019-1132-8.

388.	Relationship between non-alcoholic fatty liver disease during pregnancy and abnormal glucose metabolism during and after pregnancy
	Sattari M¹, Bril F², Egerman R^2,3, Kalavalapalli S⁴, Cusi K^4,5,6. J Investig Med. 2019 Dec 17. pii: jim-2019-001186. doi: 10.1136/jim-2019-001186. [Epub ahead of print]

389.	Bariatric Surgery in Cirrhotic Patients: Is It Safe?
	Younus H¹, Sharma A¹, Miquel R¹, Quaglia A¹, Kanchustambam SR¹, Carswell KA¹, Patel AG². Obes Surg. 2019 Dec 18. doi: 10.1007/s11695-019-04214-7. [Epub ahead of print]

390.	Nonalcoholic Fatty Liver Disease: A Challenge from Mechanisms to Therapy
	Tarantino G¹, Citro V², Capone D³. J Clin Med. 2019 Dec 19;9(1). pii: E15. doi: 10.3390/jcm9010015.

391.	Disease Severity Is Associated With Higher Healthcare Utilization in Nonalcoholic Steatohepatitis Medicare Patients
	Gordon S¹, Fraysse J², Li S³, Ozbay AB², Wong RJ⁴. Am J Gastroenterol. 2019 Dec 12. doi: 10.14309/ajg.0000000000000484. [Epub ahead of print]

392.	Insulin Resistance and Genetic Risk Predict Liver-Related Outcomes and Death in Nonalcoholic Fatty Liver Disease
	Danford CJ¹, Jiang ZG¹, Salomaa V², Färkkilä M³, Jula A², Männistö S², Lundqvist A², Valsta L², Perola M², Åberg F^4,5. Hepatol Commun. 2019 Oct 10;3(12):1704-1705. doi: 10.1002/hep4.1437. eCollection 2019 Dec.

393.	Influence of lifestyle factors and staple foods from the Mediterranean diet on non-alcoholic fatty liver disease among older individuals with metabolic syndrome features
	Bullón-Vela V¹, Abete I², Tur JA³, Pintó X⁴, Corbella E⁴, Martínez-González MA⁵, Toledo E⁵, Corella D⁶, Macías M⁷, Tinahones F⁷, Fitó M⁸, Estruch R⁹, Ros E¹⁰, Salas-Salvadó J¹¹, Daimiel L¹², Zulet MA¹³, Martínez JA²; PREDIMED Plus investigators. Nutrition. 2019 Oct 25;71:110620. doi: 10.1016/j.nut.2019.110620. [Epub ahead of print]

394.	Association between neck circumference and non-alcoholic fatty liver disease in Mexican children and adolescents with obesity
	Peña-Vélez R^1,2, Garibay-Nieto N^1,2,3, Cal-Y-Mayor-Villalobos M⁴, Laresgoiti-Servitje E⁵, Pedraza-Escudero K^1,2, García-Blanco MDC⁴, Heredia-Nieto OA⁶, Villanueva-Ortega E^1,2. J Pediatr Endocrinol Metab. 2019 Dec 16. pii: /j/jpem.ahead-of-print/jpem-2019-0204/jpem-2019-0204.xml. doi: 10.1515/jpem-2019-0204. [Epub ahead of print]

395.	A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver DiseaseAnd Non-Alcoholic Steatohepatitis
	Ganguli S¹, DeLeeuw P², Satapathy SK³. Hepat Med. 2019 Nov 15;11:159-178. doi: 10.2147/HMER.S188991. eCollection 2019.

396.	Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered
	Plaz Torres MC^1,2,3, Aghemo A^3,4, Lleo A^3,4, Bodini G^1,2,3, Furnari M¹, Marabotto E¹, Miele L⁵, Giannini EG^1,2,6. Nutrients. 2019 Dec 5;11(12). pii: E2971. doi: 10.3390/nu11122971.

397.	Higher Sodium Intake Assessed by 24 Hour Urinary Sodium Excretion Is Associated with Non-Alcoholic Fatty Liver Disease: The PREVEND Cohort Study
	van den Berg EH^1,2, Gruppen EG^1,3, Blokzijl H², Bakker SJL³, Dullaart RPF¹. J Clin Med. 2019 Dec 6;8(12). pii: E2157. doi: 10.3390/jcm8122157.

398.	High Protein Diet and Metabolic Plasticity in Non-Alcoholic Fatty Liver Disease: Myths and Truths
	De Chiara F¹, Ureta Checcllo C², Ramón Azcón J¹. Nutrients. 2019 Dec 6;11(12). pii: E2985. doi: 10.3390/nu11122985.

399.	A retrospective case control study identifies peripheral blood mononuclear cell albumin RNA expression as a biomarker for non-alcoholic fatty liver disease
	Chu X¹, Karasinski K², Donellan S², Kaniper S², Wood GC¹, Shi W¹, Edwards MA³, Soans R³, Still CD¹, Gerhard GS⁴. Langenbecks Arch Surg. 2019 Dec 11. doi: 10.1007/s00423-019-01848-0. [Epub ahead of print]

400.	Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis
	Siddiqui MS1, Van Natta ML2, Connelly MA3, Vuppalanchi R4, Neuschwander-Tetri BA5, Tonascia J2, Guy C6, Loomba R7, Dasarathy S8, Wattacheril J9, Chalasani N4, Sanyal AJ10; NASH CRN. J Hepatol. 2019 Oct 18. pii: S0168-8278(19)30607-5. doi: 10.1016/j.jhep.2019.10.006. [Epub ahead of print]

401.	Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development
	Mouries J¹, Brescia P¹, Silvestri A¹, Spadoni I², Sorribas M³, Wiest R⁴, Mileti E⁵, Galbiati M⁶, Invernizzi P⁶, Adorini L⁷, Penna G⁸, Rescigno M⁹. J Hepatol. 2019 Dec;71(6):1216-1228. doi: 10.1016/j.jhep.2019.08.005. Epub 2019 Aug 13.

402.	REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis
	Ratziu V¹, Sanyal AJ², Loomba R³, Rinella M⁴, Harrison S⁵, Anstee QM⁶, Goodman Z⁷, Bedossa P⁸, MacConell L⁹, Shringarpure R⁹, Shah A⁹, Younossi Z⁷. Contemp Clin Trials. 2019 Sep;84:105803. doi: 10.1016/j.cct.2019.06.017. Epub 2019 Jun 29.

403.	Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis
	Loomba R¹, Sanyal AJ², Kowdley KV³, Terrault N⁴, Chalasani NP⁵, Abdelmalek MF⁶, McCullough AJ⁷, Shringarpure R⁸, Ferguson B⁸, Lee L⁸, Chen J⁸, Liberman A⁸, Shapiro D⁸, Neuschwander-Tetri BA⁹. Gastroenterology. 2019 Jan;156(1):88-95.e5. doi: 10.1053/j.gastro.2018.09.021. Epub 2018 Sep 15.

404.

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Younossi ZM¹, Ratziu V², Loomba R³, Rinella M⁴, Anstee QM⁵, Goodman Z¹, Bedossa P⁶, Geier A⁷, Beckebaum S⁸, Newsome PN⁹, Sheridan D¹⁰, Sheikh MY¹¹, Trotter J¹², Knapple W¹³, Lawitz E¹⁴, Abdelmalek MF¹⁵, Kowdley KV¹⁶, Montano-Loza AJ¹⁷, Boursier J¹⁸, Mathurin P¹⁹, Bugianesi E²⁰, Mazzella G²¹, Olveira A²², Cortez-Pinto H²³, Graupera I²⁴, Orr D²⁵, Gluud LL²⁶, Dufour JF²⁷, Shapiro D²⁸, Campagna J²⁸, Zaru L²⁸, MacConell L²⁸, Shringarpure R²⁸, Harrison S²⁹, Sanyal AJ³⁰; REGENERATE Study Investigators.

Collaborators (336) Lancet. 2019 Dec 5. pii: S0140-6736(19)33041-7. doi: 10.1016/S0140-6736(19)33041-7. [Epub ahead of print]

405.	Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes
	Poynard T^1,2, Peta V^2,3, Deckmyn O³, Pais R^1,2, Ngo Y^2,3, Charlotte F⁴, Ngo A³, Munteanu M^2,3, Imbert-Bismut F⁵, Monneret D⁵, Housset C², Thabut D^1,2, Valla D⁶, Boitard C⁷, Castera L⁶, Ratziu V¹; FLIP consortium, the FibroFrance Group, the EPIC-3 program and the QUID-NASH group.

406.	The Role of Noninvasive Tests for Differentiating NASH From NAFL and Diagnosing Advanced Fibrosis Among Patients With NAFLD
	Balakrishnan M¹, Loomba R^2,3. J Clin Gastroenterol. 2019 Nov 26. doi: 10.1097/MCG.0000000000001284. [Epub ahead of print]

407.	Impact of NAFLD on the Incidence of Cardiovascular Diseases in a Primary Care Population in Germany
	Labenz C^1,2, Huber Y^1,2, Michel M^1,2, Nagel M^1,2, Galle PR^1,2, Kostev K³, Schattenberg JM^4,5. Dig Dis Sci. 2019 Dec 3. doi: 10.1007/s10620-019-05986-9. [Epub ahead of print]

408.	New drugs for NAFLD: lessons from basic models to the clinic
	Reimer KC¹, Wree A², Roderburg C², Tacke F³. Hepatol Int. 2019 Dec 4. doi: 10.1007/s12072-019-10001-4. [Epub ahead of print]

409.	Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease
	Smith GI, Shankaran M, Yoshino M, Schweitzer GG, Chondronikola M, Beals JW, Okunade AL, Patterson BW, Nyangau E, Field T, Sirlin CB, Talukdar S, Hellerstein MK, Klein S. J Clin Invest. 2019 Dec 5. pii: 134165. doi: 10.1172/JCI134165. [Epub ahead of print]

410.	A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial.
	Pedrosa M¹, Seyedkazemi S², Francque S³, Sanyal A⁴, Rinella M⁵, Charlton M⁶, Loomba R⁷, Ratziu V⁸, Kochuparampil J¹, Fischer L², Vaidyanathan S⁹, Anstee QM¹⁰. Contemp Clin Trials. 2019 Nov 13;88:105889. doi: 10.1016/j.cct.2019.105889. [Epub ahead of print]

411.	Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease
	Shili-Masmoudi S¹, Wong GL^2,3, Hiriart JB¹, Liu K^4,5, Chermak F¹, Shu SS^2,3, Foucher J¹, Tse YK^2,3, Bernard PH¹, Yip TC^2,3, Merrouche W¹, Chan HL^2,3, Wong VW^2,3, de Lédinghen V^1,6. Liver Int. 2019 Nov 20. doi: 10.1111/liv.14301. [Epub ahead of print]

412.	The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD)
	Thondam SK¹, Cuthbertson DJ², Wilding JPH³. Peptides. 2019 Nov 20:170208. doi: 10.1016/j.peptides.2019.170208. [Epub ahead of print]

413.	Moderate alcohol use in fatty liver disease; don
	Gow P^1,2, Testro AG^1,2, Hey P^1,2, Sinclair M^1,2. Hepatology. 2019 Nov 29. doi: 10.1002/hep.31049. [Epub ahead of print]

414.	Diabetes drugs for nonalcoholic fatty liver disease: a systematic review
	Blazina I¹, Selph S². Syst Rev. 2019 Nov 29;8(1):295. doi: 10.1186/s13643-019-1200-8.

415.	Systematic review and meta-analysis of Roux-en-Y gastric bypass against laparoscopic sleeve gastrectomy for amelioration of NAFLD using four criteria
	Baldwin D¹, Chennakesavalu M¹, Gangemi A². Surg Obes Relat Dis. 2019 Sep 18. pii: S1550-7289(19)30997-9. doi: 10.1016/j.soard.2019.09.060. [Epub ahead of print]

416.	Attributable Fractions of NAFLD for Mortality in the United States: Results From NHANES III With 27 Years of Follow-up
	Alvarez CS¹, Graubard BI¹, Thistle JE¹, Petrick JL^1,2, McGlynn KA¹. Hepatology. 2019 Nov 16. doi: 10.1002/hep.31040. [Epub ahead of print]

417.	Alcohol Use is Associated with Hepatic Steatosis Among Persons with Presumed Non-alcoholic Fatty Liver Disease
	Long MT¹, Massaro JM², Hoffmann U³, Benjamin EJ⁴, Naimi TS⁵. Clin Gastroenterol Hepatol. 2019 Nov 14. pii: S1542-3565(19)31309-6. doi: 10.1016/j.cgh.2019.11.022. [Epub ahead of print]

418.	Hypothetical Treatment of Patients with Nonalcoholic Steatohepatitis: Potential Impact on Important Clinical Outcomes
	Younossi ZM^1,2, Tampi RP¹, Nader F³, Younossi IM³, Cable R², Srishord M², Racila A^1,3. Liver Int. 2019 Nov 9. doi: 10.1111/liv.14292. [Epub ahead of print]

419.

GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis

Best J¹, Bechmann LP¹, Sowa JP¹, Sydor S¹, Dechêne A², Pflanz K³, Bedreli S³, Schotten C³, Geier A⁴, Berg T⁵, Fischer J⁵, Vogel A⁶, Bantel H⁶, Weinmann A⁷, Schattenberg JM⁷, Huber Y⁷, Wege H⁸, von Felden J⁸, Schulze K⁸, Bettinger D⁹, Thimme R¹⁰, Sinner F¹, Schütte K¹, Weiss KH¹¹, Toyoda H¹², Yasuda S¹², Kumada T¹³, Berhane S¹⁴, Wichert M¹⁵, Heider D¹⁶, Gerken G³, Johnson P¹⁴, Canbay A¹⁷. Clin Gastroenterol Hepatol. 2019 Nov 8. pii: S1542-3565(19)31267-4. doi: 10.1016/j.cgh.2019.11.012. [Epub ahead of print]

420.	Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
	Harrison SA¹, Bashir MR², Guy CD², Zhou R³, Moylan CA², Frias JP⁴, Alkhouri N⁵, Bansal MB⁶, Baum S⁷, Neuschwander-Tetri BA⁸, Taub R⁹, Moussa SE¹⁰. Lancet. 2019 Nov 11. pii: S0140-6736(19)32517-6. doi: 10.1016/S0140-6736(19)32517-6. [Epub ahead of print]

421.	Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives
	Pennisi G¹, Celsa C¹, Spatola F¹, Dallio M², Federico A², Petta S¹. Int J Environ Res Public Health. 2019 Nov 7;16(22). pii: E4334. doi: 10.3390/ijerph16224334.

422.	Niacin for treatment of nonalcoholic fatty liver disease (NAFLD): novel use for an old drug?
	Kashyap ML¹, Ganji S², Nakra NK², Kamanna VS³. J Clin Lipidol. 2019 Oct 14. pii: S1933-2874(19)30290-9. doi: 10.1016/j.jacl.2019.10.006. [Epub ahead of print]

423.	The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives
	Pennisi G¹, Celsa C¹, Giammanco A², Spatola F¹, Petta S¹. Int J Mol Sci. 2019 Nov 9;20(22). pii: E5613. doi: 10.3390/ijms20225613.

424.	Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study
	Harrison SA¹, Alkhouri N², Davison BA³, Sanyal A⁴, Edwards C³, Colca JR⁵, Lee BH⁵, Loomba R⁶, Cusi K⁷, Kolterman O⁸, Cotter G³, Dittrich HC⁵. J Hepatol. 2019 Nov 4. pii: S0168-8278(19)30650-6. doi: 10.1016/j.jhep.2019.10.023. [Epub ahead of print]

425.	Transarterial Chemoembolization of Hepatocellular Carcinoma: Propensity Score Matching Study Comparing Survival and Complications in Patients with Nonalcoholic Steatohepatitis Versus Other Causes Cirrhosis
	Young S¹, Sanghvi T², Rubin N³, Hall D³, Roller L³, Charaf Y³, Golzarian J³. Cardiovasc Intervent Radiol. 2019 Nov 4. doi: 10.1007/s00270-019-02363-x. [Epub ahead of print]

426.	Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Non-alcoholic Fatty Liver Disease
	Kanwal F^1,2,3, Kramer J^2,3, Li L⁴, Dai J⁴, Natarajan Y¹, Yu X^2,3, Asch SM^5,6, El-Serag HB^1,2,3. Hepatology. 2019 Nov 1. doi: 10.1002/hep.31014. [Epub ahead of print]

427.	A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health
	Moolla A^1,2, Motohashi K¹, Marjot T^1,3, Shard A³, Ainsworth M³, Gray A⁴, Holman R^2,5, Pavlides M^2,3, Ryan JD^2,3, Tomlinson JW^1,2, Cobbold JF^2,3. Frontline Gastroenterol. 2019 Oct;10(4):337-346. doi: 10.1136/flgastro-2018-101155. Epub 2019 Apr 30.

428.	Mortality Related to Nonalcoholic Fatty Liver Disease Is Increasing in the United States
	Paik JM¹, Henry L², De Avila L¹, Younossi E¹, Racila A¹, Younossi ZM^1,3. Hepatol Commun. 2019 Aug 14;3(11):1459-1471. doi: 10.1002/hep4.1419. eCollection 2019 Nov.

429.	Cardiovascular Risk Categories in Patients With Nonalcoholic Fatty Liver Disease and the Role of Low-Density Lipoprotein Cholesterol
	Labenz C¹, Prochaska JH^2,3,4, Huber Y¹, Nagel M¹, Straub BK⁵, Wild P^2,3,4, Galle PR¹, Schattenberg JM^1,6. Hepatol Commun. 2019 Sep 30;3(11):1472-1481. doi: 10.1002/hep4.1428. eCollection 2019 Nov.

430.	Hepatocellular carcinoma and non-alcoholic fatty liver disease
	Golabi P^1,2, Rhea L¹, Henry L², Younossi ZM^3,4. Hepatol Int. 2019 Nov 7. doi: 10.1007/s12072-019-09995-8. [Epub ahead of print]

431.	Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial
	Navarro VJ¹, Belle SH², D'Amato M³, Adfhal N⁴, Brunt EM⁵, Fried MW⁶, Reddy KR⁷, Wahed AS², Harrison S⁸; Silymarin in NASH and C Hepatitis (SyNCH) Study Group. PLoS One. 2019 Sep 19;14(9):e0221683. doi: 10.1371/journal.pone.0221683. eCollection 2019.

432.	Vitamin E is an effective treatment for nonalcoholic steatohepatitis in HIV mono-infected patients
	Sebastiani G^1,2, Saeed S³, Lebouche B¹, de Pokomandy A¹, Szabo J¹, Haraoui LP¹, Routy JP^1,4, Wong P², Deschenes M², Ghali P², Klein M¹; LIVEHIV Study Group. AIDS. 2019 Oct 16. doi: 10.1097/QAD.0000000000002412. [Epub ahead of print]

433.	Nonalcoholic Fatty Liver Disease Among Individuals with HIV Mono-infection: A Growing Concern?
	Morrison M¹, Hughes HY^2,3, Naggie S^4,5, Syn WK^6,7,8. Dig Dis Sci. 2019 Oct 23. doi: 10.1007/s10620-019-05861-7. [Epub ahead of print]

434.	Severe obesity is associated with liver disease severity in pediatric non-alcoholic fatty liver disease
	Seth A¹, Orkin S², Yodoshi T², Liu C³, Fei L³, Hardy J², Trout AT⁴, Arce Clachar AC², Bramlage K², Xanthakos S², Mouzaki M². Pediatr Obes. 2019 Oct 27. doi: 10.1111/ijpo.12581. [Epub ahead of print]

435.	Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the United States
	Younossi ZM^1,2, Tampi RP³, Racila A^3,2, Qiu Y⁴, Burns L⁴, Younossi I⁵, Nader F⁵. Diabetes Care. 2019 Oct 28. pii: dc191113. doi: 10.2337/dc19-1113. [Epub ahead of print]

436.	Polycystic Ovary Syndrome (PCOS) Is Associated With NASH Severity and Advanced Fibrosis
	Sarkar M¹, Terrault N², Chan W¹, Cedars M³, Huddleston H³, Duwaerts CC¹, Balitzer D⁴, Gill RM⁴. Liver Int. 2019 Oct 18. doi: 10.1111/liv.14279. [Epub ahead of print]

437.	Decreased Physical Working Capacity in Adolescents With Non-Alcoholic Fatty Liver DiseaseAssociates With Reduced Iron Availability: PWC in NAFLD Relates to Iron Bioavailability
	Mitchell T¹, McKinnon E², Ayonrinde O³, Adams LA⁴, Trinder D⁵, Chua ACG⁵, Newton RU⁶, Straker L⁷, Olynyk JK⁸. Clin Gastroenterol Hepatol. 2019 Oct 16. pii: S1542-3565(19)31116-4. doi: 10.1016/j.cgh.2019.10.017. [Epub ahead of print]

438.	Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction in Patients With Nonalcoholic Fatty Liver Disease
	Packer M¹. Am J Med. 2019 Oct 14. pii: S0002-9343(19)30843-5. doi: 10.1016/j.amjmed.2019.09.002. [Epub ahead of print]

439.	Effect of alcohol consumption on nonalcoholic fatty liver disease
	Weng G¹, Dunn W¹. Transl Gastroenterol Hepatol. 2019 Sep 17;4:70. doi: 10.21037/tgh.2019.09.02. eCollection 2019.

440.	Non-alcoholic fatty liver disease in adults: Current concepts in etiology, outcomes and management
	Marjot T^1,2, Moolla A², Cobbold JF¹, Hodson L², Tomlinson JW². Endocr Rev. 2019 Oct 20. pii: bnz009. doi: 10.1210/endrev/bnz009. [Epub ahead of print]

441.	Editorial: The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis due to NASH
	Loomba R^1,2, Adams LA^3,4. Hepatology. 2019 Sep 13. doi: 10.1002/hep.30946. [Epub ahead of print]

442.	MRI presentation of hepatocellular carcinoma in non-alcoholic steatohepatitis (NASH)
	Al-Sharhan F¹, Dohan A², Barat M³, Feddal A⁴, Terris B⁵, Pol S⁶, Mallet V⁷, Soyer P⁸. Eur J Radiol. 2019 Oct;119:108648. doi: 10.1016/j.ejrad.2019.108648. Epub 2019 Sep 7.

443.	Dietary cholesterol does not break your heart but kills your liver
	Püschel GP¹, Henkel J¹. Porto Biomed J. 2019 Jun 29;3(1):e12. doi: 10.1016/j.pbj.0000000000000012. eCollection 2018 Aug.

444.	Overview of studies of the vitamin D/vitamin D receptor system in the development of non-alcoholic fatty liver disease
	Cimini FA¹, Barchetta I¹, Carotti S², Morini S³, Cavallo MG¹. World J Gastrointest Pathophysiol. 2019 Sep 10;10(2):11-16. doi: 10.4291/wjgp.v10.i2.11.

445.	Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial
	Stanley TL¹, Fourman LT¹, Feldpausch MN¹, Purdy J², Zheng I¹, Pan CS¹, Aepfelbacher J², Buckless C³, Tsao A³, Kellogg A⁴, Branch K⁵, Lee H⁶, Liu CY⁷, Corey KE⁸, Chung RT⁸, Torriani M³, Kleiner DE⁹, Hadigan CM², Grinspoon SK¹⁰. Lancet HIV. 2019 Oct 11. pii: S2352-3018(19)30338-8. doi: 10.1016/S2352-3018(19)30338-8. [Epub ahead of print]

446.	Low Awareness of Nonalcoholic Fatty Liver Disease in a Population-Based Cohort Sample: the CARDIA Study
	Cleveland ER¹, Ning H², Vos MB³, Lewis CE⁴, Rinella ME¹, Carr JJ⁵, Lloyd-Jones DM^2,6, VanWagner LB^7,8. J Gen Intern Med. 2019 Oct 8. doi: 10.1007/s11606-019-05340-9. [Epub ahead of print]

447.	Is There a Link between Basal Metabolic Rate, Spleen Volume and Hepatic Growth Factor Levels in Patients with Obesity-Related NAFLD?
	Tarantino G¹, Citro V², Conforti P³, Balsano C⁴, Capone D⁵. J Clin Med. 2019 Sep 20;8(10). pii: E1510. doi: 10.3390/jcm8101510.

448.	Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults
	Alexander M¹, Loomis AK², van der Lei J³, Duarte-Salles T⁴, Prieto-Alhambra D⁵, Ansell D^6,7, Pasqua A⁸, Lapi F⁸, Rijnbeek P³, Mosseveld M³, Avillach P^3,9, Egger P¹, Dhalwani NN¹⁰, Kendrick S¹¹, Celis-Morales C¹², Waterworth DM¹³, Alazawi W¹⁴, Sattar N¹². BMJ. 2019 Oct 8;367:l5367. doi: 10.1136/bmj.l5367.

449.	Chronic hepatitis B and NASH: Is "fat" all bad?
	Li J¹, Cheung RC^2,3, Nguyen MH³. Hepatology. 2019 Oct 8. doi: 10.1002/hep.30983. [Epub ahead of print]

450.	A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe
	Lazarus JV¹, Ekstedt M², Marchesini G³, Mullen J⁴, Novak K⁵, Pericàs JM⁶, Roel E⁷, Romero-Gómez M⁸, Ratziu V⁹, Tacke F¹⁰, Cortez-Pinto H¹¹, Anstee QM¹²; EASL International Liver Foundation NAFLD Policy Review Collaborators. J Hepatol. 2019 Sep 10. pii: S0168-8278(19)30521-5. doi: 10.1016/j.jhep.2019.08.027. [Epub ahead of print]

451.	Associations of chronic diarrhoea with non-alcoholic fatty liver disease and obesity-related disorders among US adults
	Shin A¹, Xu H², Imperiale TF^1,3. BMJ Open Gastroenterol. 2019 Aug 12;6(1):e000322. doi: 10.1136/bmjgast-2019-000322. eCollection 2019.

452.	Genetic Causes of Liver Disease: When to Suspect a Genetic Etiology, Initial Lab Testing, and the Basics of Management
	Schonfeld EA¹, Brown RS Jr². Med Clin North Am. 2019 Nov;103(6):991-1003. doi: 10.1016/j.mcna.2019.07.003.

453.	Impact of a preoperative low-calorie diet on liver histology in patients with fatty liver diseaseundergoing bariatric surgery
	Wolf RM¹, Oshima K², Canner JK³, Steele KE⁴. Surg Obes Relat Dis. 2019 Aug 22. pii: S1550-7289(19)30380-6. doi: 10.1016/j.soard.2019.08.013. [Epub ahead of print]

454.	Metabolic profiling of adolescent non-alcoholic fatty liver disease
	Hartley A^1,2,3, Santos Ferreira DL^2,3, Anderson EL^2,3, Lawlor DA^2,3. Version 2. Wellcome Open Res. 2019 Sep 19 [revised 2019 Sep 19];3:166. doi: 10.12688/wellcomeopenres.14974.2. eCollection 2018.

455.	Reversal of NASH fibrosis with pharmacotherapy
	Alukal JJ¹, Thuluvath PJ^2,3. Hepatol Int. 2019 Sep;13(5):534-545. doi: 10.1007/s12072-019-09970-3. Epub 2019 Jul 30.

456.	Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life
	Younossi ZM^1,2, Stepanova M³, Lawitz EJ⁴, Reddy KR⁵, Wai-Sun Wong V⁶, Mangia A⁷, Muir AJ⁸, Jacobson I⁹, Djedjos CS¹⁰, Gaggar A¹⁰, Myers RP¹⁰, Younossi I³, Nader F³, Racila A³. Am J Gastroenterol. 2019 Oct;114(10):1636-1641. doi: 10.14309/ajg.0000000000000375.

457.	What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?
	Doumas M¹, Imprialos K^1,2, Stavropoulos K^1,2, Athyros VG^1,2. Curr Vasc Pharmacol. 2019;17(5):425-428. doi: 10.2174/157016111705190703102816.

458.	Statin Use is Protective Against Hepatocellular Carcinoma in Patients With Nonalcoholic FattyLiver Disease: A Case-control Study
	German MN^1,2, Lutz MK^1,2, Pickhardt PJ^2,3, Bruce RJ^2,3, Said A^1,2. J Clin Gastroenterol. 2019 Sep 17. doi: 10.1097/MCG.0000000000001260. [Epub ahead of print]

459.	Prevalence, trends, outcomes, and disparities in hospitalizations for nonalcoholic fatty liverdisease in the United States
	Adejumo AC^1,2,3,4, Samuel GO⁵, Adegbala OM⁶, Adejumo KL⁴, Ojelabi O³, Akanbi O⁷, Ogundipe OA⁸, Pani L^1,2. Ann Gastroenterol. 2019 Sep-Oct;32(5):504-513. doi: 10.20524/aog.2019.0402. Epub 2019 Jul 17.

460.	Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic FattyLiver Disease Who Have Normal Aminotransferase Levels
	Gawrieh S¹, Wilson LA², Cummings OW³, Clark JM², Loomba R⁴, Hameed B⁵, Abdelmalek MF⁶, Dasarathy S⁷, Neuschwander-Tetri BA⁸, Kowdley K⁹, Kleiner D¹⁰, Doo E¹¹, Tonascia J², Sanyal A¹², Chalasani N¹; and the NASH Clinical Research Network. Am J Gastroenterol. 2019 Oct;114(10):1626-1635. doi: 10.14309/ajg.0000000000000388.

461.	Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study
	Gawrieh S¹, Dakhoul L¹, Miller E², Scanga A³, deLemos A⁴, Kettler C¹, Burney H¹, Liu H¹, Abu-Sbeih H², Chalasani N¹, Wattacheril J⁵. Aliment Pharmacol Ther. 2019 Oct;50(7):809-821. doi: 10.1111/apt.15464. Epub 2019 Sep 1.

462.	Increased Prevalence of Colorectal Adenomas in Patients with Nonalcoholic Fatty LiverDisease: A Cross-Sectional Study
	Blackett JW¹, Verna EC², Lebwohl B^2,3. Dig Dis. 2019 Aug 30:1-9. doi: 10.1159/000502684. [Epub ahead of print]

463.	Multi-drug approaches to NASH: what's in the development pipeline?
	Johnston MP¹, Patel J¹, Byrne CD^2,3. Expert Opin Investig Drugs. 2019 Sep 23:1-8. doi: 10.1080/13543784.2020.1668926. [Epub ahead of print]

464.	ANNALS EXPRESS: A review of the clinical utility of the Enhanced Liver Fibrosis test in multiple aetiologies of Chronic Liver Disease
	Patel P¹, Connoley D¹, Jones F¹, Srivastava A¹, Rosenberg W¹. Ann Clin Biochem. 2019 Sep 17:4563219879962. doi: 10.1177/0004563219879962. [Epub ahead of print]

465.	Drug Development for Nonalcoholic Fatty Liver Disease: Landscape and Challenges
	Thiagarajan P¹, Aithal GP¹. J Clin Exp Hepatol. 2019 Jul-Aug;9(4):515-521. doi: 10.1016/j.jceh.2019.03.002. Epub 2019 Mar 13.

466.	Screening of Cardiovascular Disease in Nonalcoholic Fatty Liver Disease: Whom and How?
	Choudhary NS¹, Duseja A². J Clin Exp Hepatol. 2019 Jul-Aug;9(4):506-514. doi: 10.1016/j.jceh.2019.02.005. Epub 2019 Feb 15.

467.	Magnitude of Nonalcoholic Fatty Liver Disease: Western Perspective
	Samji NS¹, Verma R^1,2, Satapathy SK³. J Clin Exp Hepatol. 2019 Jul-Aug;9(4):497-505. doi: 10.1016/j.jceh.2019.05.001. Epub 2019 May 16.